Chapter 1
Bronchiectasis: epidemiology and causes D. Bilton*,#," and A.L. Jones*,#,"
Summary
Keywords: Aetiology, bronchiectasis, epidemiology, non-cystic fibrosis
*Dept of Cystic Fibrosis, Royal Brompton Hospital, # NIHR Biomedical Research Unit into Advanced Lung Disease, Royal Brompton Hospital, and " Dept of Cystic Fibrosis, National Heart and Lung Institute, Imperial College London, London, UK. Correspondence: D. Bilton, Royal Brompton Hospital, Sydney Street, London, SW3 6NP, UK, Email
[email protected]
D. BILTON AND A.L. JONES
Bronchiectasis remains a significant cause of morbidity and mortality in the developed world. The true prevalence of the condition remains elusive, in part, because of the innate difficulty in determining causation, when more than one respiratory condition exists in the same patient, but also due to the increasing rate of diagnosis by radiological means where no clinical symptoms are present. The wide ranging aetiology of bronchiectasis will be discussed in this chapter; however, some aspects will be discussed in greater detail throughout this Monograph. The diagnosis of bronchiectasis should be the beginning of a targeted search for causation, which may lead to directed treatment, thereby limiting the disease progression. Over the next 5 years a reduction in the number of cases labelled as idiopathic bronchiectasis should be expected, as the continual expanding knowledge of immunology and immunogenetics, with respect to large studies of patients with bronchiectasis, can be applied.
Eur Respir Mon 2011. 52, 1–10. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003110
B
ronchiectasis was first described by Laennec [1] in 1819 as part of a wider work describing the use of his novel invention, the stethoscope. In his book ‘‘De l’Auscultation Mediate ou Traite du Diagnostic des Maladies des Poumons et du Coeur’’ [1], he described the condition through the use of case reports, detailing clinical examination and correlating this with post mortem findings. He identified that any illness characterised by chronic sputum production could lead to bronchiectasis with tuberculosis and pertussis infection identified as the most likely causative conditions.
1
A century later, in 1919, A. Jex-Blake delivered a lecture at the Hospital for Consumption (London, UK) on the condition of bronchiectasis [2]. He examined the case records for the hospital over a 20-year period and gave a detailed account of the condition and its causes. He identified that bronchiectasis itself was a secondary condition to a preceding disorder of the lung and,
as such, its frequency was likely to be underestimated as the preceding condition was of such severity that the presence of bronchiectasis was overlooked. He also identified that the condition was apparent in 2% of the hospital’s admissions over the same 20-year period, but estimated that the true figure could be as high as 5%. Perhaps, unsurprisingly, in this pre-antibiotic era a third of patients were identified as having bronchiectasis secondary to an episode of pneumonia or pleurisy, a third due to chronic bronchitis and a further third due to bronchial obstruction, the majority of which were malignant tumours. Since the introduction of antibiotic therapy the incidence of bronchiectasis due to tuberculosis or other infections decreased markedly from the beginning of the 20th century. Perhaps the most striking evidence for the effect of antibiotic introduction was a report in 1969 by FIELD [3] into childhood admissions for the condition. The author reported a reduction from 24–99 per 10,000 hospital admissions to 6–13 per 10,000 admissions for five large children’s hospitals between 1952 and 1960. Despite this decline in cases in the antibiotic era of medicine, non-cystic fibrosis (CF) bronchiectasis remains a significant cause of morbidity.
EPIDEMIOLOGY AND CAUSES
Epidemiology Remarkably the current knowledge of the true incidence of bronchiectasis has changed very little from when A. Jex-Blake gave his lecture almost a century ago. In part, the reason for this remains similar to what was perceived in 1919. Bronchiectasis is often noted as a secondary phenomenon to a more severe pulmonary pathology, as is the case of asthma or chronic obstructive pulmonary disease (COPD), and as such goes unreported. Conversely, the widespread use of computer tomography (CT) as a diagnostic tool in respiratory medicine has resulted in the identification of an increased number of radiological bronchiectasis cases in patients who showed no symptoms and who would have otherwise not been classified as having it. Future studies of the prevalence of bronchiectasis should not be confined to radiological evidence alone but should include the assessment of clinical symptoms. One of the first large-scale studies to determine the incidence of bronchiectasis was performed in 1953 and examined the population of Bedford, a town in the UK [4]. The authors identified an incidence of bronchiectasis as 1.3 per 1,000 people. The relevance of this data, collected prior to the widespread use of antibiotics and where the authors excluded patients with bronchiectasis as a consequence of other pulmonary pathology, is perhaps limiting. However, more recent data has been collected from cohorts in Finland, New Zealand and the USA [5–7]. The data from Finland suggested an incidence of 2.7 per 100,000 people, while in New Zealand an overall incidence in children of 3.7 per 100,000 was noted but showed wide variations with regards ethnicity. For example, children from a Pacific Island descent had an incidence of 17.8 per 100,000 compared with an incident of 1.5 per 100,000 for those of a Northern European descent. Unsurprisingly, given the often chronic nature of its development, the prevalence of bronchiectasis and hospital admission related to bronchiectasis increased with age. Studies from the USA estimate a prevalence of 4.2 per 100,000 people in those aged 18–34 years, increasing to 271.8 per 100,000 in people aged .75 years [7].
Aetiology There are a wide range of conditions that can cause bronchiectasis and there are a number of ways in which one could classify these aetiological factors; however, an approach based on pathological processes appears to be the most logical and is described in table 1.
2
Bronchial dilatation can be caused by a structural defect in the wall itself, an effect of abnormal airway pressure on the bronchial wall or by damage to the airway elastic tissue and cartilage as a result of bronchial wall inflammation.
The lungs are continuously exposed to inhaled pathogens and have developed an advanced mechanism for trapping and removing them. The human airways are lined with ciliated epithelium with submucosal goblet cells secreting mucus that makes up the top layer of the airway surface liquid, the lower layer being the periciliary fluid that bathes the cilia and ensures they function appropriately. In healthy individuals the mucus traps inhaled pathogens and the continuously motile cilia transport the mucus and its contents out of the lung. Any defect in this mucociliary clearance mechanism can lead to the retention of pathogens resulting in the progression of airway infection, inflammation and ultimately bronchiectasis.
Structural lung conditions The effect of obstructions within the bronchus itself was identified by LAENNEC [1] as a significant cause of bronchiectasis. Obstruction of the bronchi with foreign objects or tumours is now a relatively rare cause of bronchiectasis. Unsurprisingly most patients with bronchiectasis secondary to retained objects are young children. Congenital disorders affecting the structure of the bronchial tree can lead to bronchiectasis through a direct effect on the bronchial wall itself, although impaired clearance of sputum through the abnormally dilated structures can further compound the condition.
Table 1. Aetiology of bronchiectasis Structural lung conditions Williams–Campbell syndrome Mounier–Kuhn syndrome Ehlers–Danlos syndrome Toxic damage to airways Inhalational injury Aspiration secondary to neuromuscular disease GERD Obstruction of single bronchus Tumour Foreign body Obstructive airways disease Asthma COPD AAT deficiency Defects of mucociliary clearance Ciliary dyskinesia Primary ciliary dyskinesia Secondary ciliary dyskinesia Channelopathies CFTR dysfunction ENaC dysfunction ABPA Immunodeficiency CVID XLA CGD Antibody deficiency with normal Ig Secondary immunodeficiency Haematological malignancy Post-allogeneic bone marrow transplant Drug-induced immunosuppression Infections Childhood infections Tuberculosis Pneumonia Measles Whooping cough Nontuberculous mycobacteria Bronchiectasis in systemic diseases Inflammatory bowel disease Connective tissue diseases Yellow nail syndrome Idiopathic bronchiectasis
D. BILTON AND A.L. JONES
Inflammation within the bronchial wall can be the result of an infection within the airway, inhalation of injurious agents or an endogenous condition such as an autoimmune disease.
GERD: gastro-oesophageal reflux disease; COPD: chronic obstructive pulmonary disease; AAT: a1- antitrypsin deficiency; CFTR: cystic fibrosis transmembrane conductance regulator; ENaC: epithelial sodium channel; ABPA: allergic bronchopulmonary aspergillosis; CVID: common variable immunodeficiency; XLA: X-linked agammaglobulinaemia; CGD: chronic granulomatous disease; Ig: immunoglobulin.
Williams–Campbell syndrome was first described in 1960 after the case reports of five children were studied by WILLIAMS and CAMPBELL [8]. Histological examination of the bronchial wall revealed a deficiency or absence of cartilage, mostly from the third division of the bronchi down. WILLIAMS and CAMPBELL [8] went on to describe a further 11 children with the same clinical findings of bronchiectasis and cartilage deficiency.
3
Mounier–Kuhn syndrome (tracheobronchomegaly) is characterised by dilatation of the trachea and large bronchi, usually presenting in young adults. Its underlying pathology is not clearly understood but histological examination has shown atrophy of airway cartilage and smooth muscle.
Case reports suggesting an association with Ehlers–Danlos syndrome, and the appearance of the condition in siblings, could point to an unidentified genetic cause for the condition.
Obstructive airways disease To carry on the theme of defects in the gross airway structure itself, perhaps a continuation of this is to consider whether obstructive airways diseases, namely asthma and COPD, could lead to bronchiectasis. It is natural to assume that these conditions would lead to bronchiectasis as both have clearly been shown to cause airway inflammation and structural blockage of airways, either through bronchospasm or fixed airways obstruction, in the case of COPD.
Asthma A number of studies have highlighted the presence of airway remodelling in chronic asthma patients using high-resolution CT (HRCT) scanning techniques. The airway remodelling can vary from mild airway wall thickening to blatant bronchiectasis. Bronchial wall thickening has been found in up to 82% of asthmatic patients in a cohort [9] and in patients with mild asthma [10]. As bronchial wall thickening is indicative of airway inflammation this suggests that a significant number of patients with asthma are at risk of developing bronchiectasis.
EPIDEMIOLOGY AND CAUSES
The prevalence of bronchiectasis in these studies is estimated at 17.5–40% [9–11]. In the largest of these studies, which comprised of 463 patients with severe asthma, 40% of patients were shown to have evidence of bronchiectasis on HRCT scans [11]. However, study participants were selected for HRCT on the basis of clinical indication, the most common being a suspicion of bronchiectasis. The studies suggest that bronchiectasis is associated with a more severe obstruction and is more apparent in patients who present with a longer history of asthma symptoms, consequently a subgroup of severe asthma patients appear to be at risk of developing bronchiectasis [9–11].
COPD COPD is a term encompassing a number of pathological processes including chronic bronchitis, asthma, emphysema and bronchiectasis. Therefore, it is difficult to fully attribute COPD as the cause of bronchiectasis as in some cases bronchiectasis may be the primary diagnosis. Certainly it is probable that bronchiectasis in COPD is common. A study of moderate-to-severe COPD patients demonstrated the prevalence of bronchiectasis to be 50% [12]. The COPD patients with bronchiectasis were found to have more severe exacerbations and increased sputum inflammatory markers. Further studies are required to elucidate the mechanisms that predispose COPD patients to developing bronchiectasis; severity of airflow obstruction may be a key driver in this mechanism.
a1-antitrypsin deficiency
4
a1-antitrypsin (AAT) deficiency is classically associated with predominantly lower lobe emphysema. Bronchiectasis has also been associated with the enzyme deficiency, whether this is a direct consequence of the deficiency or secondary to the emphysema-associated airways obstruction is less clear. In a study of patients with severe AAT deficiency the vast majority of subjects had some evidence of bronchiectasis on a HRCT scan (70 out of 74 subjects), with 27% having clinically significant bronchiectasis with a correlation between forced expiratory volume in 1 second (FEV1) and bronchial wall thickness [13]. In a study of the distribution of AAT alleles in a population of bronchiectasis patients, there was no difference in AAT allele distribution between healthy controls and bronchiectasis patients [14]. However, there was an over representation of hetero- and homozygote AAT deficiency alleles in those patients with bronchiectasis and coexistent asthma. Therefore, the evidence would suggest that AAT deficiency is related to airway obstruction rather than a direct effect of the enzyme deficiency on the bronchial wall structure.
Defects of mucociliary clearance Ciliary dyskinesia Abnormalities of cilia structure and/or motility cause a decreased mucus clearance from the lungs. These abnormalities can be due to a primary defect in the structure or function of the cilia or secondary damage to the cilia from external agents, such as bacteria or inhaled noxious agents.
Primary ciliary dyskinesia Airway cilia are complicated structures containing more than 250 proteins. The ciliary structures are composed of microtubules which are mobilised by structures known as dynein arms, these are divided into two groups the outer and inner dynein arms. This complicated polypeptide structure can be affected by numerous genetic mutations and, as such, primary ciliary dyskinesia (PCD) is a genetically heterogenous disorder. Among the most commonly identified mutations are those of the genes DNAI1 and DNAH5, which code for proteins responsible for the assembly of outer dynein arms. As cilia are present throughout the body, patients with PCD will often present with multiple symptoms such as sinusitis, recurrent otitis media, infertility and defects of organ lateralisation with situs inversus or situs ambiguus. The triad of bronchiectasis, chronic sinusitis and situs inversus is also known as Kartagener’s syndrome.
A number of noxious agents, both organic and inorganic, have been shown to affect the function of cilia in human airway epithelia. Certain bacteria, such as Pseudomonas aeruginosa and Haemophilus influenzae, have been shown to disable mucociliary clearance by releasing products that inhibit ciliary beat frequency, allowing them to persist and propagate infection [15, 16]. Inhaled inorganic substances such as diesel particles [17] and cigarette smoke [18] have also been shown to have a direct effect on ciliary function, inhibiting ciliary beat frequency. It is important to note here that no causal role for tobacco smoking and the development of bronchiectasis has been made, indeed outside of COPD bronchiectasis appears to be a disease of the nonsmoker. Aspiration of gastric contents is a well recognised, but perhaps under diagnosed, cause of bronchiectasis. Whilst aspiration of both acid and nonacid stomach contents leads to direct inflammation of the bronchial wall, ciliary function may also be affected by these agents.
D. BILTON AND A.L. JONES
Secondary ciliary dyskinesia
Channelopathies As previously mentioned, the epithelial lining of the airway is coated in a liquid known as the airway surface liquid. It contains two layers, the outer mucus layer and an inner periciliary layer. Ion channels within the apical surface of the epithelial levels regulate the fluid content of this layer to ensure adequate hydration. This enables the cilia to move in a liquid layer but also prevents the desiccation of the mucus into a thick, sticky substance that is difficult to mobilise.
5
Defects in the ion channels of the epithelial layer can lead to dehydration of the airway surfaces, thereby affecting the depth of the periciliary layer and bringing the cilia into contact with the viscous mucus layer, further impeding its function. The most widely recognised of these defects is that found in CF. Here, the loss of a chloride channel known as the CF transmembrane regulator (CFTR) protein leads to the inability of the epithelial cells to excrete chloride. The dysregulation of the ion transport is further compounded by the effect of CFTR on another ion channel, that of the epithelial sodium channel (ENaC). CFTR is an inhibitor of the ENaC channel and therefore the loss of CFTR is postulated to lead to hyperactivity of the sodium channel, resulting in a large
increase in the transport of sodium into the epithelial cell with a corresponding movement of water out of the airway liquid. In theory, genetic defects of the ENaC channel could lead to bronchiectasis if such a mutation led to over activity of the channel. Whilst mutations of ENaC genes have been identified in patients with idiopathic bronchiectasis [19], a significant number of these were also carriers of a CFTR mutation. Furthermore, a single CFTR mutation is frequently observed in patients with diffuse bronchiectasis. A study comparing patients with either none, one or two CFTR mutations suggested a continuum of CFTR dysfunction (as measured by nasal potential differences) existed and that this may lead to the development of bronchiectasis in some patients who are CFTR heterozygotes [20].
Allergic bronchopulmonary aspergillosis
EPIDEMIOLOGY AND CAUSES
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary condition caused by a hypersensitivity reaction to the ubiquitous environmental fungus Aspergillus fumigatus. It is most commonly seen in patients with pre-existing asthma or CF and is clinically characterised by recurrent wheeze, pulmonary infiltrates and the development of bronchiectasis. The hypersensitivity reaction has mixed features of immediate hypersensitivity (type I), antigen–antibody complexes (type III) and inflammatory cell responses (type IV) [21]. The inflammatory cell response seen in ABPA shows a predominance of T-helper cell type 2 (Th2) cells leading to a release of cytokines mediating allergic inflammation (as opposed to the Th1, cytotoxic pathway) [22]. The type I hypersensitivity reaction causes local degranulation of mast cells and histamine release leading to bronchoconstriction. The combination of airway inflammation, which leads to viscous, eosinophil-laden mucus, plugging and airway obstruction, and bronchospasm leads to a reduction in mucociliary clearance and the development of bronchiectasis. As such bronchiectasis in ABPA is common. In three large case studies it was found that central bronchiectasis was present in 69–76% of patients with ABPA [23–25].
Immunodeficiency Defects in the immune system leave the lungs vulnerable to infection and in some cases the development of bronchiectasis can be the first indication of immunodeficiency. The most common forms of primary immune deficiencies observed in patients with bronchiectasis are common variable immune deficiency (CVID), X-linked agammaglobulinaemia (XLA) and chronic granulomatous disease (CGD).
Common variable immune deficiency CVID is characterised by reduced levels of immunoglobulins (Igs) with associated recurrent bacterial infections. An increased risk of autoimmune conditions and malignancy has also been identified. The majority of patients present with recurrent pulmonary infections at a mean age 29 years [26]. CVID is the most common primary immune deficiency to cause bronchiectasis. A case series undertaken in a UK population identified 68% of the patients with CVID as having evidence of bronchiectasis [27]. The most likely cause of this high rate of incidence could be the delay in the diagnosis of CVID, with a mean duration of 4 years between reporting of symptoms and diagnosis [27].
X-linked agammaglobulinaemia
6
XLA is caused by a mutation of a tyrosine kinase gene that is involved in the development of Blymphocytes, leading to an absence of circulating B-lymphocytes and the absence of Igs. Given the severity of the immune deficiency it usually presents much earlier than CVID, usually being diagnosed in early childhood [28]. Despite treatment with replacement Igs, chronic lung disease can still develop with the risk of developing bronchiectasis increasing with age [29].
Chronic granulomatous disease CGD is a group of disorders characterised by a loss of phagocytic NADPH oxidase, without which phagocytes are unable to produce the reactive oxygen species required to kill ingested bacteria. Infections are mainly due to Staphylococcus aureus, Serratia marcescens, Salmonella sp., Klebsiella sp. and Burkholderia cepacia.
Antibody deficiency with normal Igs In a study of patients with bronchiectasis and normal IgG levels, 11% were shown to have specific antibody production deficiencies with an inability to respond to pneumococcal and H. influenzae vaccines [30].
Secondary immunodeficiency The development of bronchiectasis in HIV-infected patients has been noted in a number of case series. While recurrent pulmonary infection is likely to be the major factor in the development of bronchiectasis in these patients, the development of lymphocytic interstitial pneumonia may also be implicated [31].
Infections
A number of childhood respiratory infections have been implicated in the pathogenesis of bronchiectasis. The most widely recognised infectious causes of bronchiectasis are measles and pertussis infection in the West [32], with tuberculosis being a major cause elsewhere.
Nontuberculous mycobacterial infection Globally, Mycobacterium tuberculosis infection remains a major cause of morbidity and mortality and a significant cause of bronchiectasis. In developed countries with screening programmes and adequate access to treatment, the incidence of new infections remains low. However, the incidence of nontuberculous mycobacterial (NTM) pulmonary infections is increasing. These mycobacteria vary in pathogenecity with Mycobacterium avium complex (MAC) being the most pathogenic whilst other organisms, such as Mycobacterium gordonae and Mycobacterium abscessus, act as opportunistic pathogens and are only found in patients with underlying lung diseases. NTM is commonly present in one of three clinical forms; 1) a tuberculosis-like pattern with a predominant upper lobe fibrocavitatory disease, mostly found in older males with COPD; 2) nodular bronchiectasis, most commonly seen in middle-aged females; and 3) hypersensitivity pneumonitis [33].
D. BILTON AND A.L. JONES
Childhood infections
The second of these clinical forms is also known as ‘‘Lady Windermere syndrome’’, and was first described in 1992 in a case series of 29 predominately elderly, female patients [34]. The patients had MAC infection with bronchiectasis predominantly affecting the middle lobe and lingula. The authors postulated that persistent voluntary cough suppression could lead to chronic inflammatory processes in these poorly draining lung regions which are susceptible to MAC infection [34].
Bronchiectasis in systemic diseases Inflammatory bowel disease
7
The development of bronchiectasis in patients with ulcerative colitis is a well recognised phenomenon and the subject of a number of case series [35]. Classically, bronchiectasis develops after resection of the large bowel, suggesting a common immune system response that becomes
concentrated on the bronchial wall after the bowel is removed. The common embryonic origin and similar structures of bowel and bronchial wall (columnar epithelial and submucosal glands) add weight to this theory. The link between Crohn’s disease and bronchiectasis is less clear with only a small number of case reports detailing their coexistence [36], perhaps too few to determine a definite association.
Connective tissue diseases A number of connective tissue diseases have been noted to be associated with bronchiectasis, largely based on case series reviews of small numbers of patients. The clearest association is that between rheumatoid arthritis and bronchiectasis. Studies have estimated the incidence of bronchiectasis in rheumatoid arthritis patients to be as high as 41% with a significant number of them being asymptomatic [37]. Again no clear pathological process has been identified as the cause of this association, although studies have suggested common genetic predisposition with an association between human leukocyte antigen sub-groups [38]. An effect of the immunosuppressive agents used in rheumatoid arthritis treatment has also been postulated, although a significant number of patients develop bronchiectasis prior to the onset of arthropathy. Associations between bronchiectasis and Sjo¨gren’s syndrome [39], systemic sclerosis [40], systemic lupus erythematosus [41], ankylosing spondylitis [42, 43] and relapsing polychondritis [44] have all been made in small case series reviews.
EPIDEMIOLOGY AND CAUSES
Yellow nail syndrome Yellow nail syndrome is a rare syndrome that was first described in 1964 by SAMMAN and WHITE [45] and is characterised by bronchiectasis, lymphoedema and a characteristic appearance of the nails. The underlying pathological defect is not clear, although a recent study revealing an association with chronic rhinosinusitis suggests a possible defect in an inflammatory pathway or mucociliary clearance rather than a structural defect within the lung itself [46].
Idiopathic bronchiectasis In two large studies [47, 48], which identified the cause of bronchiectasis in adults, a significant proportion of patients (26% and 53%, respectively) were found to have no identifiable cause and were labelled as having idiopathic bronchiectasis, the majority of whom were found to be female and nonsmokers. As all the patients studied had undergone rigorous clinical testing and their history had been reported, leading to the exclusion of all known causes, including genetic disorders, it is unlikely under recognition of known causes of bronchiectasis could have occurred. Even in paediatric studies, with much shorter follow-up periods and clear exposure histories, no cause could be found for bronchiectasis in 25% of the patients [32]. It is clear, therefore, that there is still much to learn about bronchiectasis and its underlying pathogenesis.
Statement of interest None declared.
References
8
1. Laennec RTH. De l’Auscultation Mediate ou Traite du Diagnostic des Maladies des Poumons et du Coeur. [On Mediate Auscultation or Treatise on the Diagnosis of the Diseases of the Lungs and Heart]. Paris, Brosson and Chaude´, 1819. 2. Jex-Blake AJ. A lecture on bronchiectasis: delivered at the Hospital for Consumption Brompton, November 19th, 1919. Br Med J 1920; 1: 591–594. 3. Field CE. Bronchiectasis. Third report on a follow-up study of medical and surgical cases from childhood. Arch Dis Child 1969; 44: 551–561.
D. BILTON AND A.L. JONES
9
4. Wynn-Williams N. Bronchiectasis: a study centred on Bedford and its environs. Br Med J 1953; 1: 1194–1199. 5. Sa¨yna¨ja¨kangas O, Keistinen T, Tuuponen T, et al. Bronchiectasis in Finland: trends in hospital treatment. Respir Med 1997; 91: 395–398. 6. Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005; 90: 737–740. 7. Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12: 205–209. 8. Williams H, Campbell P. Generalized bronchiectasis associated with deficiency of cartilage in the bronchial tree. Arch Dis Child 1960; 35: 182–191. 9. Grenier P, Mourey-Gerosa I, Benali K, et al. Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intraobserver variability. Eur Radiol 1996; 6: 199–206. 10. Shiba K, Kasahara K, Nakajima H, et al. Structural changes of the airway wall impair respiratory function, even in mild asthma. Chest 2002; 122: 1622–1626. 11. Gupta S, Siddiqui S, Haldar P, et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136: 1521–1528. 12. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 400–407. 13. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in a1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215–1212. 14. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of a(1)-antitrypsin alleles in patients with bronchiectasis. Chest 2000; 117: 415–419. 15. Wilson R, Roberts D, Cole P. Effect of bacterial products on human ciliary function in vitro. Thorax 1985; 40: 125–131. 16. Hingley ST, Hastie AT, Kueppers F, et al. Effect of ciliostatic factors from Pseudomonas aeruginosa on rabbit respiratory cilia. Infect Immun 1986; 51: 254–262. 17. Bayram H, Devalia JL, Sapsford RJ, et al. The effect of diesel exhaust particles on cell function and release of inflammatory mediators from human bronchial epithelial cells in vitro. Am J Respir Cell Mol Biol 1998; 18: 441–448. 18. Walker TR, Kiefer JE. Ciliastatic components in the gas phase of cigarette smoke. Science 1966; 153: 1248–1250. 19. Fajac I, Viel M, Sublemontier S, et al. Could a defective epithelial sodium channel lead to bronchiectasis. Respir Res 2008; 9: 46. 20. Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181: 1078–1084. 21. Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135: 805–826. 22. Skov M, Poulsen LK, Koch C. Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis. Pediatr Pulmonol 1999; 27: 74–79. 23. Behera D, Guleria R, Jindal SK, et al. Allergic bronchopulmonary aspergillosis: a retrospective study of 35 cases. Indian J Chest Dis Allied Sci 1994; 36: 173–179. 24. Chakrabarti A, Sethi S, Raman DS, et al. Eight-year study of allergic bronchopulmonary aspergillosis in an Indian teaching hospital. Mycoses 2002; 45: 295–299. 25. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 2007; 132: 1183–1190. 26. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34–48. 27. Thickett KM, Kumararatne DS, Banerjee AK, et al. Common variable immune deficiency: respiratory manifestations, pulmonary function and high-resolution CT scan findings. QJM 2002; 95: 655–662. 28. Conley ME, Howard V. Clinical findings leading to the diagnosis of X-linked agammaglobulinemia. J Pediatr 2002; 141: 566–571. 29. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID European Society for Immunodeficiencies. Clin Immunol 1999; 93: 190–197. 30. Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005; 127: 197–204. 31. Holmes AH, Pelton S, Steinbach S, et al. HIV related bronchiectasis. Thorax 1995; 50: 1227. 32. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005; 26: 8–14. 33. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 2008; 133: 243–251. 34. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101: 1605–1609. 35. Camus P, Piard F, Ashcroft T, et al. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993; 72: 151–183. 36. Mahadeva R, Walsh G, Flower CD, et al. Clinical and radiological characteristics of lung disease in inflammatory bowel disease. Eur Respir J 2000; 15: 41–48. 37. Despaux J, Manzoni P, Toussirot E, et al. Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. Rev Rhum Engl Ed 1998; 65: 453–461. 38. Hillarby MC, McMahon MJ, Grennan DM, et al. HLA associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 1993; 32: 794–797.
10
EPIDEMIOLOGY AND CAUSES
39. Uffmann M, Kiener HP, Bankier AA, et al. Lung manifestation in asymptomatic patients with primary Sjo¨gren syndrome: assessment with high resolution CT and pulmonary function tests. J Thorac Imaging 2001; 16: 282–289. 40. Andonopoulos AP, Yarmenitis S, Georgiou P, et al. Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography. Clin Exp Rheumatol 2001; 19: 187–190. 41. Fenlon HM, Doran M, Sant SM, et al. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol 1996; 166: 301–307. 42. Souza AS Jr, Muller NL, Marchiori E, et al. Pulmonary abnormalities in ankylosing spondylitis: inspiratory and expiratory high-resolution CT findings in 17 patients. J Thorac Imaging 2004; 19: 259–263. 43. Casserly IP, Fenlon HM, Breatnach E, et al. Lung findings on high-resolution computed tomography in idiopathic ankylosing spondylitis – correlation with clinical findings, pulmonary function testing and plain radiography. Br J Rheumatol 1997; 36: 677–682. 44. Davis SD, Berkmen YM, King T. Peripheral bronchial involvement in relapsing polychondritis: demonstration by thin-section CT. AJR Am J Roentgenol 1989; 153: 953–954. 45. Samman PD, White WF. The "Yellow Nail" syndrome. Br J Dermatol 1964; 76: 153–157. 46. Nisbet M, Deveraj A, Meister M, et al. Yellow nail syndrome and bronchiectasis. Am J Respir Crit Care Med 2009; 179: A3216. Available from: http://ajrccm.atsjournals.org/cgi/reprint/179/1_MeetingAbstracts/A3216.pdf. 47. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163–1170. 48. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277–1284.
Chapter 2
Pulmonary defence mechanisms and inflammatory pathways in bronchiectasis B.N. Lambrecht*,#, K. Neyt* and C.H. GeurtsvanKessel*,"
Over recent years there has been a tremendous increase in the understanding of pulmonary immunity, mostly driven by large research efforts in understanding the basis of asthma and chronic obstructive pulmonary disease. Bronchiectasis is well understood. In this article, an overview of pulmonary defence mechanisms as well as inflammatory mechanisms is given as a basis to understand the pathogenesis of bronchiectasis.
Keywords: Bronchiectasis, inflammatory mechanisms, immunity, pulmonary defence
*Dept of Pulmonary Medicine, Laboratory of Immunoregulation and Mucosal Immunology, Ghent University, Ghent, Belgium. # Dept of Pulmonary Medicine, and " Dept of Virology, Erasmus University Medical Center, Rotterdam, The Netherlands. Correspondence: B.N. Lambrecht, Dept of Pulmonary Medicine, Laboratory of Immunoregulation and Mucosal Immunology, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium, Email
[email protected]
B.N. LAMBRECHT ET AL.
Summary
Eur Respir Mon 2011. 52, 11–21. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003210
B
11
ronchiectasis is a chronic disorder characterised by permanent dilatation of the bronchi accompanied by inflammatory changes in their walls and in the adjacent lung parenchyma. The pathogenesis is related to recurrent inflammation of the bronchial walls combined with fibrosis in the surrounding parenchyma. The resultant traction on weakened walls leads to eventual irreversible dilatation [1]. Bronchiectasis can result from defective pulmonary defence mechanisms that lead to recurrent, severe and tissue-damaging microbial insults or chronic bacterial colonisation with persistent inflammation leading to structural changes to the airway wall. Given the fact that restoration of inflammation and return to immune homeostasis is crucial in the lung to protect the delicate gas exchange machinery, it is also possible that bronchiectasis results from defective anti-inflammatory pathways that serve to dampen chronic inflammation. Therefore, in this chapter we provide a brief overview of lung defence mechanisms and how these immune defence mechanisms can contribute to chronic inflammation and structural changes to the airway wall if not properly counter-regulated by anti-inflammatory pathways. The major inflammatory cell types found in bronchiectasis are neutrophils in the airway lumen causing purulent sputum and macrophages, dendritic cells (DCs) and lymphocytes in the airway wall [2, 3].
The latter cells often occur in lymphoid aggregates or so-called tertiary lymphoid follicles, and are typically seen in patients with tubular bronchiectasis and are a major cause of small airway obstruction [4].
Mechanical and physical pulmonary defence mechanisms
PULMONARY DEFENCE AND IMMUNITY
The inspired air is contaminated with toxic gases, particulates and microbes. The first line of defence of the lung is made up of the complex physical shape of the conducting upper and lower airways, causing a highly turbulent airflow that facilitates the impaction, sedimentation and deposition of particulate matter and microorganisms on the mucosa, followed by the removal of these deposited particles by the mucociliairy blanket and/or the physical expulsion from the respiratory tract by sneezing, coughing or swallowing. Reductions in the cough reflex are associated with increased frequency of respiratory infections, but it is not known at present whether this would also predispose to development of bronchiectasis [5]. The presence of isolated middle lobe bronchiectasis and colonisation with nontuberculous mycobacteria (the so-called Lady Windermere syndrome) has been proposed to be caused by cough suppression [6]. The action of the mucociliary blanket is a dynamic and complexly regulated escalator for bringing inhaled particles to the throat so that they can be swallowed. Defects in the function of the mucociliary blanket can cause bronchiectasis. The conducting airways are lined with ciliated epithelium and the structure and function of the cilia in propulsing mucus has been extensively studied [7–9]. Genetic defects in the structure of the outer dynein arm proteins that connect microtubules in cilia are the cause of primary ciliary dyskinesia [10]. Other mutations involve the ktu gene, which is involved in the assembly of both the outer dynein and the inner dynein arm [11]. Defects in radial spoke head proteins are associated with abnormalities of the central microtubule pair of the cilium (presence of only one microtubulus rather than two) [10]. Ciliary disturbances (sometimes associated with situs inversus; Kartagener syndrome) almost always lead to bronchiectasis and are often also associated with chronic rhinosinusitis. The correct movement of cilia and function of the mucociliary escalator also depend on the low viscosity of the periciliary fluid layer, physically a hydrated sol layer, allowing sufficient separation between the apical side of the epithelium and the viscous mucous blanket covering the cilia. If the periciliary fluid layer is concentrated (i.e. like in cystic fibrosis (CF)), the periciliary fluid layer becomes thinner and the cilia become entangled in the mucus layer, thus impeding normal ciliary propulsion of the mucus [12, 13].
Humoral innate immune mechanisms in the lung Innate immune defences are evolutionary conserved pathways of defence that kill microbes in a generic pathway, often relying on the recognition and antagonism of common motifs in microbial proteins or lectins, the so-called pathogen-associated molecular patterns (PAMPs), which are so crucial for the function of the microbe that their antagonism leads to loss of pathogenicity. Just like acquired or adaptive immunity, innate immunity consists of a humoral and a cellular part.
12
Humoral innate defence mechanisms are elaborate in the lung and consist of lactoferrin, lyzozyme, defensins, complement, cathelicidins and collectins [14]. These molecules can be produced by airway structural cells or by recruited innate immune cells such as neutrophils and macrophages (see later). Lactoferrin chelates Fe2+ molecules that are crucial for the growth of some bacteria but also stimulates the function of neutrophils. Lyzozyme degrades Gram-positive cell walls. Defensins are made by neutrophils (a-defensins) and epithelial cells (b-defensins). They serve to make pores in bacterial cell walls, and thus are truly antibacterial peptides but also neutralise viruses and fungi and recruit DCs via activation of the CCR6 chemokine receptor on these cells [15]. The proper function of defensins depends on the correct salt concentration in the airway surface liquid [16]. Thus, in CF patients defensin function against Staphylococcus aureus is defective, possibly explaining the susceptibility to colonisation, although this theory has also been questioned. LL37 is a well-known airway cathelicidin that is also salt sensitive and has broad antimicrobial activity but
also has effects on innate and adaptive immune cells [17]. Surfactant protein A and D are collectins that opsonise bacteria and viruses such as influenza. A closely related collectin family member is mannose binding lectin (MBL), it is not secreted into the lung lining fluid but is an important circulating factor that can activate the complement cascade. Deficiency of MBL is a cause of recurrent bacterial infections and could be a cause of bronchiectasis. Low MBL levels in CF patients and other forms of bronchiectasis are also associated with a more rapid decline in lung function [18].
Cellular innate immune mechanisms in the lung The cellular arm of innate immunity in the lung is primarily made up of alveolar macrophages and recruited neutrophils (fig. 1). Alveolar macrophages serve an important function in the phagocytosis, killing and/or neutralisation of inhaled particulate antigens. Resident alveolar macrophages continuously encounter inhaled substances due to their exposed position in the alveolar lumen. These cells are packed with enzymes, metabolic products and cytokines that are vital to defence of the alveolar space but can potentially damage the alveolocapillary membrane. To avoid collateral damage to type I and type II alveolar epithelial cells (AEC) in response to harmless antigens, they are kept in a quiescent state, producing few inflammatory cytokines [19]. It has been estimated previously, that the pool of alveolar macrophages can handle up to 109
B.N. LAMBRECHT ET AL.
Stimulus
Ingestion by alveolar macrophages Direct triggering of epithelial cells Activation of dendritic cells
Secondary neutrophil influx
TNF-α, IL-1, G-CSF, GM-CSF, chemokines (IL-8)
13
Figure 1. When a pathogen enters the lung, it triggers both epithelial cells, macrophages and dendritic cells. The epithelial cells make chemokines that subsequently attract neutrophils that help in phacocytosing the pathogens. All recruited cells together with epithelial cells then make cytokines and growth factors that further enforce innate immune responses to the pathogen by further recruitment of inflammatory cells. TNF: tumour necrosis factor; IL: interleukin; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating factor.
14
PULMONARY DEFENCE AND IMMUNITY
intratracheally injected bacteria before there is spill-over of bacteria to DCs and before adaptive immunity is induced [20]. Elegant studies have demonstrated that in vivo elimination of alveolar macrophages using clodronate filled liposomes lead to overt inflammatory reactions to otherwise harmless particulate and soluble antigens [21], but also to an increased sensitivity to bacterial, fungal and viral infection. In their exposed position, alveolar macrophages serve as the first line of defence against inhaled pathogens not only by directly acting as the main phagocytes, but also as an important producer of pro-inflammatory chemokines, cytokines and lipid mediators; bioactive mediators that recruit other cell types to the lung. In contrast to alveolar macrophages that reside in the lung and serve as an immediate line of innate defence against inhaled pathogens, neutrophils are recruited within minutes following inoculation of microbes into the lung. The main function of neutrophils is phagocytosis and killing of microbes, particularly fungi such as Aspergillus sp. and Pneumocystis jeroveci. They can also kill microorganisms through the release of a-defensins and lyzozyme. Neutrophil killing function depends on oxidative enzymes such as those of the NADPH oxidase system and myeloperoxidase. Chronic granulomatous disease is caused by missense, nonsense, frameshift, splice or deletion mutations in the genes for p22(phox), p40(phox), p47(phox), p67(phox) (autosomal chronic granulomatous disease) or gp91(phox) (X-linked chronic granulomatous disease), which result in variable production of neutrophil-derived reactive oxygen species [22]. Neutrophil extravasation is also a highly organised process requiring the rolling, arrest and diapedesis of cells on the vessel wall. Defects in certain integrins, selectins or their activator can cause defective neutrophil recruitment and cause recurrent pulmonary infections [23]. Once recruited, neutrophils can also further enhance more neutrophil recruitment through production of cytokines (interleukin (IL)-1, tumour necrosis factor (TNF)-a and IL-6) as well as through release of calcium binding proteins of the S100 family (S100A8, A9 and A12) that act on the RAGE (receptor for advanced glycation end products) receptor.
Induction of innate immune responses in the lung The above mechanisms of innate defence act in a coordinated fashion. Although a single aspect of the innate defence system can be triggered directly through recognition of foreign PAMPs, the innate defence mechanisms are often induced simultaneously via triggering of common receptors on both phagocytes (for cellular defences) and epithelial cells (for inducing the production of humoral innate defence mechanisms). The most famous pattern recognition receptors belong to the family of Toll-like receptors (TLR)1-11, NOD-like receptors, RIG-I-like receptors and C-type lectin receptors [24]. These receptors recognise particular conserved PAMPs on specific groups of microbes. The archetypical TLR4 is expressed at the cell surface and recognises the Gram-negative cell wall component lipopolysaccharide, whereas TLR2 recognises peptidoglycan and TLR5 recognises bacterial flagellin. The endosomal TLR receptors TLR3 recognise double-stranded RNA, TLR7 and TLR8 single-stranded RNA and TLR9 unmethylated CpG motifs [24]. The exact cellular localisation and downstream signalling mechanisms of these pathways have been studied extensively over the past few years and several clinical primary immunodeficiency syndromes have been brought back to deficiencies in one of the signalling intermediates of these pathways. Deficiency of IRAK4, a critical intermediary in TLR4 signalling causes recurrent bacterial infections, particularly at a young age [25]. Deficiency of the C-type lectin receptor dectin-1 or the downstream signalling intermediate molecule CARD9 causes immunodeficiency to candida and P. jeroveci, most probably due to reduced induction of T-helper cell (Th)17 responses [26]. Conversely, over activity of these signalling cascades, for example caused by small polymorphisms in or mutations of negative regulators of these pathways are associated with auto-immunity and overzealous inflammatory pathways. As one example, polymorphisms in the ubiquitin editing enzyme TNF-a-induced protein 3 (TNFAIP3, also known as A20), cause hypersensitivity of TLR and cytokine receptors and are often found in patients with systemic lupus erythematosus [27]. Our own unpublished data also show that genetic deficiency of A20 in epithelial cells causes severe mucosal inflammation in response to inhalation of intrinsically harmless proteins, but it is
unknown at present how this could be implicated in the regulation of inflammatory pathways relevant to bronchiectasis.
Adaptive cellular immunity Like innate immunity, adaptive or acquired immunity consists of a cellular and a humoral arm. Cellular adaptive immunity is made up of different types of T-lymphocytes, whereas humoral immunity is made up of B-lymphocytes and plasma cells and their secreted product; immunoglobulins (Ig).
DCs are potent antigen presenting cells that have emerged as key regulators of adaptive immunity (see [28] for a more detailed review on the biology of lung DC function). The general function of lung DCs is to recognise and pick up foreign antigens at the periphery of the body, and subsequently migrate to the draining mediastinal lymph nodes where the antigen is processed into immunogenic peptides and displayed on major histocompatibility complex (MHC)I and MHCII molecules for presentation to naı¨ve T-cells. In fact, these cells should be seen as specialised cells of the mononuclear phagocyte system, which have evolved from the cells of the innate immune system to control adaptive immunity that came later in evolution [29]. DCs express all the pattern recognitions receptors shared with phagocytes of the innate immune system, yet at the same time also have the machinery to talk to T-cells and B-cells and relay information about the type of antigen to these cells, so that a tailor-made adaptive response is induced and long-term memory is initiated. As these cells respond to many noxious stimuli from both the outside world (PAMPs) and from within (danger-associated molecular patterns) and at the same time closely communicate with lung structural cells such as alveolar epithelial cells, endothelial cells and fibroblasts, it has been proposed that they could be crucial players in many lung diseases, particularly where T-cell responses are involved in initiation of maintenance of the disease [30]. Very recently the first case reports of patients presenting with defects in the DC system have been reported. These DC-deficient patients are at risk of severe viral skin infections and pulmonary infections with atypical mycobacteria, which also leads to bronchiectasis [31, 32]. Our own experiments employing DC-deficient mice have elucidated a crucial role for these cells in the induction of antiviral immunity to influenza virus, via induction of both CD4 and CD8 T-cell responses [33]. Similar conclusions have been reached in models of tuberculosis and bacterial lung infections [34]. Conversely, DCs are also heavily involved in maintaining immunopathology in which T-cells play a predominant role, the best example being the mucosal inflammation seen in asthma and chronic obstructive pulmonary disease (COPD) [35]. In humans with bronchiectasis, as well as in a rat model of bronchiectasis, there is an increased infiltration of the airway wall with DCs [2, 3]. The airways of patients with diffuse panbronchiolitis, a disorder of the small bronchioles that can also lead to bronchiectasis, contain increased numbers of DCs that have a clearly activated phenotype, while treatment with neomacrolides reduces the antigen presenting capacities of these DCs [36, 37].
B.N. LAMBRECHT ET AL.
Induction of adaptive cellular immunity by DCs
Constituents of adaptive cellular immunity
15
Adaptive cellular immunity consists of defined subsets of CD4+ Th cells and CD8+ cytotoxic Tcells. Once DCs transport their antigenic cargo to the draining lymph nodes, they induce the proliferation and differentiation of naı¨ve T-cells into particular types of T-cell responses (fig. 2). Discrete types of Th cells provide crucial help for different parts of the innate and adaptive immune response [38]. Th1 cells make interferon (IFN)-c and mainly provide help to monocytic cells, including macrophages and DCs, thus enforcing killing of intracelullar pathogens, and at the same time enforcing opsonisation of these through provision of B-cell help. Conversely, Th2 cells make IL-4, IL-5 and IL-13 providing help to eosinophils, mast cells and basophils to eliminate
IL-4
Th2 Gata-3 c-maf STAT6
IL-10 TGF-β Th0
Treg
IL-4 IL-5 IL-13 TNF-α
IL-10 TGF-β
Foxp3 IL-6 TGF-β IL-1 IL-23
IL-12
Th17
IL-17 IL-22
RORγ STAT3
Th1 T-bet STAT4 STAT1
IFN-γ TNF-α
complex helminths, and at the same time induce IgG1 and IgE from Bcells to arm the basophils and mast cells with effector potential. For a long time since the original description of the Th1/Th2 concept, it has been unclear which subtype of TAnti-inflammatory Suppresses lymphocytes cell help was important for induProfibrotic? cing neutrophilic responses and protection from extracellular pathogens such as fungi. This gap has Antifungal been breached recently by the disStimulates neutrophils covery of the cytokines IL-17 and Autoimmunity IL-22 which are produced by Th17 cells that induce neutrophilic inflammation and production of defensins Intracellular pathogens Stimulates macrophages by epithelial cells and are important Stimulates lgG2a for clearance of fungi and extracelDelayed hypersensitivity lular bacteria [39].
Antihelminthic Stimulates eosinophils Stimulates lgE, lgG1 Allergy
The precise signals that induce different types of Th lineage-comtheir secreted cytokines. When a T-helper cell (Th) type 0 encounters mitment of naı¨ve T-cells has been antigen on a DC, it will be induced to differentiate into various intensely studied [38]. Antigen premutually exclusive cell fates. Each T-cell differentiation programme is senting cells can provide different controlled by transcription factors such as Gata-3, forkhead box P3 levels and quality of signal one (Foxp3), RAR-related orphan receptor gamma (RORc) or T-bet, which enforce Th cell lineage choice. Eventually Th cells emerge (peptide-MHC), signal two (cothat are specialised for performing various antimicrobial tasks. stimulatory molecules) and signal IL: interleukin; Treg: T-regulatory cell; TGF: transforming growth three (instructive cytokines) to factor; TNF: tumour necrosis factor; IFN: interferon; Ig: immunoglonaı¨ve T-lymphocytes upon antigen bulin; STAT: signal transducer and activator of transcription. encounter and triggering of their pattern recognition receptors [29]. When stimulated through the unique T-cell receptor (TCR), naı¨ve CD4+ T-cells differentiate into Th1 cells in the presence of high amounts of IL-12. IL-12 instructs Th1 development via activation of signal transducer and activator of transcription (STAT)4 and the lineage instructing transcription factor T-bet. IL-17 producing cells are induced when exposed to a cocktail of cytokines including transforming growth factor (TGF)-b, IL-6, and IL1a/b, while IL-23 further enhances the proliferation of these cells. The Th17 lineage specific transcription factor RAR-related orphan receptor ct enforces Th17 characteristics in naı¨ve T-cells, and is induced by the cocktail of cytokines instructive to their development. The mechanisms leading to Th2 cell differentiation in vivo are still poorly understood, but in most instances require a source of IL-4 to activate the transcription factors STAT6 and GATA-3, and a source of IL-2, IL-7 or thymic stromal lymphopoietin to activate the transcription factor STAT5 [40–44]. Despite the overwhelming evidence that IL-4 is necessary for most Th2 responses, DCs were, however, never found to produce IL-4 and it was therefore assumed that Th2 responses would occur by default, in the absence of strong Th1 or Th17 instructive cytokines in the immunological DC T-cell synapse, or when the strength of the MHCII-TCR interaction or the degree of co-stimulation offered to naı¨ve T-cells was weak [45–48]. In this model, naı¨ve CD4 T-cells were the source of instructive IL-4. In an alternative view, IL-4 is secreted by an accessory innate immune cell type, such as natural killer T-cells, eosinophils, mast cells or basophils, that provide IL-4 in trans to activate the Th2-differentiation programme [49]. In the lung allergic response to house dust mite allergen, we have recently found that basophils help DCs to induce Th2 immunity by providing an important, but not essential source of IL-4 [50].
PULMONARY DEFENCE AND IMMUNITY
Figure 2. T-cell polarisation induced by dendritic cells (DCs) and
16
Lung DCs are also essential in instructing the selection and expansion of CD8 cytotoxic T-cells that recognise virus-infected cells, cells infected with intracellular bacteria and tumourally
transformed cells via presentation of endogenous cellular antigen on the MHCI complex [33]. An important conceptual point is that DCs do not have to be infected themselves to perform this task, but can phagocytose virally infected or transformed cells and use the process of cross-presentation to present the exogenous antigen into their MHCI loading machinery. Once activated by DCs and CD4 T-cell help, cytotoxic T-cells can lyse and kill infected cells in a process requiring granzyme and/or perforin, or kill target cells in a FasL- and/or TNF receptor-like apoptosis inducing liganddependent manner, causing apoptotic cell death in targets [51].
Humoral immune mechanisms in the lung Humoral immunity plays a predominant role in protection from severe infections with encapsulated bacterial strains. Antibodies are well known for their neutralising effects on secondary infections and this is the principle of most vaccinations against childhood infections. During a primary infection, however, antibodies, some of which have broad-spectrum specificity (so-called natural antibodies), also have the capacity to activate complement and opsonise bacterial cell walls and capsules, thus facilitating clearance of the pathogens. Antibodies of the IgA and IgG class are actively secreted into the airway lumen via the action of the polymeric Ig receptor. Airway luminal IgA is an important defence against viral entry. Maybe the most prevalent cause of bronchiectasis is deficiencies in humoral immunity, such as common variable immunodeficiency (CVID), a group of disorders characterised by low to absent Ig and various degrees of T-lymphocyte abnormalities [18, 58]. CVID can be caused by mutations in the proteins involved in T–B-cell communication such as ICOS, BAFF, TACI and APRIL [59, 60]. This is a rapidly evolving field and it is only a matter of time before all these mutations can be diagnosed on a routine basis.
B.N. LAMBRECHT ET AL.
Several defects in adaptive immunity are associated with increased susceptibility to lung infection and can be an important risk factor for later development of bronchiectasis. Defects in the IL-12/ IFNcSTAT1 axis are a well-known risk factor for mycobacterial infections and invasive Salmonellosis [52]. Defects in the IL-23//Th17 axis are associated with increased risk of fungal infections and P. jeroveci infections [53]. Patients with sporadic or autosomal dominant forms of the hyper IgE syndrome (Job’s syndrome when associated with connective tissue abnormalities) have mutations in STAT3, and hence deficient differentiation of Th17 cells [54, 55]. These patients are at risk for severe recurrent Staphyloccal infections, pneumatocoeles and mucocutaneous candidiasis. In recessive forms of the hyper IgE syndrome, mutations in DOCK8 have been described, and these patients are similarly at risk for recurrent sinopulmonary infection and have defects in Th17 generation [56]. The few biopsy studies that have been performed in bronchiectasis have seen increased infiltration of the bronchial wall with CD4 and CD8 T-cells. The neutrophilic inflammation seen in CF and other forms of bronchiectasis is typically associated with the increased presence of Th17 cells [57]. In bronchiectasis associated with allergic bronchopulmonary aspergillosis, one has also observed increased numbers of Th2 cells, thus explaining the association with sputum eosinophilia.
Organised lymphoid structures and bronchiectasis
17
The organised accumulation of lymphocytes in lymphoid organs serves to optimise both homeostatic immune surveillance, as well as chronic responses to pathogenic stimuli [61]. During embryonic development, circulating haemopoietic cells gather at predetermined sites throughout the body, where they are subsequently arranged in T- and B-cell specific areas, leading to the formation of secondary lymphoid organs, such as lymph nodes and spleen. In contrast, the body has a limited second set of selected sites that support neo-formation of organised lymphoid aggregates in adult life. However, these are only revealed at times of local, chronic inflammation when so-called tertiary lymphoid organs (TLO) appear. Just like in lymph nodes and spleen, areas of TLO are characterised by formation of specialised high endothelial venules and the organised
production of chemokines leads to cellular organisation of T-cells and B-cells in discrete areas. In humans, TLO has been observed in the joint and lung of rheumatoid arthritis [62], around the airways of COPD patients [63] and in the thyroid [64]. Certain infectious diseases are also accompanied by the formation of TLO. Influenza virus infection of the respiratory tract leads to formation of inducible bronchus-associated lymphoid tissue (iBALT) that supports T- and B-cell proliferation and productive Ig class switching in germinal centres [65, 66]. Tertiary lymphoid follicles or iBALT is frequently seen in tubular bronchiectasis, and the close association with bronchi might explain the obstruction of small bronchioles and airway obstruction that is often seen. This is certainly the case in rheumatoid arthritis-associated bronchiectasis, in which bronchial obstruction is often caused by strongly enlarged TLOs that impinge on the lumen of the airway, an entity known as follicular bronchiolitis by pathologists and reflecting the presence of B-cell follicles inside TLO structures [62]. Formation of TLO could be the result of chronic colonisation of bronchiectatic airways by microbes, and indeed it has been proposed that latent adenoviral infection is a cause of follicular bronchiectasis [4]. However, in one school of thought, TLO formation can also be seen as a source of self-specific autoantibodies and a reflection of an underlying auto-immune component of the disease. In TLO associated with rheumatoid arthritisbronchiectasis, one has indeed seen the production of pathogenic antibodies to citrullinated proteins [62].
18
PULMONARY DEFENCE AND IMMUNITY
Anti-inflammatory pathways With its large surface area, the lung is a portal of entry for many pathogens as inhaled air is contaminated with infectious agents, toxic gases and (fine) particulate matter. At the same time, inhaled microbes and toxic substances can gain easy access to the bloodstream across the delicate alveolar–capillary membrane. Innate and adaptive immune defence of this vulnerable barrier is not easy and needs to be tightly controlled as too much oedema, inflammation and cellular recruitment will lead to thickening of the alveolar wall and will jeopardise the diffusion of oxygen vital to life. Considering the large surface area of the respiratory epithelium and the volume of air inspired on a daily basis it is remarkable that there is so little inflammation under normal conditions, suggesting the presence of regulatory mechanisms that act to protect the gas-exchange mechanism. Even following severe bacterial or viral infection, a return to homeostasis is the usual outcome. Understanding the conditions by which lung immune homeostasis is regulated might be crucial to advance our insight into the pathogenesis of inflammatory lung diseases such as bronchiectasis. One type of cell that has received particular attention in suppressing immune responses in the lung is the alveolar macrophage. Alveolar macrophages adhere closely to AECs at the alveolar wall and are separated by only 0.2–0.5 mm from interstitial DCs. In macrophagedepleted mice, the DCs have a clearly enhanced antigen presenting function [67]. When mixed with DCs in vitro, alveolar macrophages suppress T-cell activation through the release of nitric oxide (mainly in rodents), prostaglandins, IL-10 and TGF-b. Alveolar macrophages also express CD200R, an inhibitory receptor that regulates the strength of innate immunity to inhaled pathogens. Another cell type that has received a lot of attention is the regulatory T-cell (Treg). Natural Tregs express high levels of CD25 and express the lineage specific transcription factor Foxp3 [68]. These cells are generated in the thymus and have a natural reactivity for self antigens as well as some foreign antigens, and mainly suppress autoimmunity [69]. Induced Tregs are generated when DCs encounter self antigen in the periphery or upon chronic immune stimulation. It is assumed that these induced Tregs serve to dampen overt immune activation to stimuli that cannot be fully eliminated, a typical example being chronic helminth infections or mycobacterial infections [70]. As bronchiectasis is a disorder of chronic inflammation accompanied by microbial colonisation, it is very likely that increased Tregs are found inside lesions, although this has not been formally addressed. It is also possible that failure of Treg function at a certain stage of the disease contributes to ongoing inflammation, which might ultimately progress to fibrosis. In this regard it is a striking observation that Tregs also make TGF-b as part of their suppressive programme. TGF-b might be at the crossroads of immunoregulation and fibrosis initiation.
Immune regulation might also stem from changes in stromal cells of the airways, such as epithelial cells. Airway epithelial cells play a predominant role in deciding whether or not an acute or chronic stimulus like endotoxin is recognised or not [71]. Epithelial cells express many pattern recognition receptors and the sensitivity of these can be regulated through negative regulators of signalling. Finally, some epithelial derived cytokines, such as IL-37, have an intrinsically antiinflammatory effect on innate immunity in the lung [72]. It is currently unknown if defects in these counter-regulatory mechanisms are involved in the maintenance of inflammation in patients with bronchiectasis.
Conclusion There has been great progress in our knowledge of innate and adaptive immune responses in the lung. Immune defects in innate and adaptive cellular and humoral immunity can all lead to bronchiectasis. In contrast to other obstructive airway diseases, such as asthma and COPD, we have not yet fully grasped the immunopathogenesis of chronic inflammation in this disorder.
Support statement
None declared.
References 1. Katzenstein AL. Nonspecific inflammatory and destructive diseases. In: Katzenstein AL, ed. Katzenstein and Askins’s Surgical Pathology of Non-Neoplastic lung disease. Philadelphia, W.B. Saunders, 1997; pp. 422–425. 2. Lapa e Silva JR, Guerreiro D, Noble B, et al. Immunopathology of experimental bronchiectasis. Am J Respir Cell Mol Biol 1989; 1: 297–304. 3. Silva JR, Jones JA, Cole PJ, et al. The immunological component of the cellular inflammatory infiltrate in bronchiectasis. Thorax 1989; 44: 668–673. 4. Bateman ED, Hayashi S, Kuwano K, et al. Latent adenoviral infection in follicular bronchiectasis. Am J Respir Crit Care Med 1995; 151: 170–176. 5. Barber CM, Curran AD, Fishwick D. Impaired cough reflex in patients with recurrent pneumonia. Thorax 2003; 58: 645–646. 6. Reich JM, Johnson RE. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101: 1605–1609. 7. Cowan MJ, Gladwin MT, Shelhamer JH. Disorders of ciliary motility. Am J Med Sci 2001; 321: 3–10. 8. de Iongh RU, Rutland J. Ciliary defects in healthy subjects, bronchiectasis, and primary ciliary dyskinesia. Am J Respir Crit Care Med 1995; 151: 1559–1567. 9. Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008; 134: 351–357. 10. Zariwala MA, Knowles MR, Omran H. Genetic defects in ciliary structure and function. Annu Rev Physiol 2007; 69: 423–450. 11. Omran H, Kobayashi D, Olbrich H, et al. Ktu/PF13 is required for cytoplasmic pre-assembly of axonemal dyneins. Nature 2008; 456: 611–616. 12. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 1998; 95: 1005–1015. 13. Matsui H, Randell SH, Peretti SW, et al. Coordinated clearance of periciliary liquid and mucus from airway surfaces. J Clin Invest 1998; 102: 1125–1131. 14. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23: 327–333.
19
Statement of interest
B.N. LAMBRECHT ET AL.
B.N. Lambrecht is supported by grants from Fonds voor Wetenschappelijk Onderzoek Flanders (Odysseus Program), European Research Council (ERC) starting grant and Multidisciplinary Research Platform (GROUP-ID consortium) of University of Ghent, Ghent, Belgium. K. Neyt is supported by a fellowship of FWO Flanders.
PULMONARY DEFENCE AND IMMUNITY
20
15. Yang D, Chertov O, Bykovskaia SN, et al. b-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999; 286: 525–528. 16. Garcia JR, Krause A, Schulz S, et al. Human b-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J 2001; 15: 1819–1821. 17. Shaykhiev R, Sierigk J, Herr C, et al. The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS. FASEB J 2010; 24: 4756–4766. 18. Gregersen S, Aalokken TM, Mynarek G, et al. Development of pulmonary abnormalities in patients with common variable immunodeficiency: associations with clinical and immunologic factors. Ann Allergy Asthma Immunol 2010; 104: 503–510. 19. Holt PG. Inhibitory activity of unstimulated alveolar macrophages on T-lymphocyte blastogenic responses. Am Rev Respir Dis 1978; 118: 791–793. 20. MacLean JA, Xia WJ, Pinto CE, et al. Sequestration of inhaled particulate antigens by lung phagocytes: a mechanism for the effective inhibition of pulmonary cell-mediated immunity. Am J Pathol 1996; 148: 657–666. 21. Thepen T, Van Rooijen N, Kraal G. Alveolar macrophage elimination in vivo is associated in vivo with an increase in pulmonary immune responses in mice. J Exp Med 1989; 170: 494–509. 22. Kuhns DB, Alvord WG, Heller T, et al. Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010; 363: 2600–2610. 23. Moser M, Bauer M, Schmid S, et al. Kindlin-3 is required for b2 integrin-mediated leukocyte adhesion to endothelial cells. Nat Med 2009; 15: 300–305. 24. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010; 11: 373–384. 25. Ku CL, Picard C, Erdos M, et al. IRAK4 and NEMO mutations in otherwise healthy children with recurrent invasive pneumococcal disease. J Med Genet 2007; 44: 16–23. 26. Ferwerda B, Ferwerda G, Plantinga TS, et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med 2009; 361: 1760–1767. 27. Musone SL, Taylor KE, Lu TT, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008; 40: 1062–1064. 28. Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of asthma. Immunity 2009; 31: 412–424. 29. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–252. 30. van Rijt LS, Jung S, Kleinjan A, et al. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J Exp Med 2005; 201: 981–991. 31. Bigley V, Haniffa M, Doulatov S, et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J Exp Med 2011; 208: 227–234. 32. Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115: 1519–1529. 33. GeurtsvanKessel CH, Willart MA, van Rijt LS, et al. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells. J Exp Med 2008; 205: 1621–1634. 34. Jiao X, Lo-Man R, Guermonprez P, et al. Dendritic cells are host cells for mycobacteria in vivo that trigger innate and acquired immunity. J Immunol 2002; 168: 1294–1301. 35. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010; 376: 835–843. 36. Ishida Y, Abe Y, Harabuchi Y. Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes. Int J Pediatr Otorhinolaryngol 2007; 71: 297–305. 37. Todate A, Chida K, Suda T, et al. Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162: 148–153. 38. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol 2010; 28: 445–489. 39. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28: 454–467. 40. Kopf M, Le Gros G, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 245–248. 41. Le Gros G, Ben-Sasson SZ, Seder R, et al. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4- producing cells. J Exp Med 1990; 172: 921–929. 42. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10: 225–235. 43. Seder RE, Paul WE, Davis MM, et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. J Exp Med 1992; 176: 1091–1098. 44. Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587–596. 45. Constant S, Pfeiffer C, Woodward A, et al. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4 T cells. J Exp Med 1995; 182: 1591–1596.
B.N. LAMBRECHT ET AL.
21
46. Jankovic D, Kullberg M, Caspar P, et al. Parasite-induced Th2 polarization is associated with down-regulated dendritic cell responsiveness to Th1 stimuli and a transient delay in T lymphocyte cycling. J Immunol 2004; 173: 2419–2427. 47. Lambrecht BN, De Veerman M, Coyle AJ, et al. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000; 106: 551–559. 48. Stumbles PA, Thomas JA, Pimm CL, et al. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 1998; 188: 2019–2031. 49. Ben-Sasson SZ, Le Gros G, Conrad H, et al. Cross-linking Fc receptors stimulate splenic non-B, non-T cells to secrete interleukin 4 and other lymphokines. Proc Natl Acad Sci USA 1990; 87: 1421–1425. 50. Hammad H, Plantinga M, Deswarte K, et al. Inflammatory dendritic cells – not basophils – are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen. J Exp Med 2010; 207: 2097–2111. 51. Hufford MM, Kim TS, Sun J, et al. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med 2011; 208: 167–180. 52. Holland SM. Interferon c, IL-12, IL-12R and STAT-1 immunodeficiency diseases: disorders of the interface of innate and adaptive immunity. Immunol Res 2007; 38: 342–346. 53. Bai H, Cheng J, Gao X, et al. IL-17/Th17 promotes type 1 T cell immunity against pulmonary intracellular bacterial infection through modulating dendritic cell function. J Immunol 2009; 183: 5886–5895. 54. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452: 773–776. 55. Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448: 1058–1062. 56. Zhang Q, Davis JC, Lamborn IT, et al. Combined immunodeficiency associated with DOCK8 mutations. N Engl J Med 2009; 361: 2046–2055. 57. Dubin PJ, McAllister F, Kolls JK. Is cystic fibrosis a TH17 disease? Inflamm Res 2007; 56: 221–227. 58. Sweinberg SK, Wodell RA, Grodofsky MP, et al. Retrospective analysis of the incidence of pulmonary disease in hypogammaglobulinemia. J Allergy Clin Immunol 1991; 88: 96–104. 59. Bayry J, Hermine O, Webster DA, et al. Common variable immunodeficiency: the immune system in chaos. Trends Mol Med 2005; 11: 370–376. 60. Grimbacher B, Hutloff A, Schlesier M, et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nature Immunol 2003; 4: 261–268. 61. Cupedo T, Mebius RE. Cellular interactions in lymph node development. J Immunol 2005; 174: 21–25. 62. Rangel-Moreno J, Hartson L, Navarro C, et al. Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 2006; 116: 3183–3194. 63. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645–2653. 64. Marinkovic T, Garin A, Yokota Y, et al. Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J Clin Invest 2006; 116: 2622–2632. 65. GeurtsvanKessel CH, Willart MA, Bergen IM, et al. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 2009; 206: 2339–2349. 66. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10: 927–934. 67. Holt PG, Oliver J, Bilyk N, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 1993; 177: 397–407. 68. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061. 69. Watanabe N, Wang YH, Lee HK, et al. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005; 436: 1181–1185. 70. Grainger JR, Smith KA, Hewitson JP, et al. Helminth secretions induce de novo T cell Foxp3 expression and regulatory function through the TGF-b pathway. J Exp Med 2010; 207: 2331–2341. 71. Hammad H, Chieppa M, Perros F, et al. House dust mite allergen induces asthma via toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15: 410–416. 72. Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol 2010; 11: 1014–1022.
Chapter 3
Histopathology of bronchiectasis M. Goddard
HISTOPATHOLOGY
Summary The clinical presentation of bronchiectasis occurs after initial irreversible damage to the airway has occurred. The clinician then has to control symptoms and limit the progression of the disease. A clearer understanding of the pathogenesis of this disease will enable the development of better treatment strategies. Bronchiectasis is a multi-factorial disease process in which there are a number of key steps, although they are not always clinically identifiable. There is often an initiator or damaging event such as a viral infection which, in an individual with a predisposing risk such as a degree of immune dysfunction or an impaired mucociliary clearance system, leads to persistent and damaging bacterial infections. These infections go on to provoke an inappropriate and self-damaging inflammatory response in which neutrophil activity leads to progressive tissue damage and a relentless cycle of infection, inflammation and bronchial wall injury. Persistent infection and chronic inflammatory cell infiltration further amplify the local inflammatory milieu and may lead to systemic complications. Keywords: Aetiology, bronchiectasis, histopathology, inflammation, neutrophils, pathogenesis
Correspondence: M. Goddard, Dept of Pathology, Papworh Hospital NHS Foundation Trust, Papworth Everard, Cambridge, CB23 3RE, UK, Email
[email protected]
Eur Respir Mon 2011. 52, 22–31. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003310
B
ronchiectasis was first described at the beginning of the 19th century by LAENNEC [1]. He ascribed the term to the pooling of secretions in the airways leading to wall weakening and dilatation. Whilst the term is often used loosely by radiologists to describe any airway dilatation, pathologically the term is used to describe an irreversible dilatation of the airway often associated with chronic suppuration.
Aetiology and classification Aetiologically, bronchiectasis may be divided into obstructive and nonobstructive types (table 1).
22
In the obstructive type of bronchiectasis airway dilation may develop from obstruction due to any cause. The disease is confined to the airways distal to the obstruction. Causes of obstruction may be luminal, such as the inhalation of foreign bodies. This is most common in children and shows a
The pathogenesis of obstructive bronchiectasis is relatively straightforward, as bronchial secretions accumulate distal to the obstruction and become infected producing inflammation and damage to the bronchial wall which becomes weakened and dilated. This was recognised by LAENNEC [1].
Table 1. Causes of bronchiectasis Bronchial obstruction Foreign bodies Tumours Carcinoid tumours Endobronchial chondromas and lipomas Mucous plugs ABPA Nonobstructive Post-infective Measles Adenovirus Pertussis Tuberculosis Mucociliary abnormalities Cystic fibrosis Ciliary dysmotility syndromes Primary ciliary dyskinesia Immunological abnormalities Hypogammaglobulinaemia IgA and IgG sub-class deficiencies Neutrophil function abnormalities Ataxia telangiectasia Associated with systemic diseases Rheumatoid arthritis Sjo¨gren’s syndrome Ankylosing spondylitis a1-antitrypsin deficiency Pulmonary fibrosis ABPA: allergic bronchopulmonary aspergillosis;
There have been several attempts to classify nonIg: immunoglobulin. obstructive bronchiectasis, which are variably based on a mixture of historic bronchographic and, more recently, high-resolution computed tomography (HRCT), appearances (saccular or cystic, fusiform or cylindric) [10] and histological appearances (follicular) with lymphoid follicles in the wall, as defined by WHITWELL [11]. Nonobstructive bronchiectasis is typically more widespread, affecting more than one lobe and most commonly affecting the basal segments of the lower lobes [11–13]. The left lung is more frequently affected than the right and the disease process typically involves the middle-order bronchi (fourth to ninth generations).
M. GODDARD
predilection for the right lower lobe and posterior segment of the right upper lobe [2–5]. The risk of developing bronchiectasis following foreign body inhalation has been assessed as 3–16% [6]. However, other causes of obstruction include mucus inspissation in allergic bronchopulmonary aspergillosis (ABPA) [7], with central or upper lobe bronchiectasis, and distal to broncholitis. Tumours may also cause obstruction and bronchiectasis but this is more prevalent in the slower growing often polypoid tumours, such as carcinoid tumours, endobronchial lipomas and chondromas [8]. Extrinsic compression of the bronchus may also lead to obstruction, and typically hilar tuberculous lymphadenopathy can lead to bronchiectasis, particularly of the right middle and lower lobes. The middle lobe, because of its relatively narrow lumen, is at particular risk of compression or obstruction, a condition sometimes referred to as middle lobe syndrome [9].
23
This classification is now probably unsatisfactory and of little pathological significance; although the distribution of changes may provide a clue to the underlying aetiology. Post-infective bronchiectasis is traditionally the most common underlying cause, is most often basal and may be confined to a single lobe. However, nonobstructive bronchiectasis may occur in association with a number of other conditions. In diseases where mucociliary clearance is impaired, bronchiectasis frequently, if not inevitably, develops. In cystic fibrosis [14] and ciliary dysmotility syndromes, such as primary ciliary dyskinesia arising from a defect in the dynein arms [15], bronchiectais is more widespread, sometimes with upper lobe predominance. The association of bronchiectasis with disturbances in mucociliary clearance mechanisms highlights the importance of local defence mechanisms within the airways in aetiological terms and in terms of the pathogenesis of the disease. There may be primary defects in the immune system with abnormalities of neutrophil function, hypogammaglobulinaemia [16], immunoglobulin (Ig)A and IgG sub-class deficiencies [17], and in ataxia telangiectasia. Bronchiectasis may also be associated with some autoimmune conditions including ulcerative colitis [18], rheumatoid disease [19], Sjo¨gren’s syndrome [20] and ankylosing spondylitis. Bronchiectasis is also associated with several noninflammatory conditions within the lung, such as a1-antitrypsin deficiency, and is reported in some cases of pulmonary fibrosis but in these cases may be due to traction effects of the surrounding fibrosis.
Of the known causes or associations of bronchiectasis, childhood infection is probably the most common accounting for up to 30% of cases, with immunodeficiencies present in up to 18%. However, in some studies, no underlying abnormality can be detected in .50% of cases.
Histopathological appearances Histopathologically, bronchiectatic airways appear dilated and on examination have a crosssectional area that is much larger than the accompanying pulmonary artery (fig. 1). The airway lumen is often filled with a mucopurulent exudate with neutrophils and macrophages (figs 2 and 3). The respiratory epithelium lining shows variable changes from a reserve cell hyperplasia to squamous metaplasia (fig. 4) with active inflammation shown by epithelial and mucosal infiltration by neutrophils and in severe exacerbations, ulceration (figs 5 and 6). The bronchial wall is often destroyed due to loss of fibromuscular tissues and the elastic framework, and may show erosion and loss of cartilage [21]. There is usually a reduction in submucosal glands. The wall may be thin but is more often greatly thickened with extensive peribronchial fibrosis extending into the adjacent lung parenchyma (fig. 7) [22]. There is an associated chronic inflammatory cell infiltrate within the wall, predominantly lymphocytes and plasma cells, and in some cases lymphoid follicles with germinal centres may be prominent [23]. The presence of B-cell immune activation through the presence of germinal centres and plasma cells in the walls of bronchiectatic airways, would support the role of antibodies in the immune response to persistent infection. However, bronchiectasis is associated with some autoimmune connective tissue diseases, in particular rheumatoid arthritis [19, 24, 25], and a role for autoimmunity in the destruction of the airway has also been suggested.
HISTOPATHOLOGY
Eosinophils may be seen as part of the infiltrate as with any chronic airways inflammation. Whilst nonspecific, they raise the possibility of an associated fungal infection such as Aspergillus. Although eosinophils are commonly seen in the mucus plugs of ABPA, their presence within the airway wall inflammation is nonspecific. Granulomas and multinucleate giant cells may be seen in the wall and might be a reaction to the inspissated luminal material but the possibility of concomitant fungal or mycobacterial infection should always be considered. In established bronchiectasis, the histological pattern of chronic inflammation within the airway wall with superimposed active inflammation, most likely reacting to concomitant infection, has a fairly uniform appearance and provides little insight into the underlying aetiology or pathogenesis.
24
Figure 1. Low-power view of a bronchiectatic airway; note the airway lumen is much larger than that of the accompanying pulmonary artery. Magnification64.
The surrounding lung parenchyma may show a number of changes. Where there is distal luminal obliteration of bronchi and bronchioles, the lung parenchyma may
The airways are supplied by the bronchial arteries and the inflammatory destruction and healing processes result in the formation of bronchopulmonary anastamoses, probably due to a mixture of new vessel formation and the re-opening of pre-existing, pre-capillary bronchopulmonary connections (fig. 8). Ulceration of the airways can lead to severe haemorrhage and haemoptysis. The formation of anastamoses and the loss of some of the alveolar capillary bed leads to the development of pulmonary hypertension [27].
Figure 2. Bronchiectatic airway wall with dense chronic inflammatory cell infiltrate, which includes lymphocytes, plasma cells and eosinophils. Magnification620.
M. GODDARD
show atelectasis due to absorption and collapse. Obliterative changes in small airways are important in contributing to airflow obstruction in bronchiectasis [10, 11]. Destructive inflammation may lead to the formation of an abscess cavity, although this may be difficult to distinguish from a distended, ulcerated airway. There may be accompanying interstitial pneumonitis, particularly in cases of follicular bronchiectasis, and also changes of an organising pneumonia. Small airway changes, such as bronchiolectasis, may be seen as part of the whole disease process or may be part of an underlying disease leading to more proximal dilatation, as has been seen with small airways disease, such as bronchiolitis [18, 26].
Focal proliferations of neuroendocrine cells are also seen and may lead to the formation of multiple tumourlets, small aggregates of neuroendocrine cells in the walls of small airways. These are not specific to bronchiectasis and may be seen in a number of chronic lung conditions [28].
Figure 3. Bronchiectatic airway wall with luminal pus, neutrophil infiltration of the airway epithelium and a dense chronic inflammatory cell infiltrate. Magnification640.
25
It has also been recognised that the persistent chronic activation of the immune system in the wall of the airway may lead to the development of bronchus-associated lymphoid tissue (BALT), especially in bronchiectasis associated with Sjo¨gren’s syndrome [29]. Increased incidence of BALTomas,
low-grade, B-cell lymphomas, is associated with Sjo¨gren’s syndrome but not specifically related to bronchiectasis [20]. In chronic disease, further complications may arise. Locally, the lung may develop abscesses and even empyema, although this is less common as the pleural space is often obliterated by fibrous adhesions. Bronchiectatic spaces may become colonised by saprophytic fungi, most commonly Aspergillus sp.
HISTOPATHOLOGY
Systemic dissemination of infection may lead to abscesses in other organs, notably the brain, and chronic suppuration may be complicated by systemic amyloidosis (type AA). The incidence in bronchiectasis is unclear but in one study of patients with systemic amyloidosis requiring haemodialysis, 40% had underlying bronchiectasis [30]. Figure 4. Squamous metaplasia of the epithelium lining in bronchiectasis. Magnification640.
Pathogenesis
The pathogenesis of bronchiectasis is complex and a number of different mechanisms contribute to the development of a similar morphological appearance and different factors act together to set up a cycle of inflammation and destruction that leads to damage and destruction of the bronchial wall [31]. The initiator to this sequence is usually damage to the bronchial epithelium. This may be due to an external insult or to an intrinsic deficiency within the patient. The most common predisposing factor to the development of bronchiectasis is a severe childhood respiratory infection, which may be viral, such as measles or adenovirus, or bacterial, such as Bordetella pertussis [32–34]. The resultant permanent dilatation of the airways is thought to be due not only to inflammation and destruction of the bronchial wall but also, in part, to a traction effect produced by collapse of the surrounding lung parenchyma. However, the persistence of infection and inflammation are of paramount importance in the progression of the disease.
Figure 5. Severely inflamed ulcerated bronchiectatic airway with
26
no epithelium and surface granulation tissue. Magnification620.
Whilst an underlying cause is not established in all cases, the number and type of associations for bronchiectasis gives us some indication of what the important underlying pathogenetic mechanisms may be.
In post-infectious causes, the initiating viral infection appears to be transitory and, in the case of adenoviruises, it has not been possible to demonstrate the persistence of the virus within bronchiectasis by in situ hybridisation [35]. However, some respiratory viruses have been shown to lead to abnormalities in ciliary function, which may persist for several weeks [36].
In the early stages of bronchiectasis, the most common bacterial isolate is Haemophilus influenzae, which has the capacity to directly damage the airway epithelium and induce the production of inflammatory mediators [37]. The typical immune response to H. influenzae is a T-helper (Th)1 response. However, some bronchiectasis patients with persistent infection have been found to have a Th2 response with a cytokine profile of interleukin (IL)-4 and IL-10. The release of cytokines contributes to the inflammatory response within the airway and at the same time may also result in a failure of the response to satisfactorily remove the organism [38].
Figure 7. A bronchiectatic airway showing an attenuated inflamed epithelium with surrounding inflammation and fibrosis extending into the peribronchial lung parenchyma. Magnification620.
27
Over time, a number of other organisms have been found to be established within the airways, particularly Streptococcus pneumoniae and Pseudomonas aeruginosa. The initial damage to the epithelium lining allows this secondary bacterial colonisation to occur, which further inhibits ciliary clearance and promotes the persistence of infection and damaging inflammation [39]. The importance of this persistence in bacterial colonisation may be related to the production of heatlabile products by the bacteria, which further damage ciliated cells and inhibit ciliary activity. P. aeruginosa can be a particular problem as it is protected from cellular and humoral attack because it survives in a biofilm on the mucosal surface [40]. Pseudomonas has been shown
M. GODDARD
Clinically, it is the recurrence and persistence of bacterial infections in the airways with which most patients present that are of most importance and are linked to the progression of the disease. There is a Figure 6. Ulcerated airway with surrounding fibrosis of the wall. prevailing view that bacterial infecMagnification610. tion in the lower respiratory tract provokes an exaggerated and uncontrolled neutrophilic response and that the complex interplay between bacterial infection and airway inflammation, along with the release of tissue damaging substances, leads to the progressive damage which typifies bronchiectasis.
to produce phenazine pigments that can inhibit ciliary action through a mechanism which leads to a reduction in cellular cAMP and ATP. Furthermore, pseudomonal pyocyanin can lead to epithelial disruption and rhamnolipids have a ciliostatic effect [41, 42]. Alveolar macrophages are an important mediator of defence against Pseudomonas and stimulated macrophages secrete cytokines that both recruit and activate neutrophils, thus potentially amplifying both the inflammatory response and the potential for further tissue damage [43, 44]. The resultant inflammatory reaction is an important pathogenic mechanwall. Magnification620. ism in the weakening of the bronchial wall. Much of the damage appears to relate to the release of proteolytic enzymes and oxygen free radicals from neutrophils. The severity of an inflammatory response is dependent on the interplay of several cytokines, which may be both pro- and anti-inflammatory [45]. In a well-regulated system, the inflammatory cascade is proportionate to the triggering bacterial stimulation and is switched off. There is evidence that in bronchiectasis the inflammatory response is disproportionate to the infective burden and that the inflammatory response persists [43, 46]. Indeed, in the early phases of bronchiectasis, active airway inflammation has even been reported in the absence of identifiable microbial infection, suggesting a dysregulation of the cytokine network independent of infection [47].
HISTOPATHOLOGY
Figure 8. Thick-walled bronchial artery in a bronchiecatic airway
Neutrophils are potent effectors in inflammatory responses and secrete anti-microbial substances, as well as reactive oxygen free radicals [48]. Bronchoalveolar lavage (BAL) studies have demonstrated that neutrophils are consistently present in patients with bronchiectasis, even when sterile and clinically stable, but increase in the presence of potential pathogens [49, 50]. Recruitment and migration of neutrophils in airways is facilitated by the activation of neutrophils and the upregulation of adhesion molecules on endothelial cells [51–53]. These changes are regulated by cytokines, particularly IL-1 and tumour necrosis factor (TNF)-a, as well as lipopolysaccharide (LPS), which have been shown to be increased in the airways of patients with bronchiectasis [54, 55]. Activated neutrophils secrete potentially tissue damaging enzymes such as neutrophil elastase, proteinase 3 and metalloproteinases. Levels of these enzymes in BAL samples have been shown to correlate with neutrophil numbers and markers of disease activity such as 24hour sputum production [56]. These enzymes can directly damage the structural integrity of the airway via damage to the basement membrane and elastin framework [57–60]. Neutrophils are also an important source of oxygen free radicals. Release of oxygen free radicals are an important part of the defence against infection and are regulated by a protective anti-oxidant system. However, the excessive release of these oxidants can overwhelm the defence mechanisms and cause tissue damage via lipid peroxidation. Furthermore, reactive oxygen species may amplify the inflammatory response through the induction of cytokine and chemokine production by the stimulation of genes regulated by nuclear factor-kB. Studies in bronchiectatic patients have shown increased levels of exhaled H2O2 correlating with neutrophil counts and disease activity [61, 62].
28
Macrophages also play a role in the disease progression as they secrete TNF-a, which promotes neutrophil recruitment, as well as other inflammatory mediators including IL-8, monocyte chemotactic protein-1 and chemokines [23, 63]. Lymphocytes are also typically present in
bronchial biopsies within the lamina propria and may also infiltrate the overlying epithelium. Studies assessing the relative proportions of CD4+ and CD8+ have produced mixed and, at times, conflicting results. Nonetheless, their presence indicates a cell-mediated immune response contributing to the overall inflammatory process [22]. Whilst the epithelial layer may be seen as a protective barrier through mucociliary clearance and generation of anti-bacterial substances, it also contributes to the inflammatory process through the direct generation of pro-inflammatory cytokines [64]. Exposure to LPS leads to the generation of IL-8 and TNF-a which, as stated previously, are important in neutrophil recruitment. Bronchial epithelial cells are also able to upregulate surface adhesion molecules, such as intracellular adhesion molecule-1, aiding the migration of neutrophils [65, 66]. Thus, a number of pathways lead to the activation and recruitment of neutrophils into the airways which, if not adequately regulated and controlled, results in the destruction of local tissue and the persistence and progression of bronchiectasis. Individual variability in this innate response may help to explain why not all individuals exposed to predisposing triggers will go on to develop bronchiectasis and offers potential targets for therapeutic intervention.
Statement of interest None declared.
29
1. Laennec RTH. De l’Auscultation Mediatle ou Traite du Diagnostic des Maladies des Poumons et du Couer. [On Mediate Auscultation or Treatise on the Diagnosis of the Lungs and Heart.] Paris, Brosson and Claude, 1819. 2. Weissberg D, Schwartz T. Foreign bodies in the tracheobronchial tree. Chest 1987; 91: 730–733. 3. Limper AH, Prakash UB. Tracheobronchial foreign bodies in adults. Ann Intern Med 1990; 112: 604–609. 4. Scala R, Aronne D, Palumbo U, et al. Prevalence, age, distribution and aetiology of bronchiectasis: a retrospective study on 144 symptomatic patients. Monaldi Arch Chest Dis 2000; 55: 101–105. 5. Tsao PC, Lin CY. Clinical spectrum of bronchiectasis in children. Act Paeditr Taiwan 2002; 43: 271–275. 6. Barker AF, Bardana EJ. Bronchiectasis: update of an orphan disease. Am Rev Respir Dis 1988; 137: 969–978. 7. Bosten C, Myer J, Greenberger P, et al. Pathologic features of allergic bronchopulmonary aspergillosis. Am J Surg Pathol 1988; 12: 216–222. 8. Box K, Kerr KM, Jefferey RR, et al. Endobronchial lipoma associated with lobar bronchiectasis. Repsir Med 1991; 85: 71–72. 9. Kwon KY, Myers JL, Swensen SJ, et al. Middle lobe syndrome: a clinicopathological study of 21 patients. Hum Pathol 1995; 26: 302–307. 10. Reid LM. Reductions in bronchial subdivisions in bronchiectasis. Thorax 1950; 5: 223–247. 11. Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax 1952; 7: 213–239. 12. Ogilvie AG. The natural history of bronchiectasis. A clinical, roentgenologic and pathologic study. Arch Intern Med 1941; 68: 395–465. 13. Percy KMA, King DC. Bronchiectasis: A study of prognosis based on a follow-up of 400 cases. Am Rev Tuber 1940; 41: 531–548. 14. Ogninc G, Kampalath B, Tomashefski JF. Destruction and loss of bronchial cartilage in cystic fibrosis. Hum Pathol 19888, 29: 65–73. 15. Rossman CM, Forrest JB, Lee RM, et al. The dyskinetic cilia syndrome. Ciliary motility in immotile cilia syndrome. Chest 1980; 78: 580–582. 16. Watts WJ, Watts MD, Dai W, et al. Respiratory dysfunction in patients with common variable hypogammaglobulinaemia. Am Rev Respir Dis 1986; 134: 699–703. 17. Gracia JD, Rodrigo MJ, Morrell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996; 153: 650–655. 18. Butland RJ, Cole P, Citron KM, et al. Chronic bronchial suppuration and inflammatory bowel disease. Q J Med 1981; 50: 63–75. 19. Tahanami I, Imamuma T, Yamamoto Y, et al. Bronchiectasis complicating rheumatoid arthritis. Respir Med 1995; 89: 453–454. 20. Strimlan CV, Rosenow EC, Diverite MB, et al. Pulmonary manifestations of Sjogren’s syndrome. Chest 1976; 70: 354–361. 21. Hayward J, Reid ML. The cartilage of intra-pulmonary bronchi in normal lungs, in bronchiectasis and in massive collapse. Thorax 1952; 7: 98–110.
M. GODDARD
References
HISTOPATHOLOGY
30
22. Silva JR, Jones JA, Cole PJ, et al. The immunological component of the cellular inflammatory infiltrate in bronchiecatsis. Thorax 1989; 44: 668–673. 23. Gaga M, Bentley AM, Humbert M, et al. Increases in CD4+ T lymphocytes, macrophages, neutrophils and interleukin 8 positive cells in the airways of patients with bronchiectasis. Thorax 1998; 53: 685–691. 24. Solanki E, Neville E. Bronchiectasis and rheumatoid disease. Is there an association? Br J Rheumatol 1992; 31: 691–693. 25. Mahon MJ, Swinson DR, Shettar S, et al. Bronchiectasis and rheumatoid arthritis: a clinical study. Ann Rheum Dis 1993; 52: 776–779. 26. Moles KM, VArjhess G, Hayes JR. Pulmonary involvement in ulcerative colitis. Br J Dis Chest 1988; 82: 79–83. 27. Liebow AA, Hales MR, Linskog GE. Enlargement of the bronchial arteries and their anastomoses with the pulmonary arteries in bronchiectasis. Am J Pathol 1949; 25: 211–231. 28. Whitwell F. Tumourlets of lung. J Pathol Bact 1955; 70: 529–541. 29. Yousem SA, Colby TV, Carrington CB. Follicular bronchitis/bronchiolitis. Hum Pathol 1985; 16: 700–706. 30. Akcay S, Akman B, Ozdemir H, et al. Bronchiectasis related amyloidosis as a cause of chronic renal failure. Ren Fail 2002; 24: 815–823. 31. Cole PJ. Inflammation: a two edged sword – the model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6–15. 32. Warne WP. Factors causing bronchiectasis. JAMA 1935; 105: 1666–1670. 33. Glauser EM, Cook CD, Harris GBC. Bronchiectasis: a review of 187 cases. Acta Pediatr Scand 1966; 165: 1–15. 34. Whooping cough in the United States and Britain. N Engl J Med 1983; 309: 108–109. 35. Hogg JC, Irving WL, Porter H, et al. In situ hybridisation studies of adenoviral infections of the lung and their relationship to follicular bronchiectasis. Am Rev Respir Dis 1989; 139: 1531–1535. 36. Rayner CFJ, Rutman A, Dewar A, et al. Ciliary disorientation in patients with chronic reparatory tract inflammation. Am J Respir Crit Care Med 1995; 151: 800–804. 37. Starner TD, Zhang N, Kim G, et al. Haemophilus influenzae forms biofilms on airways epithelia: implications in cystic fibrosis. Am J Respir Crit Care Med 2006; 174: 213–230. 38. King PT, Hutchinson PE, Johnson PD, et al. Adaptive immunity to non typeable Haemophilus influenzae. Am J Respir Crit Care Med 2003; 167: 587–592. 39. Wilson R, Dowlin RB, Jackson AD. The biology of bacterial colonisation and invasion of the respiratory mucosa. Eur Respir J 1996; 9: 1523–1530. 40. Mathee K, Ciofu O, Sternberg C, et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 1999; 145: 1349–1357. 41. Lau GW, Hasset DJ, Ran H. The role of pyocyanin in Pseudomonas aeruginosa infection. Trends Mol Med 2004; 10: 599–606. 42. Caldwell C, Chen Y, Goetzmann HS, et al. Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis. Am J Pathol 2009; 175: 2473–2488. 43. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can’t they clear infection? Respir Res 2003; 4: 8. 44. Lu W, Hisatsume A, Koga T, et al. Cutting edge: enhanced pulmonary clearance of Pseudomonas aeruginosa by Muc1 knockout mice. J Immunol 2006; 176: 3890–3894. 45. Wouters EFM. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26–33. 46. Aldallal N, Mc Naughton EE, Manzel LJ, et al. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166: 1248–1256. 47. Angrill J, Agusti C, De Celis R, et al. Bronchial inflammation and colonisation in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164: 1628–1632. 48. Liu Y, Shaw Sk, Ma S, et al. Regulation of leucocyte transmigration: cell surface interactions and signalling events. J Immunol 2004; 172: 7–13. 49. Eller J, Lap e Silva JR, Poulter LW, et al. Cells and cytokines in chronic bronchial infection. Ann NY Acad Sci 1994; 725: 331–345. 50. Loukides S, Bouros D, Papatjheodorou G, et al. Exhaled H2O2 in steady-state bronchiectasis: relationship with cellular composition in induced sputum, spirometry, and extent and severity of disease. Chest 2002; 121: 81–87. 51. Adams DH, Shaw S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet 1994; 343: 831–836. 52. Hogg JC. Leukocyte traffic in the lung. Ann Rev Physiol 1995; 57: 97–114. 53. Zheng L, Tipoe G, Lam WK, et al. Upregulation of circulating adhesion molecules in bronchiectasis. Eur Respir J 2000; 16: 691–696. 54. Carlos T, Kovach N, Schwarz B, et al. Human monocytes bind to two cytokine induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1. Blood 1991; 77: 2266–2271. 55. Dustin ML, Rothlein R, Bhan AF, et al. Induction by IL-1 and interferon-c: tissue distribution, biochemistry and function of a nature adherence molecule (ICAM-1). J Immunol 1986; 137: 245–254. 56. Pang JA, Cheng A, Chan HS, et al. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and bronchoalveolar lavage. Ann Rev Respir Dis 1988; 139: 14–17.
31
M. GODDARD
57. Sepper R, Kontinnen YT, Ding Y, et al. Human neutrophil collagenase (MMP-8) identified in bronchiectasis BAL fluid, correlates with severity of disease. Chest 1995; 107: 1641–1647. 58. Zheng L, Lam WK, Tipoe GL, et al. Overexpression of matrix metalloproteinases-8 and -9 in bronchiectasis airways in vivo. Eur Respir J 2002; 20: 170–176. 59. Sepper R, Kontinnen YT, Sorsa T, et al. Gelatinolytic and type-IV collagenolytic activity in bronchiectasis. Chest 1994; 106: 1129–1133. 60. Doring G. The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114–S117. 61. Lloberes P, Monserrat E, Monserrat JM, et al. Sputum sol phase proteins and elastase activity in patients with clinically stable bronchiectasis. Thorax 1992; 47: 88–92. 62. Loukides S, Horvath I, Wodehouse T, et al. Elevated levels of expired breath hydrogen peroxide in bronchiectasis. Am J Respir Crit Care Med 1998; 158: 991–994. 63. Simpson JI, Grissell TV, Gibson PG. Innate immune activation in bronchiectasis. Eur Respir J 2004; 24: Suppl. 48, 210S. 64. Devalia JL, Davies RJ. Airway epithelial cells and mediators of inflammation. Respir Med 1993; 87: 405–408. 65. Look DC, Rapp SR, Keller BT, et al. Selective induction of intercellular adhesion molecule-1 by interferon-c in airway epithelial cells. Am J Physiol 1992; 263: L79–L87. 66. Humlicek AL, Pang L, Look DC. Modulation of airway inflammation and clearance by epithelial ICAM-1. Am J Physiol Lung Cell Mol Physiol 2004; 287: L598–L607.
Chapter 4
Assessment and investigation of adults with bronchiectasis M. Drain and J.S. Elborn
ASSESSMENT AND INVESTIGATION
Summary The diagnosis of bronchiectasis is made on the basis of highresolution computed tomography (HRCT) scan findings. A diagnosis of bronchiectasis should be considered in all patients with persistent cough productive of sputum, where another clear diagnosis has not been made. This includes patients with an initial diagnosis of chronic obstructive pulmonary disease or severe asthma. Once bronchiectasis has been confirmed by HRCT scanning, patients should undergo a range of investigations to determine whether or not there is an underlying cause. This can usually be determined in approximately 50% of patients with bronchiectasis. The common conditions which should be sought are cystic fibrosis, immunodeficiency syndromes, primary ciliary dyskinesia, and autoimmune diseases, such as rheumatoid arthritis and ulcerative colitis. For many of these conditions, there is specific treatment to improve symptoms and reduce lung injury but, without an accurate diagnosis, appropriate therapy may not be instituted. Keywords: Bronchiectasis, computed tomography scan, cystic fibrosis, primary ciliary dyskinesia, primary immunodeficiency
B
Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK. Correspondence: J.S. Elborn, Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, UK, Email
[email protected]
Eur Respir Mon 2011. 52, 32–43. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003410
32
ronchiectasis is a generic diagnostic term that describes the pathological dilation of the airways found in a number of chronic lung conditions. The aetiology of bronchiectasis is varied (table 1), and, in most series, an underlying cause can only be definitively identified in 50% of cases [1, 2]. The importance of determining a cause lies in facilitating treatment that may improve symptoms, reduce exacerbations and alter the course of the disease by preserving lung function. In one series in children, extensive investigation detected a specific cause in 74% of those investigated, and this led to a change in treatment in 56% [3]. In an adult series from the same geographical area, a diagnosis was again reached in 74%, and the treatment of 37% of these was affected by knowledge of the diagnosis [4].
Congenital
Acquired
Cystic fibrosis# Primary ciliary dyskinesia# a1-Antitrypsin deficiency Congenital anatomical defects Tracheo-oesophageal fistula Bronchotracheomalacia Tracheomegaly Pulmonary sequestration Yellow nail syndrome Marfan’s syndrome Cystic fibrosis# Primary ciliary dyskinesia#
Following infection# Bacterial# Whooping cough Tuberculosis Nontuberculous mycobacteria Viral Measles HIV# Fungal ABPA# Immunodeficiency Primary Common variable immunodeficiency# X-linked agammaglobulinaemia# IgA deficiency MHC class II deficiency B-cell deficiency Hyper-IgE syndrome Secondary Following chemotherapy# Haematological malignancy# Graft-versus-host disease Interstitial lung disease# (traction bronchiectasis) Autoimmune disease Rheumatoid arthritis# Ulcerative colitis Sjo¨gren’s syndrome Sarcoidosis Following surgery Inhaled foreign body Chronic GORD
ABPA: allergic bronchopulmonary aspergillosis; Ig: immunoglobulin; MHC: major histocompatibility complex; GORD: gastro-oesophageal reflux disease. #: more common conditions that should be considered when making an initial diagnosis [2].
Childhood respiratory infection, e.g. whooping cough, measles, tuberculosis (TB) or severe bacterial pneumonia, is cited as being responsible for a large proportion of cases of bronchiectasis, i.e. up to 50% [4–6]. This potential cause, however, is subject to recall bias, particularly since the majority of cases present in the fifth and sixth decades of life. Many people of this age have had measles, whooping cough or other childhood infections associated with respiratory infection, including pneumonia. In addition, the first episode of pulmonary infection could represent the first exacerbation of bronchiectasis. Bronchiectasis is found in association with numerous multisystemic diseases, such as cystic fibrosis (CF) [7], immunodeficiencies [8], a1-antitrypsin (a1-AT) deficiency [9], primary ciliary dyskinesia (PCD) [10], rheumatoid arthritis and inflammatory bowel diseases, especially ulcerative colitis [1, 7, 11].
M. DRAIN AND J.S. ELBORN
Table 1. Causes of bronchiectasis in adults
Prevalence The prevalence of bronchiectasis is almost certainly underestimated. This is because it is a condition that many healthcare practitioners are unfamiliar with, and it is frequently misdiagnosed as asthma or chronic obstructive pulmonary disease (COPD) due to the similarities in clinical findings (table 2).
33
In the USA, the prevalence of bronchiectasis has been estimated at 4.2 per 100,000 population among those aged 18–34 years, rising to 272 per 100,000 population in those aged .75 years [12].
Table 2. Clinical findings in chronic obstructive pulmonary disease (COPD), asthma and bronchiectasis
Symptom Cough Sputum production Dyspnoea Wheeze Haemoptysis Fever Lethargy Recurrent infection Clinical signs Finger clubbing Breath sounds Added sounds Lung function Spirometry Reversibility Lung volumes Transfer factor Hypoxia Radiology Chest radiography
ASSESSMENT AND INVESTIGATION
CT findings
COPD
Bronchiectasis
Asthma
+ + ++ + +/+/+
+ ++ +/+/+ + + ++
+ +/+ ++ +
No Q/wheeze Wheeze
Extensive disease Normal/Q Crackles
No Normal/wheeze Wheeze
FEV1Q, FVCQ FEV1/ FVCQ 15% Q/q Normal Yes
FEV1Q/normal FVCQ/normal FEV1/FVCQ/normal 40% Normal/Q Normal/Q Yes/no
FEV1Q/normal, FVC normal FEV1Q/normal Yes Normal Normal No
Chronic inflammatory changes, hyperinflation Hyperinflation, airtrapping, bullae, may have mildly dilated airways or thickened bronchial wall
Tramlines, ring shadows/normal
Normal/ hyperinflation Normal/air-trapping, may have mildly dilated airways or thickened bronchial wall
Dilated bronchi, thickened bronchial wall, lack of tapering of bronchi, bronchi visible in outer 1–2 cm, air-trapping
CT: computed tomography; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; -: uncommon; +/-: occurs sometimes; +: common; ++: very common; Q: decrease; q: increase.
However, these values are derived from a database of claims from 30 different healthcare insurance plans made over a 2-year period. They are likely to underestimate the true prevalence as they exclude not only the uninsured population but also those who use alternative plans. It cannot, therefore, be claimed that they are truly representative of the real population prevalence. The prevalence of non-CF bronchiectasis in Northern Ireland is estimated at around 5,000 in a population of approximately 2 million [13], leading to 300–400 admissions per annum for the treatment of an infective exacerbation. In children, bronchiectasis is less common. It can be extrapolated that the prevalence should be falling following the advent of improved antibiotic therapies and vaccination of children during the first year of life. Only two national studies have been reported with very different rates, 0.5 per 100,000 population in Finland [14] and 3.7 per 100,000 population in New Zealand [15]. In certain indigenous population groups, the prevalence is much higher, e.g. the New Zealand figure doubles among the Maori and Pacific Islander populations [11, 15], Aboriginal rural communities have 14.7 per 1,000 population affected among those aged ,16 years [16] and 16 per 1,000 population in Alaskan natives [17]. This is thought to occur due to an increased rate of severe pulmonary infection in early childhood, due to a combination of socioeconomic factors rather than solely a genetic predisposition.
Approach to diagnosis
34
The diagnostic approach to a patient with bronchiectasis should first establish that there is radiological evidence of airways dilatation and secondarily consider possible underlying conditions [1].
People presenting with a chronic productive cough lasting for .4 weeks or recurrent episodes, with two or more episodes occurring over 8 weeks, should have the diagnosis of bronchiectasis considered [2]. In the scheme outlined in figure 1, all of the first-line investigations should be considered as routine in patients being investigated for bronchiectasis. Most people have already undergone some investigations prior to referral, such as a sputum culture, chest radiography or computed tomography (CT), which may guide further investigations.
Symptoms and physical findings Cough productive of sputum is the most common symptom associated with bronchiectasis [1, 18–21]. In some studies, 25% of patients do not report excessive daily sputum production, but describe a marked increase in volume during an exacerbation [1, 18]. Occasional haemoptysis is a frequent symptom and is reported by half of all patients. This is often associated with a pulmonary exacerbation. Shortness of breath, fever and chest pain are also common complaints among non-CF bronchiectasis patients [18], although they are common symptoms in other chronic inflammatory lung disease that may coexist, e.g. COPD and asthma (table 2). Patients presenting with such symptoms who do not respond as expected to usual therapy should raise the possibility of bronchiectasis and this should be investigated. Some symptoms point to specific diagnoses (table 3).
Physical examination
Diagnostic suspicion of bronchiectasis
Consider other Negative diagnosis
Chest HRCT scan
Sputum culture (including mycobacteria)
Spirometry
Chest radiography
Assessment of functional status and infection in all patients
Positive
Sweat [Cl-] (CF)
Genetics Nasal PD
Igs (CVID)
α1-AT levels and phenotype (α1-AT)
Vaccination studies: Pneumovax and tetanus
Genetics
Nasal NO RF/autoantibodies (PCD) (CTD)
EM studies Genetics Functional studies
Aspergillus IgE and IgG and eosinophilia (ABPA)
M. DRAIN AND J.S. ELBORN
Physical findings are of modest help in the assessment of patients with bronchiectasis. The classic findings of wet crackles and finger clubbing are now uncommon and should trigger investigation for conditions associated with severe bronchiectasis, such as CF. Crackles with some associated
First-line diagnostic investigations to be considered in all patients
Further studies in case of diagnostic suspicion or doubt
Figure 1. Diagnostic approach to bronchiectasis. HRCT: high-resolution computed tomography; [Cl-]: chloride
35
ion concentration; CF: cystic fibrosis; Ig: immunoglobulin; a1-AT: a1-antitrypsin; PCD: primary ciliary dyskinesia; NO: nitric oxide; RF: rheumatoid factor; CTD: connective tissue disease; ABPA: allergic bronchopulmonary aspergillosis; PD: potential difference; EM: electron microscopy; CVID: common variable immunodeficiency.
Table 3. Specific historical features suggestive of a particular diagnosis in adults Primary ciliary dyskinesia Cystic fibrosis
Common variable immunodeficiency
Neonatal respiratory distress, middle ear disease, infertility Culture of Staphylococcus aureus, Pseudomonas aeruginosa or Burkholderia cepacia complex, malabsorption symptoms, infertility, recurrent pancreatitis, nasal polyposis Recurrent respiratory, urinary, gastrointestinal and skin infections
wheeze are the most common findings, with finger clubbing now a rare feature, and usually associated with severe disease. Other aspects of examination should focus on clinical signs of associated diseases, such as CF, immune deficiency or a connective tissue disease.
Diagnostic tests Blood tests
ASSESSMENT AND INVESTIGATION
A complete blood count, although nonspecific, is important in monitoring the ongoing condition of each individual patient. Haemoglobin level can be low secondary to anaemia of chronic disease, and, conversely, patients may be polycythaemic secondary to chronic hypoxia. An elevated white cell count may indicate the presence of acute infection. The differential white cell count can reveal lymphopenia, which may prompt further investigation for immunodeficiency syndromes or eosinophilia, which can occur in but is not diagnostic of allergic bronchopulmonary aspergillosis (ABPA). C-reactive protein (CRP) is an acute-phase reactant commonly measured in respiratory patients with acute exacerbations in order to assist in determining whether or not there is a systemic inflammatory response [1, 22, 23]. In bronchiectasis patients in a stable state, it has been shown that CRP levels are elevated from baseline [22]. The CRP level also correlated with decline in lung function and severity of disease on high-resolution CT (HRCT) in the same series [22].
Radiology Although suspected with a history of recurrent lower respiratory tract infection on a background of chronic cough and sputum production, the diagnosis of bronchiectasis can only be confirmed radiologically [2]. The gold-standard investigation is HRCT. This was first described in 1982 [16], and permits a detailed examination of the lung architecture using a noninvasive technique. Historically, the diagnosis was based on bronchography, which involved instillation of a radioopaque dye into the airways and fluoroscopic screening. This technique has been superseded due to the greater detail available in a safer more easily tolerated imaging method and is now obsolete. Volumetric HRCT has some advantages over conventional HRCT as it provides more-detailed images, but it is more prone to image degradation due to motion artefact and requires a higher radiation dose. Standard HRCT is appropriate for the majority of patients. Findings on HRCT are bronchial wall thickening with dilatation of the bronchi to a diameter greater than that of the accompanying arteriole (the signet-ring sign); lack of normal tapering of bronchi/bronchioles on sequential slices; and visualisation of bronchi in the outer 1–2 cm (fig. 2) [1, 23, 24]. The bronchiectatic changes in CF have been quantified using a number of scoring systems, but the value of these in diagnosis or follow-up care has not been established.
36
The histopathological appearance of bronchiectasis has been further subcategorised as cylindrical, saccular and varicose, depending on the shape of the bronchi [25]. The true clinical significance of these subdivisions is unclear. However, cystic bronchiectasis has been associated with an increased frequency of exacerbation and more-clinically significant disease [24]. HRCT appearance can also be used to confirm any other parenchymal or bronchiolar pathology, such as interstitial lung
a)
b)
c)
changes in bronchiectasis. a) Signet-ring sign, i.e. dilatation of the bronchi to a diameter greater than that of the accompanying vessel. b) Visualisation of the bronchi in the outer 1–2 cm. c) Thickened bronchial walls. The circled areas indicate ring shadows.
disease [25, 26]. The distribution of ectatic airways throughout the lung fields can be used to guide investigation of underlying causes, but most changes are nonspecific (table 4) [27, 28]. Although the diagnosis is confirmed radiologically using HRCT, a posteroanterior chest radiograph should be obtained as a baseline with which to compare future films in the event of acute exacerbation. Depending on the distribution of the bronchiectasis and the degree of damage, the chest radiograph may show minimal change from normal or be markedly abnormal. Traditionally, the radiographic changes associated with bronchiectasis are tramlines and ring shadows [18]; these markings correspond to the thickened mucosa of the more-severely inflamed airways in transverse or cross-section.
M. DRAIN AND J.S. ELBORN
Figure 2. High-resolution computed tomography
Table 4. High-resolution computed tomography features of bronchiectasis General features Bronchial dilatation (bronchus diameter greater than that of adjacent vessel) Bronchial wall thickening Bronchial plugging Areas of reduced attenuation (mosaic pattern) Specific features ABPA: upper-zone central bronchiectasis Cystic fibrosis: upper-zone bronchiectasis NTM/MAC: Middle-lobe irregular branching and tree-in-bud appearance
37
ABPA: allergic bronchopulmonary aspergillosis; NTM: nontuberculous mycobacteria; MAC: Mycobacterium avium-intracellulare complex.
Once the diagnosis of bronchiectasis has been confirmed, a detailed clinical work-up should be undertaken in order to determine the extent of the impact on lung function, morbidity and prognosis, the underlying cause of the existing structural lung damage and the most prevalent infecting organisms. The benefits of this are that not only can treatment be tailored to the individual, but also a potentially treatable underlying condition may be uncovered [1, 24, 25]. A comprehensive clinical assessment, including a detailed history and physical examination, are required to illicit any pointers towards a specific diagnosis. This should be followed up by extensive investigation to allow determination of baseline functional status and lung function and to permit guidance of treatment. During the course of investigation, underlying conditions which are known to have an association with bronchiectasis, albeit not a causative one, may be discovered.
ASSESSMENT AND INVESTIGATION
Pulmonary function testing and other physiological factors Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) should be measured at the time of the diagnostic evaluation and at least annually, more frequently in the setting of PCD, immunodeficiency or connective tissue disease [21, 24]. Spirometric results may be normal in some patients, although usually show a pattern of airflow limitation, with a decreased FEV1 and a reduced FEV1/FVC ratio. FVC may be normal or slightly reduced, although this finding alone may be indicative of mucous impaction [2, 24]. Airway hyperresponsiveness has also been demonstrated. In 40% of patients, an FEV1 reversibility of .15% following administration of b-agonist can be demonstrated [29]. In addition, 30–69% of patients who do not exhibit a reduced FEV1 at baseline, show a 20% decrease in FEV1 following histamine or methacholine challenge [30, 31], indicating clinically significant hyperresponsiveness. FEV1 has the strongest correlation with severity of structural abnormality on HRCT [32, 33]; however, it correlates poorly with clinical fluctuations in disease course. Full pulmonary function testing, including lung volumes and gas transfer coefficient, should be carried out at the outset in adult presentations in order to give a picture of the overall functional status of the lungs and also to assist in the diagnosis of underlying conditions [2]. Reduced lung volumes and transfer factor should prompt consideration of underlying interstitial lung disease. Elevated lung volumes can be secondary to air-trapping or indicate mucous impaction of smallcalibre airways. Exercise testing, such as the incremental shuttle test and 6-minute walking test, are widely used tools for the assessment of functional capacity in chronic pulmonary disease patients and can be applied to bronchiectatic patients [34]. However, such tests have no value in diagnosis and there are no data to support their use outside of clinical studies [35]. Limitation of exercise capacity has not been shown to correlate with severity of airway damage on HRCT [36]. Studies in post-resection patients have shown that exercise testing is more informative as an ongoing assessment of lung function than static spirometry, particularly in patients whose performance or symptoms do not correlate with spirometric results [37].
Specific investigations Cystic fibrosis
38
CF is the single most common cause of structural bronchiectasis in children and a reasonably common diagnosis in adults [2, 7, 24]. Increasingly, CF is diagnosed later in life, with many patients now being diagnosed in their third and fourth decades of life, and some even later [38–43]. Given this, all adults presenting with bronchiectasis and other features of CF should undergo comprehensive investigation in order to rule out CF. Pilocarpine iontophoresis for sweat chloride ion concentration ([Cl-]) measurement, should be carried out in all patients with bronchiectasis and a clinical suspicion of CF [2, 44]. The results should be interpreted as detailed in table 5. A sweat [Cl-]
of ,30 mM effectively excludes CF as a diagnosis, although one CF-disease-causing mutation has been described with normal sweat [Cl-] [44]. If the sweat [Cl-] is .60 mM, a diagnosis of CF is confirmed. If the sweat test result is 30–60 mM, the identification of one or more disease-causing mutations determines which diagnostic category the patient falls into, CF or CF transmembrane conductance regulator (CFTR)-related disorder (table 5) [44]. The diagnostic category of CFTR-related disorder has recently emerged and describes single-organ disease, most frequently bronchiectasis, with an associated sweat [Cl-] of 30–60 mM or one or two disease-causing mutations of the CFTR. In some cases of diagnostic uncertainty, measurement of nasal potential difference may help to determine CFTR dysfunction. This may help to distinguish CF from a CFTR-related disorder [44].
Immunological investigations
Specific IgG subclass deficiency can be detected in serum or by checking the antibody response to vaccination with either pneumococcal or Haemophilus influenzae and tetanus toxoid vaccines. This is performed by measuring antibody levels prior to administration of a dose and again 4 weeks later in order to investigate whether or not the individual has mounted an appropriate response [45]. Specific antibody response studies should be undertaken in consultation with an immunologist as interpretation of responses is complex, and a decision to treat patients with specific deficiencies with Ig replacement requires a range of considerations and should undertaken by an immunologist with expertise in this area [2]. Replacing deficient IgG is usually effective in reducing the frequency of infection and preventing further lung damage [45–47]. Neutrophil, Tcell, B-cell and complement disorders are a rare cause of bronchiectasis, and functional studies should be discussed with a specialist immunologist. All patients with an identified immunodeficiency should be managed with a specialist immunologist [2].
Primary ciliary dyskinesia PCD is an autosomal recessive disorder leading to immotile cilia, and occurs in 1 in 15,000 to 1 in 40,000 of the population. It results in bronchiectasis and sinusitis and, in around half of cases, Kartagener’s syndrome (bronchiectasis, sinusitis and situs inversus) [10]. Diagnosis is based on exhaled nasal nitric oxide levels and electron microscopy of nasal biopsy specimens [48]. Reduced nitric oxide level has a specificity of 98% and a positive predictive value of 92% for PCD [48], and may be used as a screening tool to select those in whom nasal mucosal biopsy for electron microscopy is required. The diagnostic gold standard is transmission electron microscopy of nasal biopsy specimens to view the ultrastructural defects in the dynein arms within individual cilia [10]. Recent studies suggest that 15% of patients with functional PCD show no ultrastructural defects and so there is a high falsenegative diagnostic rate [10]. Genetic testing is now becoming more readily available and may go some way towards overcoming limitations to ultrastructure as a diagnostic method [10].
M. DRAIN AND J.S. ELBORN
A range of immunological abnormalities are associated with non-CF bronchiectasis [24]. The prevalence of each in bronchiectasis varies from study to study. Humoral immunity can be affected by low levels of any of the major immunoglobulin (Ig) classes, IgM, IgG and IgA [1, 24, 45, 46]), and, in some cases, IgG subclasses, IgG1, IgG2, IgG3 and IgG4. The specific antibody response to polysaccharide and peptide vaccines provides additional information about the innate immune response to antigenic stimulus [11].
Table 5. Sweat test diagnostic criteria for cystic fibrosis (CF) Sweat [Cl-] mM
Diagnostic conclusion
o60 30–60 f30
CF confirmed Equivocal: further investigation required: CFTR DNA test Not CF
39
[Cl-]: chloride ion concentration; CFTR: CF transmembrane conductance regulator.
Allergic bronchopulmonary aspergillosis IgE is a sensitive marker for ABPA if levels are .1,000 IU?L-1. Aspergillus precipitins or specific IgG directed against Aspergillus confirm the diagnosis. This condition responds well to a combination of high-dose oral corticosteroid and oral antifungal therapy [2, 49–51].
a1-Antitrypsin deficiency In order to diagnose a1-AT deficiency, serum levels of a1-AT should be checked with the biochemical phenotype requested in those patients with low levels, particularly if there is a family history of respiratory disease of young onset, or in family members who have never smoked or show evidence of bullous disease on HRCT [9]. Genetic tests for the different genotypes (M, Z and S) are also now available.
Connective tissue disorders
ASSESSMENT AND INVESTIGATION
Autoimmune disease covers a spectrum of conditions, which, although rare individually, can cause bronchiectasis and, depending on the condition, may respond to directed treatment. These conditions can be screened for by thorough history-taking and measurement of rheumatoid factor and other specific autoantibodies, such as antineutrophilic cytoplasmic antibody and cryoglobulin [2]. More common autoimmune conditions with a strong association with bronchiectasis are rheumatoid arthritis and ulcerative colitis. It is recommended that patients attending specialist rheumatology or gastroenterology clinics for monitoring of these conditions who develop chronic cough or respiratory symptoms should undergo lung function testing and HRCT in order to rule out bronchiectasis.
Gastro-oesophageal reflux Gastro-oesophageal reflux disease has been associated with bronchiectasis, although it is unclear whether or not there is a direct causal relationship. If suspected, barium studies and fluoroscopy are indicated [2, 24].
Infection and sputum microbiology Sputum microbiology is a key investigation in the diagnosis of patients with bronchiectasis [52]. H. influenzae is the most-frequently isolated pathogen, being found in up to 35% of patients. Staphylococcus aureus, Streptococcus pneumoniae, Moraxella catarrhalis and Pseudomonas aeruginosa are also commonly identified organisms [53]. Aspergillus sp. may also be found, and may be related to a diagnosis of ABPA. The presence of P. aeruginosa in sputum from people with bronchiectasis is associated with more-severe lung disease and may also have a negative impact upon prognosis [54, 55].
Monitoring disease activity Monitoring disease activity in bronchiectasis can be difficult as there is little fluctuation in lung function as measured by spirometry [2]. The inflammatory response to infection in bronchiectasis has been shown to be compartmentalised, with higher concentrations of inflammatory mediators being found in the airways than in the systemic circulation [3, 56]. Patients’ symptoms are a very important guide to pulmonary exacerbations, with increased cough, sputum volume and purulence, and haemoptysis and reduced energy all being common symptoms.
40
Sputum analysis plays a pivotal role in the assessment of bronchiectasis, with antibiotic therapy being directed by the results of sputum culture and antibiotic sensitivity testing. Sputum culture should be performed at all outpatient reviews and when symptoms deteriorate.
Although exacerbation rate does not clearly correlate with particular organisms, it has been shown to increase with increasing resistance of organisms to antibiotics [54]. Longitudinal studies demonstrate that subjects who carry the same organism after a 5-year period tend to carry increasingly resistant organisms, making exacerbations more difficult to treat successfully [54]. Recent studies using molecular identification techniques in the sputum of CF patients have revealed a wider spectrum of organisms in significant quantities than culture alone [57]. This has led to the discovery that the CF microbiome is much more extensive and diverse than was previously suspected. This is also likely to be the case in non-CF bronchiectasis. Molecular diagnostic methods are considerably more expensive than culture-based methods and not freely available in most clinical microbiological laboratory settings. Exacerbations are often associated with new isolates of bacteria and respond to antibiotic therapies. However, in many such episodes, no clinically significant organism can be identified as the precipitating factor. Although it may be some time before molecular diagnostics enter clinical practice, it is worth bearing in mind, in the case of an infection not responding to standard antibiotic therapy, that there are other potentially pathogenic organisms present that may require alternative treatment. As a rule of thumb, sputum culture is more likely to underestimate the prevalence of bacterial infection, and each positive culture should be treated with appropriate antibiotics. A thorough structured approach to the investigation of patients with suspected bronchiectasis will enable further learning about the natural history of the condition and improve patient outcomes by appropriate direction of treatment.
References 1. Dagli E. Non cystic fibrosis bronchiectasis. Paediatr Respir Rev 2000; 1: 64–70. 2. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1–i58. 3. Li AM, Sonnappa S, Lex C, et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 2005; 26: 8–14. 4. Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163–1170. 5. Scala R, Aranne P, Palumbo V, et al. Prevalence, age distribution and aetiology of bronchiectasis; a retrospective study on 144 symptomatic cases. Monaldi Arch Chest Dis 2000; 55: 101–105. 6. Valery PC, Torzillo PJ, Mulholland K, et al. Hospital-based case–control study of bronchiectasis in indigenous children in Central Australia. Pediatr Infect Dis J 2004; 23: 902–908. 7. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277–1284. 8. DeGracia J, Rodrigo MJ, Morell F, et al. IgG subclass deficiencies associated with bronchiectasis. Am J Respir Crit Care Med 1996; 153: 650–655. 9. Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in a1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 1215–1221. 10. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med 2004; 169: 459–467. 11. Liote H. Etiological work-up for bronchectasis in adults. Rev Pneumol Clin 2004; 60: 255–264. 12. Weycker D, Edelsberg J, Oster G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12: 205–209. 13. Department of Health, Social Services and Public Safety. A Healthier Future. A Strategic Framework for Respiratory Conditions. Belfast, Department of Health, Social Services and Public Safety, 2006. 14. Sa¨yna¨jakangas O, Keistinen T, Tuuponen T, et al. Evaluation of the incidence and age distribution of bronchiectasis from the Finnish hospital discharge register. Cent Eur J Public Health 1998; 6: 235–237. 15. Twiss J, Metcalfe R, Edwards E, et al. New Zealand national incidence of bronchiectasis is too high for a developed country. Arch Dis Child 2005; 90: 737–740.
41
None declared.
M. DRAIN AND J.S. ELBORN
Statement of interest
ASSESSMENT AND INVESTIGATION
42
16. Chang AB, Grimwood K, Maguire G, et al. Management of bronchiectasis and chronic suppurative lung disease in indigenous children and adults from rural and remote Australian communities. Med J Aust 2008; 189: 386–393. 17. Singleton R, Morris A, Redding G, et al. Bronchiectasis in Alaska native children: causes and clinical courses. Pediatr Pulmonol 2000; 29: 182–187. 18. Nicotra MB, Rivera M, Dale AM, et al. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 1995; 108: 955–961. 19. Shields MD, Bush A, Everard ML, et al. BTS guidelines. Recommendations for the assessment and management of cough in children. Thorax 2008; 63: Suppl. 3, iii1–iii15. 20. Patel IS, Viahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 70: 400–407. 21. Ellis DA, Thornley PE, Wightman AJ, et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax 1981; 36: 659–664. 22. Watt AP, Brown V, Courtney J, et al. Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis. Thorax 2004; 59: 231–236. 23. Naidich DP, McCauley DI, Khouri NF, et al. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982; 6: 437–444. 24. O’Donnell AE. Bronchiectasis. Chest 2008; 134: 815–823. 25. Hansell DM. Bronchiectasis. Radiol Clin North Am 1998; 36: 107–128. 26. Gudbjerg CE. Roentgenologic diagnosis of bronchiectasis: an analysis of 112 cases. Acta Radiol 1955; 43: 209–225. 27. Remy Jardin M, Amara A, Campistron P, et al. Diagnosis of bronchiectasis with multislice spiral CT: accuracy of 3-mm-thick structured sections. Eur Radiol 2003; 13: 1165–1171. 28. Reiff DB, Wells AU, Carr DH, et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261–267. 29. Murphy MB, Reen DJ, Fitzgerald MX. Atopy, immunological changes, and respiratory function in bronchiectasis. Thorax 1984; 39: 179–184. 30. Swaminathan S, Kuppurao KV, Somu N, et al. Reduced exercise capacity in non-cystic fibrosis bronchiectasis. Indian J Pediatr 2003; 70: 553–556. 31. Pang J, Chan HS, Sung JY. Prevalence of asthma, atopy, and bronchial hyperreactivity in bronchiectasis: a controlled study. Thorax 1989; 44: 948–951. 32. Sheehan RE, Wells AU, Copley SJ. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20: 581–587. 33. Roberts HR, Wells AU, Milne DG. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55: 198–204. 34. Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-minute walk test in bronchiectasis. Respir Med 2009; 103: 780–785. 35. Newall C, Stockley RA, Hill SL. Exercise training and inspiratory muscle training in patients with bronchiectasis. Thorax 2005; 60: 943–948. 36. Edwards EA, Narang I, Li A, et al. HRCT lung abnormalities are not a surrogate for exercise limitation in bronchiectasis. Eur Respir J 2004; 24: 538–544. 37. Tsubota N, Yanagawa M, Yoshimura M, et al. The superiority of exercise testing over spirometry in the evaluation of postoperative lung function for patients with pulmonary disease. Surg Today 1994; 24: 103–105. 38. McCloskey M, Redmond AOB, Hill B, et al. Clinical features associated with a delayed diagnosis in CF. Ir J Med Sci 2000; 67: 402–407. 39. King PT, Freezer NJ, Holmes PW, et al. Role of CFTR mutations in adult bronchiectasis. Thorax 2004; 59: 357–358. 40. Hubert D, Fajac I, Bienvenu T, et al. Diagnosis of cystic fibrosis in adults with diffuse bronchiectasis. J Cyst Fibros 2004; 3: 15–22. 41. Gilljam M, Ellis L, Corey M, et al. Clinical manifestations of cystic fibrosis among patients with diagnosis in adulthood. Chest 2004; 126: 1215–1224. 42. Paranjape SM, Zeitlin PL. Atypical cystic fibrosis and CFTR-related disease. Clin Rev Allergy Immunol 2008; 35: 116–123. 43. Knowles MR, Durac PR. What is cystic fibrosis. N Engl J Med 2002; 347: 439–442. 44. DeBoeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006; 61: 627–635. 45. Stead A, Douglas JG, Broadfoot CJ, et al. Humoral immunity and bronchiectasis. Clin Exp Immunol 2002; 130: 325–330. 46. Bernatowska E, Madalin´ski K, Janowicz W, et al. Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment. Clin Immunol Immunopathol 1987; 43: 153–162. 47. Eijkhout HW, van Der Meer JW, Kallenberg CG, et al. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized, double-blind, multicenter crossover trial. Ann Intern Med 2001; 135: 165–174.
43
M. DRAIN AND J.S. ELBORN
48. Horvath I, Loukides S, Wodehouse T, et al. Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax 2003; 58: 68–72. 49. Greenberger PA, Miller TP, Roberts M, et al. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy 1993; 70: 333–338. 50. Bahous J, Malo JL, Paquin R, et al. Allergic bronchopulmonary aspergillosis and sensitization to Aspergillus fumigatus in chronic bronchiectasis in adults. Clin Allergy 1985; 15: 571–579. 51. Wang JL, Patterson R, Rosenberg M, et al. Serum IgE and IgG antibody activity against Aspergillus fumigatus as a diagnostic aid in allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1978; 177: 917–927. 52. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57: 15–19. 53. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003; 14: 488–492. 54. Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754–1760. 55. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007; 101: 1633–1638. 56. Hill SL, Morrison HM, Burnett D, et al. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986; 41: 559–565. 57. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177: 995–1001.
Chapter 5
Radiological features of bronchiectasis P.L. Perera* and N.J. Screaton#
RADIOLOGICAL FEATURES
Summary Imaging plays a crucial role in the diagnosis and monitoring of bronchiectasis and the management of complications. Chest radiography is useful as an initial screening tool and during acute exacerbations, but has limited sensitivity and specificity. High-resolution computed tomography (HRCT) is the reference standard for diagnosis and quantification of bronchiectasis, providing detailed morphological information. Computed tomography (CT) is also valuable in diagnosing and managing complications. Routine surveillance using HRCT has been mooted, particularly in cystic fibrosis (CF), where advances in treatment have increased life expectancy considerably, but cumulative radiation dose remains a concern. Pulmonary magnetic resonance imaging is an evolving technique that provides both structural and functional information. Its advantage is the lack of ionising radiation. Limitations include cost, availability and its inferior spatial resolution compared to CT. The technique requires further evaluation, but has potential benefits where serial follow-up imaging is being considered, such as in CF. Evaluation of mucociliary clearance using radionuclide scintigraphy may be of value, particularly in drug development. Keywords: Bronchiectasis, cystic fibrosis, diagnostic imaging, magnetic resonance imaging, mucociliary clearance, spiral computed tomography
B
*Dept of Radiology, Norfolk and Norwich University Hospital, Norwich, and # Diagnostic Imaging Dept, Papworth Hospital, Papworth Everard, UK. Correspondence: N.J. Screaton, Diagnostic Imaging Dept, Papworth Hospital, Papworth Everard, CB23 3RE, UK, Email
[email protected]
Eur Respir Mon 2011. 52, 44–67. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003510
44
ronchiectasis is characterised by irreversible dilation of bronchi, which may be focal or diffuse, and usually occurs with associated inflammation. Its pathogenesis is complex and often multifactorial, with bronchial wall inflammation, bronchial wall weakness and infection often occurring in parallel and with numerous aetiological factors. Since it was first described by LAENNEC [1] in 1819, there have been considerable advances in the understanding, diagnosis and treatment of bronchiectasis. Imaging now forms the cornerstone of diagnosis of bronchiectasis and its complications and plays an increasing role in disease monitoring and therapeutic planning. The present review focuses on imaging features in bronchiectasis and their role in diagnosis and monitoring of disease. Several imaging modalities are available, with varying strengths and
limitations, which are outlined below. The choice of diagnostic/monitoring strategy shows some variation depending on access to each modality and interpretive expertise. Image-guided intervention, such as percutaneous pleural aspiration/drainage and angiography with embolisation play important roles in treating complications, but are beyond the scope of the present review.
Chest radiography Chest radiography (CXR) is usually the initial study performed in both suspected bronchiectasis and the evaluation of nonspecific respiratory symptoms, such as dyspnoea and haemoptysis, when bronchiectasis may be identified incidentally. Signs on CXR include the identification of parallel linear densities, tram-track opacities, or ring shadows reflecting thickened and abnormally dilated bronchial walls. These bronchial abnormalities form a spectrum from subtle or barely perceptible 5-mm ring shadows to obvious cysts. Tubular branching opacities conforming to the expected bronchial branching pattern may result from fluid or mucous filling of bronchi. Peribronchial fibrosis results in a loss of definition of vessel walls (fig. 1) [2–5].
The radiograph may raise the initial suspicion of bronchiectasis, triggering more definitive imaging. However, its projectional nature and limited contrast resolution lead to limited sensitivity and specificity, particularly in mild disease. CXR also plays a role in the follow-up of bronchiectasis and management of exacerbations, although, again, the relative insensitivity to change is highlighted by proponents of computed tomography (CT) and magnetic resonance (MR) imaging (MRI) [2–5]. The reported accuracy of CXR has changed over the years as the management emphasis has shifted from being reactive to complications to one of early detection and proactive management, and as the diagnostic reference standard has shifted from bronchography to CT. In 1955, GUDJBERG [6] reported only 7.1% of 114 bronchiectatic patients having a normal CXR, perhaps reflecting the more florid nature of the condition during this period. In 1987, CURRIE et al. [7] reported an overall sensitivity of 47%, and only 13% on a lobar basis, in 19 patients with bronchographically proven bronchiectasis. The same study confirmed significant interobserver variation in CXR interpretation, with two experienced readers disagreeing on the diagnosis of bronchiectasis in 22% of cases [7]. In comparison to CXR, CT is both more sensitive and provides more specific information. BHALLA et al. [8] showed that, out of a total of 162 bronchopulmonary segments reviewed, bronchiectasis was detected in 124 on high-resolution CT (HRCT) and only 71 on CXR.
P.L. PERERA AND N.J. SCREATON
Signs of complications/exacerbations, such as patchy densities due to mucoid impaction and consolidation, volume loss secondary to bronchial mucoid obstruction or chronic cicatrisation, are also seen. In the more diffuse forms of bronchiectasis, such as cystic fibrosis (CF), generalised hyperinflation and oligaemia are often present, consistent with severe small airways obstruction.
Radiographic scoring systems, such as those of CHRISPIN and NORMAN [9] and BRASFIELD et al. [10], have been developed and subsequently modified for patients with CF. These can be useful clinically, but are more commonly used for comparison in research. CLEVELAND et al. [11] showed that a score based on the scoring system of BRASFIELD et al. [10] could be used to assess the longitudinal progression of lung disease in CF, and was at least as effective as spirometry in this regard. Although CXR has limitations in specificity in diagnosing bronchiectasis and in detecting early or subtle changes, it is useful for assessing more florid cases of bronchiectasis, in CF and in follow-up of bronchiectatic patients.
Computed tomography
45
The CT signs of bronchiectasis were first described by NAIDICH et al. [12] in 1982. Although initial studies using 8–10-mm slice thickness showed low sensitivity [13–15], the advent of HRCT led to markedly improved sensitivity, resulting in HRCT replacing bronchography as the diagnostic reference standard. GRENIER et al. [16] showed that HRCT with 1.5-mm collimation at 10-mm
a)
RADIOLOGICAL FEATURES
b)
intervals was accurate in the recognition of bronchiectasis using bronchography as the gold standard in 36 patients. Multidetector CT (MDCT) with volumetric acquisition further increases the sensitivity in detection of subtle nontapering airways. DODD et al. [17] compared contiguous 1-mm MDCT with 1-mm incremental HRCT with 10-mm interspaces in 61 bronchiectatic patients and 19 normal controls. Using MDCT as the gold standard, the sensitivity, specificity and positive and negative predictive values of incremental HRCT in detecting bronchiectasis were 71, 93, 88 and 81%, respectively. Interobserver agreement for the presence, extent and severity of bronchiectasis was also better for MDCT (kappa 0.64, 0.5 and 0.48, respectively) than for incremental HRCT (kappa 0.65, 046 and 0.25, respectively).
Optimal HRCT technique is important for maximising diagnostic accuracy. Importantly, thin slices of 1–2 mm and a high-resolution lung reconstruction algorithm are used to optimise spatial resolution. Incremental imaging with 10-mm slice interspace reduces radiation dose, but helical MDCT permits volumetric acquisition in a single breathhold, which is often the preferred technique. Electronic images should be viewed in stack/cine mode using the appropriate window settings (centred -400– -950 HU; width 1,000–1,600 HU). Difficulties in diagnosing bronchiectasis can arise from cardiorespiratory motion artefact, use Figure 1. Chest radiography showing a) cystic bronchiectasis with multiple cystic airspaces and b) cylindrical bronchiectasis and tramof inappropriate window widths and track opacities in a cystic fibrosis patient. levels, and the relatively thick-walled appearance of bronchial walls on expiratory scans. Tractional airway dilation associated with pulmonary fibrosis has a characteristic corkscrew appearance and should be differentiated from pathological bronchiectasis.
CT signs of bronchiectasis
46
Bronchial dilation, the cardinal sign of bronchiectasis, is characterised on HRCT by a bronchoarterial ratio (BAR) of .1, lack of bronchial tapering, and visibility of airways within 1 cm of the pleural surface or abutting the mediastinal pleural surface [2, 12, 16, 18, 19].
The different morphological types of bronchiectasis corresponding to the bronchographic classification of REID [20] show differing radiological features [16, 21], but this is of little relevance in terms of aetiology and rather reflects varying severity of the disease. Although, in cylindrical bronchiectasis, there is uniform dilation of airways with nontapering walls, in varicose bronchiectasis, dilated bronchi have a beaded appearance and, in cystic bronchiectasis, grosser bronchial dilation gives the appearance of cysts (fig. 2). The BAR refers to the ratio of the internal bronchial diameter to the diameter of the accompanying pulmonary artery at an equivalent branching level. A BAR of .1 is considered abnormal [14, 15, 19] and is otherwise known as the signet-ring sign (fig. 3).
Figure 2. High-resolution computed tomography image showing cystic bronchiectasis (same patient as in fig. 1a).
Physiological influence on BAR was highlighted by LYNCH et al. [23], who showed that 59% of 27 normal volunteers living in Colorado, USA (1,600 m above sea level) had at least one bronchus that had an internal diameter larger than its accompanying artery. KIM et al. [18] confirmed this environmental influence on BAR by demonstrating that residents living at 1,600 m exhibited significantly higher BARs than those living at sea level (0.76 and 0.62, respectively; p,0.001). Physiological variation can also occur due to regional hypoxia, and so secondary vasoconstriction causing apparent bronchial dilation must be recognised in order to prevent a spurious diagnosis of bronchiectasis. Conversely, if there is arterial dilation (e.g. due to pulmonary arterial hypertension), bronchiectasis could be missed. A practical problem in assessing BAR is the need to identify the accompanying artery, which may be difficult in the presence of other lung pathology, such as consolidation. In the setting of consolidation, the presence of bronchial dilation may be a reversible phenomenon and so caution should be observed when interpreting CT data during an acute illness. Although objective measurement may be performed, visual inspection is the usual method of assessing bronchial dilation. DIEDERICH et al. [24] showed this to have good interobserver agreement for detection (kappa 0.78) and severity assessment (kappa 0.68).
Figure 3. High-resolution computed tomography image demonstrating signs of bronchiectasis, the signet-ring sign (short arrow) and peripheral airway visible within 1 cm of the pleural surface (long arrow).
47
Lack of bronchial tapering or tram-track appearance of the parallel bronchial walls is a sensitive feature of bronchiectasis often identified in more horizontally orientated airways in the mid-zones. KANG et al. [25] showed that lack of tapering on HRCT was more sensitive than bronchial dilation in bronchiectasis (79 and 60%, respectively) using pathology as the reference standard. However, the sign can be difficult to interpret in nonvolumetric CT studies. KIM et al. [18] demonstrated lack of tapering on HRCT in 95% of patients with bronchiectasis, but also in 10% of normal subjects. It has been suggested that bronchial diameter should remain unchanged for at least 2 cm distal to a branching point for this sign to be robust (fig. 4) [26].
P.L. PERERA AND N.J. SCREATON
The accuracy of the BAR can be limited by a number of factors, including physiological variation and orientation of the bronchovascular bundle with respect to the imaging plane [16, 22, 23]. Comparison is best performed on perpendicularly orientated airways. When oblique to the acquisition plane, airways and vessels appear ovoid and their short axis should be compared.
Visibility of peripheral airways is another important direct sign of bronchiectasis [17]. Current HRCT techniques permit visualisation of airways of up to 2 mm in diameter and walls of around 0.2 mm in thickness. KIM et al. [18] showed that normal bronchi are not visualised within 1 cm of the costal pleura, but may be seen within 1 cm of the mediastinal pleura. Visible bronchi within 1 cm of the costal pleura or abutting the mediastinal surface were seen in 81 and 53% of HRCT images of known bronchiectatic patients (fig. 4). Ancillary signs commonly identified in bronchiectatic patients include bronchial wall thickening, mucoid tomography image showing nontapering impaction and air-trapping. Minor volume loss can be bronchi, in keeping with bronchiectasis. seen in the early stages of bronchiectasis. Larger areas of collapse secondary to mucous plugging may be seen in more advanced disease. Patchy consolidation is sometimes seen reflecting superimposed infection. Figure 4. High-resolution computed
RADIOLOGICAL FEATURES
Bronchial wall thickening is often seen in the presence of bronchiectasis [25], but is a variable nondiagnostic feature. It may result from reversible airway wall inflammation [27] or smooth muscle hypertrophy and fibroblastic proliferation. Minor bronchial wall thickening has, however, also been described in normal individuals, asthmatics, asymptomatic smokers and during lower respiratory tract infections [23, 28]. Identification of bronchial wall thickening on HRCT is often made subjectively and is associated with significant interobserver variation, with no universally agreed definition. REMY-JARDIN and REMY [28] defined a thickened bronchus as being twice as thick as a normal bronchus; however, this definition is difficult in diffuse disease DIEDERICH et al. [24] defined a thick-walled bronchus by an internal diameter of ,80% of its external diameter and showed good interobserver agreement (kappa 0.66). However, this can lead to overdiagnosis of thickening in the presence of bronchoconstriction and underestimation with marked bronchodilation. An alternative approach, used by BHALLA et al. [8] in CF and subsequently modified by REIFF et al. [29], is to compare bronchial wall thickness to the diameter of the adjacent artery. As with assessment of BAR, peribronchial fibrosis and consolidation pose practical difficulties in identifying accompanying vessels (fig. 5). Mucous plugging of dilated bronchi is readily identified, causing either complete or partial luminal filling (fig. 5). Plugging of the smaller peripheral airways and peribronchiolar inflammation are characterised by a tree-in-bud appearance, with V- and Y-shaped branching nodular opacities [30]. Mucous plugging was scored in terms of number and generation of involved bronchopulonary segments using the scoring system of BHALLA et al. [8], and may be reversible.
*
Figure 5. High-resolution computed tomo-
48
graphy image demonstrating bronchiectasis with bronchial wall thickening (asterisk) and mucous plugging (arrow) in the right lower lobe.
Air-trapping results either from mucous plugging and abnormal bronchial compliance [31] or inflammation/ fibrosis of the small airways [2]. On HRCT, airtrapping is characterised by patchy lobular areas of low attenuation with regional vasoconstriction, which causes a mosaic attenuation pattern, accentuated on expiratory images, although inspiratory images are usually characteristic (fig. 6). Air-trapping and bronchiectasis coexist in the same lobe in approximately half of cases [25]. Whether it is the bronchiectasis and recurrent infections driving obliterative bronchiolitis (OB) or primary small airways disease that precedes the
onset of bronchiectasis is debated, and may vary [31]. The latter is supported both by the observation that, in patients with CT-proven bronchiectasis, expiratory HRCT identifies air-trapping in 17% of lobes with no bronchiectatic features and that, in patients with rheumatoid arthritis (RA)-associated OB, the onset of symptoms and obstructive function may predate the onset of bronchiectasis by several years [32].
Imaging and aetiology of bronchiectasis
However, in a large study comparing HRCT features in bronchiectasis of defined aetiology with idiopathic bronchiectasis, REIFF et al. [29] concluded that, although some HRCT features were more common in some aetiological groups, the differences were not sufficient to be diagnostic. LEE et al. [40] reinforced this observation in a study of 108 bronchiectatic patients in whom the correct cause was identified on CT in only 45% of cases. A confident diagnosis was asserted in a minority (9%) and was correct in only 35%. Interobserver agreement in likely aetiology was also poor (kappa 0.2) [40]. However, more recently, CARTIER et al. [41] obtained accurate diagnoses on the basis of HRCT in 61% of 82 patients with bronchiectasis of known cause, with moderately good agreement (kappa 0.53). Confident and accurate diagnosis was made in 44% of patients (kappa 0.53). Accuracy was highest in CF (68%), previous tuberculosis (67%) and ABPA (56%). Part of the reason for the higher number of accurate diagnoses was attributed to the exclusion of patients in whom the aetiology of bronchiectasis was not known. They concluded that the combination of radiological pattern and clinical scenario would have improved the accuracy of the evaluation. HRCT is important in the assessment of mycobacterial infection. This is particularly true of nontuberculous mycobacteria (NTM), where the diagnosis is often first suggested on HRCT. CT signs of NTM include bronchiectasis, nodules, tree-in-bud opacity, patchy consolidation and cavities, often affecting the upper lobes and superior segments of lower lobes in the classic subtype and middle lobe/lingula in the nonclassic subtype [42]. The presence of this combination of features with a middle lobe and lingual predominance, especially in the setting of elderly females with no underlying malignancy or immunocompromise, is particularly suggestive of nonclassic NTM [43, 44]. Bronchiectasis is more common in NTM infection, being seen in up to 94% of patients with Mycobacterium avium complex and 27% of patients with M. tuberculosis [45].
P.L. PERERA AND N.J. SCREATON
There are many aetiologies associated with bronchFigure 6. Inspiratory high-resolution computed tomography image showing bronchiectasis, but a specific underlying cause is found in iectasis and widespread areas of low ,40% of patients [33]. In some cases, the distribution attenuation, representing air-trapping. and pattern of bronchiectasis on HRCT may suggest the aetiology. Allergic bronchopulmonary aspergillosis (ABPA) typically demonstrates an upper zone and central predominance [34–37], hypogammaglobulinaemia may be associated with bronchiectasis with disproportionate bronchial wall thickening, middle lobe predominance is common in immotile cilia syndrome [38] and idiopathic bronchiectasis often has a lower lobe distribution [39].
Bronchiectasis in CF usually has a bilateral, proximal, parahilar and upper lobe predominance. Other findings include bronchial wall thickening, peribronchial interstitial thickening, mucous plugging, tree-in-bud opacification, superadded consolidation and mosaic attenuation. SHAH et al. [27] assessed the CT changes in 19 symptomatic adult CF patients before and after 2 weeks of therapy and identified air–fluid levels in bronchiectatic airways, mucous plugging, centrilobular nodules and peribronchial thickening as potentially reversible signs.
49
Bronchiectasis with a central or proximal predominance is the characteristic finding in ABPA (fig. 7a). REIFF et al. [29] showed that the prevalence of central bronchiectasis was higher in ABPA (11 out of 30) than in idiopathic bronchiectasis (26 out of 179) (p,0.005). However, the sensitivity of the observation of central bronchiectasis in diagnosing ABPA was only 37%. PANCHAL et al. [46]
a)
b)
RADIOLOGICAL FEATURES
Figure 7. High-resolution computed tomo-
demonstrated central bronchiectasis in 85% of lobes and 52% of lung segments in a series of 23 patients with ABPA. Other common findings in ABPA include mucous plugging, high-attenuation mucus, tree-inbud opacities, atelectasis, peripheral consolidation or ground-glass opacification, mosaic perfusion and airtrapping. The bronchiectasis is often cystic or varicose. WARD et al. [47] assessed CT images from 44 asthmatic patients with ABPA and 38 without and found much higher levels of bronchiectasis, centrilobular nodules and mucous impaction in ABPA. They concluded that randomly distributed predominantly central moderate-to-severe bronchiectasis affecting three or more lobes, bronchial wall thickening and centrilobular nodules in asthmatics is highly suggestive of ABPA (fig. 7b). High-attenuation mucous plugs are reported to occur in 18–28% of patients with ABPA, and, if observed, are thought to be characteristic [48–50]. In a study of 155 patients with ABPA, AGARWAL et al. [48] found this sign in 29 patients, and that it correlated with greater severity and greater likelihood of relapse.
graphy showing a) proximal bronchiectasis affecting segmental airways and b) highattenuation mucous plugs in patients with allergic bronchopulmonary aspergillosis. No intravenous contrast medium was used in (b).
In summary, there are some recognised clinical conditions in which assessment of bronchiectasis forms an important part of management. CT images in bronchiectatic patients should be examined for features suggesting ABPA, CF, immotile cilia, opportunist mycobacteria and tracheobronchomegaly, but these observation need to be correlated with clinical and laboratory findings.
CT scoring of bronchiectasis Although the extent, severity and distribution of bronchiectasis may be evaluated subjectively, more-robust objective scoring systems have been developed particularly for use in the research arena. With the development of novel software tools, it is now possible to objectively quantify parameters, such as airway wall area and volume, in a semi-automatic manner. Both subjective and objective quantification permit correlations between structure and function to be evaluated. CT scoring systems are based on collective scores for the extent and distribution of a range of morphological abnormalities, including bronchial dilation, bronchial thickening, abscesses, mucous plugging, emphysema, collapse and consolidation. The HRCT score of BHALLA et al. [8] was devised to evaluate the severity of CF in an objective manner. Severity of bronchial dilation and thickening were defined relative to the adjacent pulmonary artery, and other parameters were scored according to the number of bronchopulmonary segments involved, as shown in table 1.
50
This scoring system has been modified many times, and has also been adapted for use in MRI assessment of CF. Modifications have included incorporation of additional findings, such as airtrapping/mosaic attenuation, ground-glass opacification, acinar nodules and septal thickening, with some scores being per segment and others based on lobar scoring. Each scoring system attempts to produce both a total score, by combining features, and specific morphological scores. These have been demonstrated to be more sensitive to disease and show better correlation with both clinical features and lung function than the CXR-based scoring systems. OIKONOMOU et al. [51]
Table 1. Summary of computed tomography scoring system Score 0
1
2
3
Severity of bronchiectasis
Absent
Moderate (luminal diameter 2–3 times that of adjacent blood vessel)
Severe (luminal diameter .3 times that of adjacent blood vessel)
Peribronchial thickening
Absent
Mild (luminal diameter slightly greater than that of adjacent blood vessel) Mild (wall thickness equal to diameter of adjacent vessel)
Severe (wall thickness .2 times the diameter of adjacent vessel)
Extent of bronchiectasis BP segments n Extent of mucous plugging BP segments n Sacculations or abscesses BP segments n Bronchial divisions involved (bronchiectasis/ plugging) generations Bullae Bullae n Emphysema BP segments n Collapse/consolidation
Absent
Present 1–5 Present 1–5 Present 1–5 Up to 4th
Moderate (wall thickness greater than and up to twice the diameter of adjacent vessel) Present 6–9 Present 6–9 Present 6–9 Up to 5th
Unilateral not .4 Present 1–5 Subsegmental
Bilateral not .4 Present .5 Segmental/lobar
Absent Absent Absent
Absent Absent Absent
Present .9 Present .9 Present .9 Up to 6th and distal
Present .4
BP: bronchopulmonary. Reproduced from [8] with permission from the publisher.
suggested a simplified scoring system evaluating severity of bronchiectasis, bronchial wall thickening and atelectasis consolidation. They found strong correlation between the simplified scores and the complete scores. SHAH et al. [27] used a modified Bhalla score in bronchiectatic patients undergoing HRCT at baseline and 2 weeks after exacerbation in order to identify reversible findings, and showed that air–fluid levels, centrilobular nodules, mucous plugging and peribronchial thickening improved following treatment in 100, 36, 33 and 11% of cases, respectively. DE JONG et al. [52] compared the original scoring system of BHALLA et al. [8] and four modified Bhalla systems [53–56]. Three observers reviewed thin-slice CT images of 25 children with CF using the various scoring systems. Interobserver variability was analysed using kappa coefficients and found to be generally good (kappa .0.76; p,0.05). However, inter- and intra-observer agreement was less for mild disease, as well as for parameters such as mosaic perfusion, acinar nodules and airspace disease. All five scoring systems correlated strongly with forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), forced expiratory flow between 25 and 75% of vital capacity (FEF25–75), FEV1/FVC ratio and each other.
P.L. PERERA AND N.J. SCREATON
Category
Quantitative computerised evaluation of the airways presents a number of challenges, including obtaining a plane perpendicular to the airway, exclusion of the adjacent artery, determining the borders of the bronchus, artefacts and partial volume averaging. Three different methods have been used to obtain airway measurements, full width at half maximum, model fitting approaches and boundary fitting approaches [19]. A detailed description of these techniques is beyond the scope of the present chapter.
51
GORIS et al. [57] looked at automated evaluation of the extent of air-trapping in 25 patients with mild CF compared to 10 controls; six anatomically matched CT slices were obtained during
inspiration and expiration. Computerised lung segmentation was performed and automated software used to quantify air-trapping, using analysis of a histogram of the distribution of densities in the lung, and assessing contiguous low-attenuation voxel regions. In mild CF, air-trapping did not correlate with global pulmonary function test (PFT) results, except for the ratio of residual volume (RV) to total lung capacity (TLC); however, the size of the air-trapping defects was the best discriminator between patients and control subjects (p,0.005). KIRALY et al. [58] looked at fully automated methods of obtaining three-dimensional (3D) images and quantification of airway abnormalities. Working from thin-slice image acquisition and using computerised segmentation techniques, they obtained 3D images of the airways with colour-coded maps showing BAR, wall thickness and mucous plugging. These have, however, not been fully clinically validated. Although these objective tools are interesting, further studies are required to evaluate the various computerised imaging parameters and their relation to functional and clinical findings in bronchiectasis. A note of caution was raised by MATSUOKA et al. [59], who used semiautomatic image processing to assess the airways of 52 asymptomatic patients with no cardiopulmonary disease. They found that luminal area and wall area increased in 10 and 29% of subjects, respectively, suggesting caution in over-reliance on changes in airway calibre in disease monitoring.
RADIOLOGICAL FEATURES
Structure–function relationships Relationships between HRCT data and functional and clinical characteristics have been widely explored. WONG-YOU-CHEONG et al. [60] showed a clear negative correlation between FEV1 and extent of bronchiectasis on HRCT (p,0.002; r5 -0.43). SMITH et al. [61] showed correlation between extent of bronchiectasis on HRCT and both dyspnoea (p,0.01; r50.38) and FEV1 (p,0.01; r5 -0.43). More recently, DE JONG et al. [52] showed strong correlations between five scoring systems [8, 53–56] and FEV1 (r5 -0.69– -0.73), FEF25–75 (r5 -0.76– -0.82) and FEV1/ FVC ratio (r5-0.72– -0.78). Correlation with FVC was moderate (r5 -0.54– -0.58). Authors have investigated which morphological abnormalities are most strongly associated with a functional deficit. LYNCH et al. [62], in a study of 261 bronchiectatic patients, found significant correlation between severity of bronchiectasis, FEV1 (r5 -0.362) and FVC (r5 -0.362), and between bronchial wall thickening and FEV1 (r5 -0.367) and FVC (r5 -0.239). Cystic bronchiectasis was found to show worse PFT results than cylindrical or varicose disease. In a study of 100 patients with bronchiectasis, ROBERTS et al. [63] found good correlation between FEV1 and bronchial wall thickening (r5 -0.51; p50.00005) and extent of decreased attenuation on expiratory HRCT (r5 -0.55, p50.00005) on univariate analysis. These were the only factors that independently correlated with degree of airflow limitation on multivariate analysis. In this study, obstructive lung function was not strongly associated with severity of bronchiectasis, bronchodilation, or retained sections in bronchiectasis (r5 -0.42, -0.35 and -0.19, respectively, on univariate analysis). Bronchial dilation as an independent factor was positively associated with airflow obstruction on regression analysis (r250.42). The authors concluded that airflow limitation in bronchiectasis occurred mainly due to inflammatory or obstructive/constrictive bronchiolitis. They also suggested that areas of low attenuation attributed to emphysema in bronchiectatic patients in previous studies (e.g. [64]) should be interpreted with caution, suggesting that the emphysema demonstrated was often due to air-trapping related to intrinsic small airways disease rather than emphysema, as evidenced by preserved gas transfer in the both of these studies.
52
HRCT scoring can also be correlated with clinical parameters. In a study of 61 CF children, baseline and follow-up PFT and HRCT scores were compared to the number of respiratory exacerbations over 2 years. Only the HRCT score (r50.91; p50.001) and bronchiectatic score (r50.083; p50.01) correlated significantly with exacerbation frequency. All HRCT parameters
progressed over this time period except for bronchial wall thickening and mucous plugging, suggesting that these are reversible features [65]. OOI et al. [66] studied 60 patients with stable bronchiectasis with HRCT. They showed good correlation between the extents of bronchiectasis, bronchial wall thickening and mosaic attenuation and FEV1 (r5 -0.43– -0.60), FVC (r5 -0.36– -0.46), FEF25–50 (r5 -0.38– -0.57) and FEV1/FVC (r5 -0.31– -0.49). Regression analysis showed that extent of bronchiectasis and wall thickening were the most significant determinants of airflow obstruction, correlating with all PFT parameters This study also demonstrated associations between bronchial wall thickening and clinical factors, such as exacerbation frequency and 24-hour sputum production (r5 -0.32 and -0.30). ALZEER [67] found that the HRCT score correlated well with FEV1 (r5 -0.51), as well as with systolic pulmonary artery pressure (Ppa,sys) (r50.23), in a study of 94 bronchiectatic patients.
The validity of the use of PFTs as the gold standard in evaluating HRCT has been questioned by several authors. BRODY et al. [69] and HELBICH et al. [53] have shown that early HRCT changes, including mosaic attenuation and bronchial dilation, can be seen early in disease in the presence of normal PFT results. LONG et al. [70] showed HRCT changes, including wall thickening and bronchial dilation in CF infants with a mean age of 2 years, further emphasising the sensitivity of HRCT. Regular low-dose HRCT for the surveillance of CF has been adopted by several centres since the late 1990s [71]. This was initially in the form of 1-mm slice incremental HRCT (with 10mm interspaces), but, more recently, of full-lung volumetric HRCT. CT is performed as early as an age of 2 years, when it is performed as controlled-ventilation CT (CVCT), requiring sedation or general anaesthesia. The rationale for using this imaging-intensive approach is that PFT results may lag behind structural CT changes, difficulty in reliably performing PFTs in young children and the ability of imaging to follow relevant objective structural markers, such as bronchiectasis, bronchial wall thickening, air-trapping and mucous plugging. Furthermore, in the modern era, improved therapy has slowed the annual decline in PFT results such that individual variability and changes due to other factors, such as technique, puberty and infections, have made PFTs even less reliable for disease monitoring. However, the benefit has to be viewed in the setting of radiation risk. DE JONG et al. [72] used a computational model to estimate mortality effects of regular CTs. The mean radiation dose for the published CT protocol was 1 mSv. Survival reduction associated with annual scans from the age of 2 years until death for CF patients with a median survival of 26 and 50 years, were approximately 1 month and 2 years, respectively. Cumulative cancer mortality was approximately 2 and 13% at age 40 and 65 years, respectively. Biannual CTs exhibit half the risk. This highlights the increasing reduction in survival with increasing age, an important point given the increasing life expectancy of CF patients.
P.L. PERERA AND N.J. SCREATON
Studies on the utility of HRCT in the follow-up of non-CF bronchiectatic patients have been limited. In a study of 48 patients, SHEEHAN et al. [68] compared serial CT studies with PFTs, showing correlation of changes in PFT results with air-trapping due to mucous plugging. Greater severity of mucous plugging, bronchiectasis and bronchial wall thickening were predictive of decreased FEV1. In a study evaluating morphological features in bronchiectasis at baseline and 2 weeks after exacerbation, SHAH et al. [27] showed that changes in HRCT score during exacerbation of bronchiectasis also correlate with improvement in FEV1/FVC (r50.39; p50.049). Severity of bronchiectasis was the component most strongly associated with PFT results (r50.4 for FEV1 and r50.5 for FVC), whereas tree in bud and mucous plugging were not strongly correlated.
53
DE JONG et al. [73] studied 48 young patients with CF using serial low-dose HRCT and PFTs 2 years apart. In all children, there was progressive structural HRCT change with deterioration in HRCT scores by 2.2–3.5% overall, but particularly with peripheral extension of bronchiectasis and mucous plugging, despite stable (or, in some cases, improved) lung function. This may reflect poor PFT technique in young CF children, the use of predicted FEV1 (with reference to a global population) and/or the greater sensitivity of HRCT for detection of early and regional changes.
JUDGE et al. [74] assessed serial HRCT performed 18 months apart in 39 consecutive CF patients and found that the modified HRCT score declined faster (2.7% per year; p,0.001) than did FEV1 (2.3% per year). Six patients demonstrated worsening HRCT score with no change in PFT result. DE JONG et al. [75], in a study of 119 children and adults with CF, showed that PFT results, component and CT scores deteriorated over 2 years. The CT score (and its components) and PFT results showed similar rates of deterioration in adults and children (p.0.09). Peripheral bronchiectasis worsened by 1.7% per year in children (p,0.0001) and by 1.5% per year in adults (p,0.0001).
RADIOLOGICAL FEATURES
In view of the potential for discordance between morphology and function and the complementary nature of these variables, authors have attempted to create more-robust clinically useful composite scoring systems combining PFT results and HRCT findings [76]. Studies on assessment following therapy have been limited. ROBINSON et al. [76] used a composite scoring system using many of the HRCT parameters described above and combining them with PFT measures of obstructive function (FEV1 and FEF25–75). They showed the composite measurement to be more sensitive for assessing response to treatment in 25 CF children who were randomised to a treatment arm and a nebulised saline arm; FEF25–50 showed 13% improvement, global HRCT 5% and composite score 30%. Small studies have shown some HRCT features to be useful in post-treatment evaluation. NASR et al. [77] showed a significant improvement in total HRCT score following recombinant human (rh) deoxyribonuclease (DNAse) therapy compared to placebo. GORIS et al. [57] compared 25 CF patients with 10 age-matched controls using PFTs and automated quantitative assessment of lung density. No significant difference was seen in PFT results, but significant differences in air-trapping were seen, with the size of defects being the best discriminator. There was a significant decrease in mean HRCT score from 25 to 22 (p50.014), with improvement in peribronchial thickening (p50.007), mucous plugging (p50.002) and overall appearance (p50.025). There have been some differences in the degree of correlation between PFT results and HRCT findings of bronchiectasis in the various studies, which could be attributed to several causes, including the scoring system used, radiological interpretation, parameters assessed, population studied, reliability of PFTs and data analysis (multivariate versus univariate). However, the link between measures of obstructive lung function (FEV1 and FEF25–50) and bronchial wall thickness/ total HRCT score has been consistently shown.
Role of HRCT in bronchiectasis CT is invaluable in the diagnosis of bronchiectasis, but also plays an important role in the evaluation of complications and assessment and monitoring of disease severity. HRCT provides good clinical correlation, and the use of scoring systems holds promise for monitoring of bronchiectasis. The more robust CT scoring systems have been formulated in CF patients. HRCT is sometimes of value in identifying the aetiology of bronchiectasis. Advantages of HRCT over PFTs include its ability to identify focal changes as well as provide a global score, in addition to assessing multiple parameters, some of which are reversible and others irreversible (fig. 8). Current British Thoracic Society guidelines recommend HRCT at diagnosis and during exacerbations, but not for routine follow-up. An exception is in bronchiectasis secondary to humoral immunodeficiency, where follow-up HRCT may be beneficial [78].
54
HRCT is now widely regarded as part of the standard clinical evaluation of patients with CF. The ability to quantify extent and severity of disease and to serve as a useful outcome marker, and the potential for assessing treatment response, make this a particularly valuable investigation. However, although HRCT provides valuable information on initial assessment, the role and periodicity of serial imaging in CF remains controversial in view of increasing life expectancy and cumulative radiation exposure. Some authors suggest that HRCT should form part of the routine monitoring of CF, but with due consideration to the excess radiation [71]. With appropriate
scanning technique, it is estimated that a chest CT every other year from birth to age 30 years would involve an effective dose of 15 mSv compared to the mean background radiation dose over this period of 90 mSv [79]. Thus HRCT forms an important part of the investigation and diagnosis of bronchiectasis and exacerbations. It is particularly useful in CF, where it has been shown to be a good marker of outcome and has demonstrated the ability to pick up subtle and early changes with greater sensitivity than PFTs.
Interest in the use of MRI for lung imaging arose in Figure 8. Coronal reconstruction from the mid-1980s. The inherent difficulties in pulmonary high-resolution computed tomography MRI are well documented. Lungs have an intrinsically showing a bronchial collateral vessel. low proton density, which results in poor signal generation. This low signal is further degraded by susceptibility artefact resulting from the innumerable air–tissue interfaces and cardiac and respiratory motion. However, the advent of parallel imaging and new rapid imaging sequences have permitted marked improvement in temporal and spatial resolution. Although spatial resolution using conventional proton MRI is less than that using CT, MRI offers significant morphological information and has advantages in enabling improved tissue characterisation and providing functional imaging, including vascular flow and respiratory mechanics. The use of novel imaging techniques, such as oxygen-enhanced MRI and hyperpolarised helium-3 MRI, potentially permits derivation of further functional parameters, including regional ventilation, regional oxygen concentration and evaluation of lung microstructure using the apparent diffusion coefficient (ADC). Although application of this technique currently lies largely in the research arena, a significant advantage of MRI is the lack of radiation, which is particularly important in patients who require recurrent imaging and the younger population group. This is pertinent when considering the potential cumulative lifetime radiation dose from annual/biannual low-dose CT examination in the CF population that are currently advocated by some groups [71], especially in view of the rapid improvement in life expectancy in this patient group, which is projected to continue. Thus it is unsurprising that much of the work on thoracic MRI imaging has been focused on patients with CF.
Conventional proton MRI features
P.L. PERERA AND N.J. SCREATON
Magnetic resonance imaging
Owing to the limited spatial resolution of MRI, assessment of bronchial wall thickness and bronchiectasis are dependent upon bronchial level, wall thickness and wall signal. Thirdgeneration bronchi and beyond are poorly visualised on MRI, except in pathological states, when the wall and luminal signal are raised due to wall thickening, inflammation and mucus [80]. Inflammation and oedema contribute to wall thickening. Gadolinium-enhanced images may be useful in demonstrating inflammatory change.
55
Mucous plugging on MRI results in homogeneous high T2-signal intensity in proximal airways or an abnormal branching grape-like pattern more peripherally, equivalent to the tree-in-bud opacities seen on HRCT. In contrast to CT, the improved tissue characterisation of MRI can also differentiate between mucus, haemorrhage and bronchial wall thickening [81]. Air–fluid levels may be identified on MRI, particularly in cystic or varicose bronchiectasis. Unlike CT, using contrast-enhanced MRI sequences, thickened airway walls can be differentiated from mucous plugging. Consolidation may also be identified as high T2-signal inflammatory fluid contrasts with the low airway signal, equivalent to the classical air bronchogram. Air-trapping and mosaic perfusion are not readily seen on conventional proton MRI in the absence of gadolinium (figs 9 and 10).
a)
b)
Figure 9. a) Transverse magnetic resonance (T2-weighted half-Fourier acquisition single-shot turbo spin-
RADIOLOGICAL FEATURES
echo (HASTE)) image and b) corresponding computed tomography image in a 14-year-old female with cystic fibrosis. In both images, bronchial wall thickening, bronchiectasis, peripheral mucous plugging and dorsal consolidations are demonstrated, as shown by the arrows. Reproduced from [81] with permission from the publisher.
An early study of 17 CF patients (aged 7–30 years) in 1995 [82] found MRI to be inferior to CT in the assessment of bronchiectasis. Correlations between CT and MRI (r for each observer) were good for bronchial dilation (r50.81 and 0.50), bronchial thickening (r50.82 and 0.60) and mucous plugging (r50.93 and 0.70). Progress in MRI technique in recent years has led to marked improvement in its accuracy. In a study of six paediatric patients with CF, HEBESTREIT et al. [83] found that CXR and MRI provided equal information, and considered MRI suitable for follow-up. In a more recent study in 2007, PUDERBACH et al. [84] evaluated 31 patients with CF using CXR, MDCT and MRI. MRI and MDCT were assessed using a modified Helbich score, whereas CXR was evaluated using a modified Chrispin–Norman score. Mosaic perfusion was excluded from the original scoring system as this cannot be quantified on MRI. They concluded that morphological a)
b)
56
Figure 10. T1-weighted magnetic resonance imaging showing appearance a) before and b) after contrast medium in a 43-year-old cystic fibrosis patient. The post-contrast images demonstrate extensive bronchial wall enhancement and permit differentiation of a thickened wall from intrabronchial secretions, with intrabronchial fluid having an air–fluid level (arrow). Reproduced from [81] with permission from the publisher.
MRI showed comparable results to MDCT and CXR. Median extent scores for MRI, MDCT and CXR scores were 13, 13.5 and 14, and correlation between modalities ranged 0.63–0.80 (MRI/CT 0.80, p,0.0001; MRI/CXR 0.63, p,0.0018; CXR/CT 0.75, p,0.0001). The median lobe-related concordance was 80% for bronchiectasis, 77% for mucous plugging, 93% for sacculation/abscesses and 100% for collapse/consolidation. MONTELLA et al. [85] evaluated patients with primary ciliary dyskinesia using HRCT and MRI. They used a modified Helbich score for both HRCT and morphological MRI assessment, showing mean scores of 12 for both, good-to-excellent agreement between HRCT and MRI scores (r.0.8), and good correlation between both CT and MRI scores and FEV1 and FVC.
Functional MRI A significant advantage of MRI over CT is its superior ability to assess function. Within the lungs this mainly involves evaluation of haemodynamic function and perfusion and ventilation studies.
Perfusion imaging
EICHINGER et al. [90] performed morphological and contrast-enhanced MRI sequences on 11 patients with CF; 198 lung segments were scored for morphological (3 point score of none, moderate or severe) and perfusion defects (0 normal; 1 impaired perfusion). In 86% of segments considered morphologically normal, homogenous perfusion was demonstrated, whereas 97% of segments with severe morphological changes were associated with perfusion defects. Of segments with moderate morphological changes, 53%showed normal and 47% impaired perfusion. Thus contrast-enhanced MRI appears to be a feasible method of assessing regional perfusion defects as a surrogate for small airways disease, although further work is required in order to improve sensitivity in moderately affected areas of lung. In bronchiectasis, increased blood flow though bronchial and nonbronchial systemic collateral vessels results in a systemic arterial to pulmonary venous shunt. Using conventional proton MRI and phase-contrast flow-sensitive sequences, aortic and pulmonary arterial flow can be readily quantified. In a study of 10 patients with CF and 15 healthy volunteers, LEY et al. [91] found a significantly increased shunt in CF patients (1.3 L?min-1) compared to healthy volunteers (0.1 L?min-1).
P.L. PERERA AND N.J. SCREATON
In the presence of small airways obstruction, regional ventilation defects lead to impaired gas exchange and reflex hypoxic vasoconstriction [86]. Perfusion imaging can thus serve as a marker of airway obstruction. ITTI et al. [87] used radionuclide imaging to show that the degree of abnormal lung perfusion correlates well with disease severity in CF, as measured by PFTs and the Shwachman radiographic score. Contrast-enhanced pulmonary MRI imaging can be used to acquire a 3D data set in just 1.5 seconds [88, 89]. This also has advantages over scintigraphy in terms of radiation dose and provides regional information.
Oxygen-enhanced MRI exploits the weak paramagnetic properties of oxygen, which cause a shortening of T1 at high concentration and can be used as a gaseous contrast agent. The solubility of oxygen means that images represent a combination of ventilation and perfusion. A limitation is the low signal-to-noise ratio [81]. JAKOB et al. [92] studied five CF patients and five healthy volunteers using oxygen-enhanced MRI, showing inhomogeneity of the lung parenchyma in the CF patients.
Hyperpolarised noble-gas-enhanced MRI
57
Imaging of hyperpolarised noble gases using MRI is a relatively new imaging technique that shows promise in the research arena in the evaluation of several ventilatory functional parameters. Hyperpolarised helium-3 and hyperpolarised xenon-129 are gaseous contrast agents that provide a very high MR signal [35]. Since oxygen promotes depolarisation, the polarised helium-3 is mixed
with nitrogen rather than air before being administered by active inhalation via a device such as a plastic Tedlar bag or respirator-driven gas delivery system. The bag method uses a mixture of 300 mL helium-3 and 700 mL nitrogen and requires a single anoxic breathhold. The respiratordriven system provides an accurate single dose followed by an air chaser and hence no anoxic breathhold is required. Polarisation is not renewable and has to be used carefully during the scan, with use of sequences to maximise use of finite magnetisation [93]. Dedicated receiver coils for the relevant resonance frequency of helium-3 and xenon-129 are also required. The different physical properties of helium-3 and xenon-129 present different opportunities. Although helium-3 provides a better signal and greater polarisation levels have been obtained, its larger diffusion coefficient results in signal loss. In addition, although helium-3 is virtually insoluble in water, xenon-129 is highly soluble and hence has potential for use in assessing perfusion [93]. On a purely practical basis, the limited supply of helium-3, estimated at 200 kg globally [94], compared to that of xenon-129 is likely to lead to xenon-129 eventually emerging as agent of choice [95].
RADIOLOGICAL FEATURES
The main techniques used in hyperpolarised noble gas imaging are static ventilation imaging and dynamic ventilation imaging, as well as assessment of lung microstructure using ADC and regional oxygen tension imaging. MCMAHON et al. [96] showed that static helium-3 MRI ventilation in CF correlated strongly with HRCT assessment of structural abnormalities (R5¡0.89; p,0.001), and that the correlation was higher between helium-3 MRI and PFT results than helium-3 MRI and HRCT. In a further observational study of 18 patients aged 5–17 years with CF undergoing hyperpolarised helium-2 MRI, VAN BEEK et al. [97] confirmed moderate correlation between a visual score of ventilation on MRI and global assessment of pulmonary function (FEV1 r5 -0.41 and FVC r5 -0.42). In a study comparing healthy volunteers and CF patients, MENTORE et al. [98] performed spirometry and hyperpolarised helium-3 imaging at baseline in all cases, and following various interventions in the eight CF patients. Treatments in the CF group included bronchodilators, DNAse and chest physiotherapy. The number of ventilation defects was scored. The helium-3 ventilation score correlated moderately with spirometry, and was higher in CF patients than controls (mean 8.2 and 1.6, respectively). The helium-3 ventilation score was raised in comparison to controls even in CF patients with normal spirometric results. Defects in the eight treated patients decreased in response to bronchodilator therapy (p50.025). WOODHOUSE et al. [99] demonstrated reproducibility of regional and total lung volume measurements using hyperpolarised helium-3 MR in two examinations performed 30 minutes apart in a group of five young CF sufferers. The ADC of helium-3 or xenon-129 in the lung and the paramagnetic effect of oxygen are two novel methods with the potential for extracting clinically relevant data. The ADC provides a measure of the diffusion of gas and thus an assessment of the degree to which free diffusion is restricted. Helium-3 has a very high self-diffusion coefficient, but, in the lung, diffusion becomes restricted by the boundaries of the airspaces, and thus the ADC can be used to interrogate the microstructure of the lung [93].
58
The oxygen-induced depolarisation of helium-3 or xenon-129 results in signal decay proportional to the concentration of oxygen [100], permitting estimation of regional oxygen concentration and uptake and regional pulmonary perfusion, and providing a regional ventilation/perfusion (V/Q) map at a much higher resolution than that of radionuclide imaging [101]. PATZ et al. [95] measured regional oxygen concentrations using xenon-129, and, although this is inherently more complex than with helium-3 due to diffusion into septal tissue and vasculature, an oxygen tension (PO2) equivalent can be calculated, which can provide valuable functional information.
A limitation of hyperpolarised noble gas MRI is that the signal is also influenced by factors other than ventilation, including the sensitivity of the MR coil and local oxygen concentration in the lung. The need for noble gas isotopes and both polarisation hardware and additional MRI hardware, together with considerable physical and technical support, mean that hyperpolarised noble gas imaging remains expensive and limited to the research environment. However, the potential to perform noninvasive evaluation of regional ventilation, diffusion, regional oxygen concentration, lung microstructure and perfusion without the use of ionising radiation has potential, especially in the research setting.
Summary MRI has potential in the imaging of bronchiectasis, particularly in conditions such as CF, in which young patients may require serial imaging for disease monitoring and assessment of response to treatment. Compared to HRCT, the ability of MR to provide functional imaging and lack of radiation could compensate for its limited spatial resolution. With improvement in MRI techniques, recent studies have shown good reproducibility and good correlation with PFT results. Further work is required to improve spatial resolution, develop robust validated scoring systems and evaluate correlations with clinical outcomes. Currently cost, limited availability and limited spatial resolution limit the use of MRI in bronchiectasis largely to the research arena. Although hyperpolarised noble gas imaging has great potential in terms of provision of functional data, technical issues and set-up and ongoing costs suggest its role will be limited to research for the foreseeable future.
Prior to the advent of HRCT, ventilation (with or without perfusion) scintigraphy was used to aid disease evaluation in bronchiectasis. DOLLERY and HUGH-JONES [102] studied the physiological implications of bronchiectasis and found reduced blood flow and impaired ventilation in bronchiectatic areas. V/Q scintigraphy typically demonstrates matched ventilation and perfusion defects, reflecting abnormal ventilation secondary to bronchiectasis and associated small airways obstruction [103]. PIFFERI et al. [104] studied 16 children aged 4–18 years with clinical and CXR evidence of bronchiectasis, performing HRCT and V/Q scintigraphy. The extent of bronchiectasis, degree of air-trapping on expiratory HRCT and ventilation and perfusion scores from V/Q scintigraphy were assessed. HRCT scores for bronchiectasis and air-trapping showed a strong correlation with perfusion (r50.82; p,0.001) and ventilation scores (r50.72; p,0.01). There was a moderate negative correlation between FEV1 and HRCT bronchiectatic scores (r5 -0.53; p50.02), airtrapping (r5 -0.64; p50.007) and atelectatic score (r5 -0.54; p50.03).
P.L. PERERA AND N.J. SCREATON
Scintigraphy
The authors concluded that HRCT provides a comprehensive assessment of children with bronchiectasis, and V/Q scintigraphy and lung function are additive tools to aid diagnosis and guide therapeutic management. The ongoing issue of radiation dose and absence of useful anatomical information, however, limit the value of V/Q scintigraphy in routine practice.
Mucociliary clearance
59
The interaction between the cilia on respiratory epithelium and the periciliary mucous layer (periciliary liquid (PCL))/overlying mucous layer, together known as the airway surface liquid (ASL) layer, has been widely investigated. Coordinated function is responsible for the constant clearance of foreign material, including microorganisms and other debris, towards the pharynx and ultimate expectoration or swallowing. Impaired mucociliary function has been implicated in many disease processes, but particularly bronchiectasis. Techniques to objectively measure mucociliary clearance (MCC) in vivo have been sought in order to improve understanding of the disease processes and evaluate therapeutic response.
Techniques for measuring MCC In vivo assessment of MCC relies on the inhalation of radiolabelled particulate material that becomes trapped in the mucous layer and can be imaged scintigraphically. Data acquired from the gamma camera over time can be presented either as a series of images for visual inspection or, more commonly, as time–activity curves (fig. 11). Technetium-99m-labelled human albumin, iron oxide and technetium-99–sulfur colloid are some of the aerosols used. Sulfur colloid is nondiffusible, remains extravascular and is expelled by MCC/ swallowing. Deposition of particles is affected by many factors. Some, such as particle size and breathing pattern, can be controlled for, whereas others reflect the underlying lung condition (e.g. obstruction and lung size). Thus, in order to make comparisons, it is important to standardise the nature of the aerosolised particles (size and distribution) and provide a consistent nebulised flow in order to produce a reproducible deposition rate [105]. In order to define the margins of the lung and differentiate central (C) and peripheral (P) lung regions, an initial ventilation study utilising a xenon-133 or krypton-81 scan [106] can be performed immediately prior to administration of particulate material. Following this, the patient b)
c)
C P
L
R
d)
e) 100 90 80 70 60 50 40 30 20 10 0
● ■ ■ ●
90
■ ●
■
■
●
80
●
■
●
■
●
■
■
■
● ●
70
●
60 VCs 60 0
20
40 60 Time minutes
80
◆ ◆ ◆
Retention at 120 minutes %
100
Retention %
RADIOLOGICAL FEATURES
a)
100
◆
◆◆ ◆◆
◆
◆ ◆
◆ ◆ ◆ ◆
1.0
1.5
2.0 C/P ratio
2.5
3.0
Figure 11. Measurement of mucociliary clearance (MCC). a) A xenon-133 equilibrium scan was used to identify
60
the left (L) and right (R) lung boundaries in a normal subject, and assign central (C) and peripheral (P) regions of interest (b). c) Deposition image obtained immediately after inhalation of technetium–sulfur colloid in the same subject. d) Mean rate of clearance of technetium–sulfur colloid from 12 subjects with cystic fibrosis at baseline (&) h and immediately after inhalation of hypertonic saline ($) [16]. The fast phase (approximately 0–20 minutes; – – – – –), reflecting clearance from large airways, and slow phase (from 40 minutes to start of cough clearance measurement; --------), reflecting smaller airway clearance, are highlighted. e) Effect of ratio of radioactive counts measured in the C and P regions on rate of MCC, as denoted by particle retention at 120 minutes, in a cohort of normal study subjects. VC: voluntary cough. Reproduced from [105] with permission from the publisher.
inhales nebulised radiolabelled aerosol. Various adjuncts are used during nebulisation in order to provide consistent reproducible dosing, including pneumotachographic devices with visual feedback to control inhalation flow rate and tidal volume within specific ranges, metronomes to guide the timing of inhalation and exhalation, and aerosol dosimetric equipment to pulse aerosol delivery during specific portions of the breathing cycle [105].
The rate of clearance from central airways is up to 100–1,000 times faster than that from peripheral airways [108, 109]. A two-phase MCC pattern is typically seen, with an initial rapid phase lasting approximately 30 minutes and reflecting clearance from the central airways and a prolonged slower phase. The latter occurs over 1–2 hours and is thought to represent movement of particles to compartments that are more difficult to clear (e.g. absorption of PCL) or slow clearance from peripheral airway/alveolar deposition. 24-hour measurement of clearance has also been used to assess the pattern of clearance during the slower phase, which could also be of value in assessing response to treatment. This, however, requires a higher administered radiation dose due to the 6-hour half-life of technetium. A static measurement at 24 hours can be used as a marker of deposition in the nonciliate airways or alveoli [110]. The relative contributions to the 24-hour measurement of slow clearance from peripheral airways, alveolar deposition and mixing in a poorly cleared part of the ASL, are not fully understood [105]. The static 24-hour measurement is useful in aiding calculation of other parameters, such as the tracheobronchial retention (TBR) curve, which is derived by subtracting the 24-hour retention from the corrected lung retention (LR) curve. A potentially more accurate means of assessing peripheral clearance is inhaling particles of different sizes, smaller (4 mm) particles being deposited more peripherally than larger (7.5 mm) ones [111]. YEATES et al. [108] proposed labelling the differently sized aerosolised particles with different radioisotopes to permit simultaneous measurement of central and peripheral regional clearance. This method is not widely used due to practical difficulties. Some authors [106] advocate measurement of activity solely in the lung periphery, where uptake is more homogenous. This avoids the potential errors caused by differential uptake in central and peripheral airways and confounding by variability of initial deposition. It is, however, limited by a low signal-to-noise ratio due to lower deposition peripherally and intrinsically slower clearance in these regions. It is also not possible to assess response to therapy in the central airways using this method.
P.L. PERERA AND N.J. SCREATON
Following inhalation, the patient is positioned in front of the gamma camera and the gamma radiation emitted is detected and recorded. The results are analysed graphically with reference to the zones defined on the initial ventilation scan. At this stage of analysis, it is important to account for decay of radioisotope and background radiation level. Given the variability of deposition of radiolabelled aerosol in various parts of the airways, it is important to measure the initial deposition pattern. The deposition pattern is usually presented as a ratio between C and P or as the penetration index (PI), which is the ratio of radioactive counts per pixel in P to counts per pixel in C [107]. A high initial C/P deposition ratio or low PI is associated with a higher clearance rate in the central airways, making this a potential confounding factor in analysing final clearance data.
Additional imaging following various interventions, such as cough clearance (CC) assessed after a standardised pattern of coughing, can also be performed. This has some limitations, as performing this late in the study makes it less sensitive as the central airways would have been largely cleared of radioisotope. A further normalisation measurement of C/P ratio must be performed prior to CC.
Clinical applications
61
Measurement of MCC has important research applications in both understanding disease processes and assessing therapeutic response. To date, the technique has not been broadly adopted clinically, being cumbersome to establish.
Disorders that impair MCC can seriously affect respiratory function, with build-up of thick mucus in the airways/lungs and inability to expel harmful material. This can predispose to complications, such as infection and structural lung disease. Other factors may influence MCC, which is faster in nonsmokers and enhanced by b2-agonists, particularly in nonsmokers [112]. CF is a prominent example of a condition in which measurement of MCC could prove useful. Scintigraphic evaluation has also been used to demonstrate impaired MCC in primary ciliary dyskinesia [110] and following lung transplantation [113]. There have been limited studies in idiopathic bronchiectasis [114].
RADIOLOGICAL FEATURES
In CF, disordered ion transport leads to dehydration of the ASL layer [115], impaired ciliary motion and decreased mucus clearance, ultimately leading to degradation of cilia [105], exacerbating the cycle of frequent infections. Ongoing research is focused on the earliest stages of disease pathogenesis and therapeutic interventions to target defective mucus clearance. Biomarkers objectively measuring MCC have the potential to assess response to treatment at an early stage in contrast to longer-term end-points, such as clinical or functional parameters, and thus to expedite drug development. In a study of 24 patients with CF, DONALDSON et al. [116] showed improved MCC, measured using technetium-99-labelled iron oxide, at both 1 and 24 hours after inhalation of hypertonic saline, and that pretreatment with amiloride reduced the magnitude of this improvement. Using radiolabelled iron oxide BENNETT et al. [106] demonstrated significantly reduced baseline MCC at 40 minutes in CF patients compared to healthy volunteers. In the CF group, treatment with uridine 5’-triphosphate and amiloride in combination improved peripheral MCC to near-normal levels. Similar studies have used technetium–sulfur colloid to demonstrate improved MCC and CC following inhaled hypertonic saline and mannitol in CF patients [117]. In summary, MCC can be measured using radiolabelled particulate materials, such as technetium99–sulfur colloid. In the research setting, this provides a potential biomarker for evaluation of mucociliary dysfunction and, in particular, assessment of the impact of targeted therapies. This is especially true in conditions such as CF, in which impaired MCC plays a significant part in the pathophysiology of the disease and where treatment is targeted at improving this.
Conclusions Imaging plays a central role in the diagnosis, characterisation and quantification of disease severity in bronchiectasis, as well as the evaluation of complications. Currently CXR and CT are the main modalities. CXR is the initial screening tool, but has well-documented limitations in sensitivity and specificity, particularly in early disease. Radiography also plays an important role in the diagnosis of complications. HRCT is the reference standard in identifying airway dilation, permitting detection of disease and quantification of extent. Routine surveillance CT has potential for the diagnosis of structural disease at an early stage and impact on patient care, particularly where these is discordance with functional parameters. Radiation dose, however, remains an area of concern requiring further elucidation, particularly in the cohort of CF patients given their ever-increasing life expectancy and the potentially large cumulative radiation dose. Although the present review concentrates on the monitoring of disease, CT is an excellent problem-solving tool, permitting the diagnosis of both infective complications, such as abscess, empyema and aspergilloma, as well as identification of small pneumothoraces or enlarged systemic collateral vessels (fig. 11) and aiding relevant image-guided intervention.
62
MRI offers opportunities to image the lung structure and its function without the use of ionising radiation. The spatial resolution is inferior to that of CT but has improved substantially over recent years. An increasing role for structural (proton) MRI is anticipated, but widespread adoption will require further evidence to support its effectiveness. Although hyperpolarised noble gases permit interrogation of a range of physiological parameters, the set-up costs of this technique
are likely to ensure it remains a predominantly research tool for at least the foreseeable future. Evaluation of MCC using scintigraphy is another area in which there is great potential, particularly in order to expedite and reduce costs of drug development.
Statement of interest None declared.
2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21.
22. 23. 24. 25. 26. 27.
Laennec RTH. De l’Auscultation Mediate ou Traite du Diagnostic des Maladies des Poumons et du Coeur. [On Mediate Auscultation or Treatise on the Diagnosis of the Diseases of the Lungs and Heart]. Paris, Brosson and Chaude´, 1819. Hansell DM. Bronchiectasis. Radiol Clin North Am 1998; 36: 107–128. Javidan-Nejad C, Bhalla S. Bronchiectasis. Radiol Clin North Am 2009; 47: 289–306. Smith IE, Flower CDR. Imaging in bronchiectasis. Br J Radiol 1996; 69: 589–593. Collins J, Stern EJ, eds. Chest Radiology. The Essentials. 2nd Edn. Philadelphia, Lippincott Williams & Wilkins, 2007. Gudjberg CE. Roentologic diagnosis of bronchiectasis. Acta Radiol 1955; 43: 209–226. Currie DC, Cooke JC, Morgan AD, et al. Interpretation of bronchograms and chest radiographs in patients with chronic sputum production. Thorax 1987; 42: 278–284. Bhalla M, Turcios N, Aponte V, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology 1991; 179: 783–788. Chrispin AR, Norman AP. The systematic evaluation of the chest radiograph in cystic fibrosis. Pediatr Radiol 1974; 2: 101–106. Brasfield D, Hicks G, Soong S, et al. Evaluation of scoring system of the chest radiograph in cystic fibrosis: a collaborative study. AJR Am J Roentgenol 1980; 134: 1195–1198. Cleveland RH, Zurakowski D, Slattery DM, et al. Chest radiographs for outcome assessment in cystic fibrosis. Proc Am Thorac Soc 2007; 4: 302–305. Naidich DP, McCauley DI, Khouri NF, et al. Computed tomography of bronchiectasis. J Comput Assist Tomogr 1982; 6: 437–444. Phillips MS, Williams MP, Flower CD. How useful is computed tomography in the diagnosis and assessment of bronchiectasis? Clin Radiol 1986; 37: 321–325. Cooke JC, Currie DC, Morgan AD, et al. Role of computed tomography in diagnosis of bronchiectasis. Thorax 1987; 42: 272–277. Silverman PM, Godwin JD. CT/bronchographic correlations in bronchiectasis. J Comput Assist Tomogr 1987; 11: 52–56. Grenier P, Maurice F, Musset D, et al. Bronchiectasis: assessment by thin-section CT. Radiology 1986; 161: 95–99. Dodd JD, Souza CA, Muller NL. Conventional high-resolution CT versus helical high-resolution MDCT in the detection of bronchiectasis. AJR Am J Roentgenol 2006; 187: 414–420. Kim JS, Muller NL, Park CS, et al. Cylindrical bronchiectasis: diagnostic findings on thin-section CT. AJR Am J Roentgenol 1997; 168: 751–754. Webb WR, Muller NL, Naidich DP. High-resolution CT of the lung. 3rd Edn. Philadelphia, Lippincott, Williams & Wilkins, 2000. Reid LM. Reduction in bronchial subdivisions in bronchiectasis. Thorax 1950; 5: 233–247. Munro NC, Cooke JC, Currie DC. Comparison of thin section computed tomography with bronchography for identifying bronchiectatic segments in patients with chronic sputum production. Thorax 1990; 45: 135–139. Kim SJ, Im G, Kim OA, et al. Normal bronchial and pulmonary arterial diameters measured by thin section CT. J Comput Assist Tomogr 1995; 19: 365–369. Lynch DA, Newell JD, Tschomper BA, et al. Uncomplicated asthma in adults: comparison of CT appearance of the lungs in asthmatic and healthy subjects. Radiology 1993; 188: 829–833. Diederich S, Jurriaans E, Flower CD. Interobserver variation in the diagnosis of bronchiectasis on high-resolution computed tomography. Eur Radiol 1996; 6: 801–806. Kang EY, Miller RR, Muller NL. Bronchiectasis: comparison of preoperative thin-section CT and pathologic findings in resected specimens. Radiology 1995; 195: 649–654. Kim JS, Muller NL, Park CS, et al. Bronchoarterial ratio on thin section CT: comparison between high altitude and sea level. J Comput Assist Tomogr 1997; 21: 306–311. Shah RM, Sexauer W, Ostrum BJ, et al. High-resolution CT in the acute exacerbation of cystic fibrosis: evaluation of acute findings, reversibility of those findings, and clinical correlation. AJR Am J Roentgenol 1997; 169: 375–380.
63
1.
P.L. PERERA AND N.J. SCREATON
References
RADIOLOGICAL FEATURES
64
28. Remy-Jardin M, Remy J. Comparison of vertical and oblique CT in evaluation of bronchial tree. J Comput Assist Tomogr 1988; 12: 956–962. 29. Reiff DB, Wells AU, Carr DH, et al. CT findings in bronchiectasis: limited value in distinguishing between idiopathic and specific types. AJR Am J Roentgenol 1995; 165: 261–267. 30. Nishimura K, Kitaichi M, Izumi T, et al. Diffuse panbronchiolitis: correlation of high-resolution CT and pathologic findings. Radiology 1992; 184: 779–785. 31. Stern EJ, Frank MS. Small-airway diseases of the lungs: findings at expiratory CT. AJR Am J Roentgenol 1994; 163: 37–41. 32. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology 1994; 193: 375–382. 33. Cole PJ. Bronchiectasis. In: Brewis RAL, Corrin B, Geddes DM, et al., eds. Respiratory Medicine. 2nd Edn. London, W.B. Saunders, 1995; pp. 1286–1317. 34. Currie DC, Goldman JM, Cole PJ. Comparison of narrow section computed tomography and plain chest radiography in chronic allergic bronchopulmonary aspergillosis. Clin Radiol 1987; 38: 593–596. 35. Greenberger PA. Allergic bronchopulmonary aspergillosis and fungoses. Clin Chest Med 1988; 9: 599–608. 36. McCarthy D, Simon G, Hargreave F. The radiological appearances in allergic broncho-pulmonary aspergillosis. Clin Radiol 1970; 21: 366–375. 37. Neeld DA, Goodman LR, Gurney IW, et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990; 142: 1200–1206. 38. Nadel HR, Stringer DA, Levison H, et al. The immotile cilia syndrome: radiological manifestations. Radiology 1985; 154: 651–655. 39. Westcott JL. Bronchiectasis. Radiol Clin North Am 1991; 29: 1031–1042. 40. Lee PH, Car DH, Rubens MB, et al. Accuracy of CT in predicting the cause of bronchiectasis. Clin Radiol 1995; 50: 839–841. 41. Cartier Y, Kavanagh PV, Johkoh T, et al. Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases. AJR Am J Roentgenol 1999; 173: 47–52. 42. McGuinness G, Naidich DP. CT of airways disease and bronchiectasis. Radiol Clin North Am 2002; 40: 1–19. 43. Hartman TE, Swenson SJ, Williams DE. Mycobacterium avium-intracellulare complex evaluation with CT. Radiology 1993; 187: 23–26. 44. Moore EH. Atypical mycobacterial infection in the lung: CT appearance. Radiology 1993; 187: 777–782. 45. Primack SL, Logan PM, Hartman TE, et al. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194: 413–417. 46. Panchal N, Bhagat R, Pant C, et al. Allergic bronchopulmonary aspergillosis: the spectrum of computed toography appearances. Respir Med 1997; 91: 213–219. 47. Ward S, Heyneman L, Lee MJ, et al. Accuracy of CT in the diagnosis of allergic bronchopulmonary aspergillosis in asthmatic patients. AJR Am J Roentgenol 1999; 173: 937–942. 48. Agarwal R, Gupta D, Aggarwal AN, et al. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest 2007; 132: 1183–1190. 49. Logan PM, Muller NL. High attenuation mucus plugging in allergic bronchopulmonary aspergillosis. Can Assoc Radiol J 1996; 47: 374–377. 50. Silva CIS, Colby TV, Muller NL. Asthma and associated conditions: high resolution CT and pathological findings. AJR Am J Roentgenol 2004; 183: 817–824. 51. Oikonomou A, Tsanakas J, Hatziagorou E, et al. High resolution computed tomography of the chest in cystic fibrosis (CF): is simplification of scoring systems feasible? Eur Radiol 2008; 18: 538–547. 52. de Jong PA, Ottink MD, Robben SGF, et al. Pulmonary disease assessment in cystic fibrosis: comparison of CT scoring systems and value of bronchial and arterial dimension measurements. Radiology 2004; 231: 434–439. 53. Helbich TH, Heinz-Peer G, Eichler I, et al. Cystic fibrosis: CT assessment of lung involvement in children and adults. Radiology 1999; 213: 537–544. 54. Santamaria F, Grillo G, Guidi G, et al. Cystic fibrosis: when should high-resolution computed tomography of the chest be obtained? Pediatrics 1998; 101: 908–913. 55. Brody AS, Molina PL, Klein JS, et al. High-resolution computed tomography of the chest in children with cystic fibrosis: support for use as an outcome surrogate. Pediatr Radiol 1999; 29: 731–735. 56. Castile RG, Long FR, Flucke RL, et al. Correlation of structural and functional abnormalities in the lungs of infants with cystic fibrosis. Pediatr Pulmonol 2000; 20: 24–27. 57. Goris ML, Zhu HJ, Blankenberg F, et al. An automated approach to quantitative air trapping measurements in mild cystic fibrosis. Chest 2003; 123: 1655–1663. 58. Kiraly AP, Odry BL, Godoy MC, et al. Computer-aided diagnosis of the airways: beyond nodule detection. J Thorac Imaging 2008; 23: 105–113.
P.L. PERERA AND N.J. SCREATON
65
59. Matsuoka S, Kurihara Y, Nakajima Y, et al. Serial change in airway lumen and wall thickness at thin-section CT in asymptomatic subjects. Radiology 2005; 234: 595–603. 60. Wong-You-Cheong J, Leahy B, Taylor P, et al. Airways obstruction and bronchiectasis: correlation with duration of symptoms and extent of bronchiectasis on computed tomography. Clin Radiol 1992; 45: 256–259. 61. Smith IE, Jurriaans E, Diederich S, et al. Chronic sputum production: correlations between clinical features and findings on high resolution computed tomographic scanning of the chest. Thorax 1996; 51: 914–918. 62. Lynch DA, Newell J, Hale V, et al. Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol 1999; 173: 53–58. 63. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed tomography features and pulmonary function tests. Thorax 2000; 55: 198–204. 64. Loubeyre P, Paret M, Revel D, et al. Thin-section CT detection of emphysema associated with bronchiectasis and correlation with pulmonary function tests. Chest 1996; 109: 360–365. 65. Brody AS, Sucharew H, Campbell JD, et al. Computed tomography correlates with pulmonary exacerbations in children with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1128–1132. 66. Ooi GC, Khong PL, Chan-Yeung M, et al. High-resolution CT quantification of bronchiectasis: clinical and functional correlation. Radiology 2002; 225: 663–672. 67. Alzeer AH. HRCT score in bronchiectasis: correlation with pulmonary function tests and pulmonary artery pressure. Ann Thorac Med 2008; 3: 82–86. 68. Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20: 581–587. 69. Brody AS, Klein JS, Molina PL, et al. High resolution computed tomography in young patients with cystic fibrosis: distribution of abnormalities and correlation with pulmonary function tests. J Pediatr 2004; 14: 32–38. 70. Long FR, Williams RS, Castile RG. Structural airway abnormalities in infants and young children with cystic fibrosis. J Pediatr 2004; 144: 154–161. 71. Tiddens HA, de Jong PA. Update on the applications of chest computed tomography scanning to cystic fibrosis. Curr Opin Pulm Med 2006; 12: 433–439. 72. de Jong PA, Mayo JR, Golmohammadi K, et al. Estimation of cancer mortality associated with repetitive computed tomography scanning. Am J Respir Crit Care 2006; 173: 199–203. 73. de Jong PA, Nakano Y, Lequin MH, et al. Progressive damage on high resolution computed tomography despite stable lung function in cystic fibrosis. Eur Respir J 2004; 23: 93–97. 74. Judge EP, Dodd JD, Masterson JB, et al. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. Chest 2006; 130: 1424–1432. 75. de Jong PA, Lindblad A, Rubin L, et al. Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax 2006; 61: 80–85. 76. Robinson TE, Leung AN, Northway WH, et al. composite spirometric–computed tomography outcome measure in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2003; 168: 588–593. 77. Nasr SZ, Kuhns LR, Brown RW, et al. Use of computerized tomography and chest X-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001; 31: 377–382. 78. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65: Suppl. 1, i1–i58. 79. Brody AS, Tiddens HA, Castile RG, et al. Computed tomography in the evaluation of cystic fibrosis lung disease. Am J Respir Crit Care Med 2005; 172: 1246–1252. 80. Puderbach M, Eichinger M, Gahr J, et al. Proton MRI appearance of cystic fibrosis: comparison to CT. Eur Radiol 2007; 17: 716–724. 81. Altes TA, Eichinger M, Puderbach M. Magnetic resonance imaging of the lung in cystic fibrosis. Proc Am Thorac Soc 2007; 4: 321–327. 82. Carr DH, Oades P, Trotman-Dickenson B, et al. Magnetic resonance scanning in cystic fibrosis: comparison with computed tomography. Clin Radiol 1995; 50: 84–89. 83. Hebestreit A, Schultz G, Trusen A, et al. Follow-up of acute pulmonary complications in cystic fibrosis by magnetic resonance imaging: a pilot study. Acta Paediatr 2004; 93: 414–416. 84. Puderbach M, Eichinger M, Haeselbarth J, et al. Assessment of morphological MRI for pulmonary changes in cystic fibrosis (CF) patients: comparison to thin-section CT and chest X-ray. Invest Radiol 2007; 42: 715–725. 85. Montella S, Santamaria F, Salvatore M, et al. Lung disease assessment in primary ciliary dyskinesia: a comparison between chest high-field magnetic resonance imaging and high-resolution computed tomography findings. Ital J Pediatr 2009; 35: 24. 86. Euler US, Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Phys Scand 1947; 12: 301–320.
RADIOLOGICAL FEATURES
66
87. Itti E, Fauroux B, Pigeot J, et al. Quantitative lung perfusion scan as a predictor of aerosol distribution heterogeneity and disease severity in children with cystic fibrosis. Nucl Med Commun 2004; 25: 563–569. 88. Fink C, Bock M, Puderbach M, et al. Partially parallel three-dimensional magnetic resonance imaging for the assessment of lung perfusion – initial results. Invest Radiol 2003; 38: 482–488. 89. Ley S, Fink C, Puderbach M, et al. Kontrastmittelversta¨rkte 3D-MR-Perfusion der Lunge: Einsatz paralleler Bildgebungstechniken bei gesunden Probanden. [Contrast-enhanced 3D MR perfusion of the lung: application of parallel imaging technique in healthy subjects.] Rofo 2004; 176: 330–334. 90. Eichinger M, Puderbach M, Fink C, et al. Contrast-enhanced 3D MRI of lung perfusion in children with cystic fibrosis – initial results. Eur Radiol 2006; 16: 2147–2152. 91. Ley S, Puderbach M, Fink C, et al. Assessment of hemodynamic changes in the systemic and pulmonary arterial circulation in patients with cystic fibrosis using phase-contrast MRI. Eur Radiol 2005; 15: 1575–1580. 92. Jakob PM, Wang T, Schultz G, et al. Assessment of human pulmonary function using oxygen-enhanced T1 imaging in patients with cystic fibrosis. Magn Reson Med 2004; 51: 1009–1016. 93. van Beek EJ, Wild JM, Kauczor HU, et al. Functional MRI of the lung using hyperpolarized 3-helium gas. J Magn Reson Imaging 2004; 20: 540–554. 94. Kauczor H-U, Surkau R, Roberts T. MRI using hyperpolarized noble gases. Eur Radiol 1998; 8: 820–827. 95. Patz S, Hersman W, Muradian I. Hyperpolarized 129Xe MRI: a viable functional lung imaging modality? Eur J Radiol 2007; 64: 335–344. 96. McMahon CJ, Dodd JD, Hill C, et al. Hyperpolarized 3helium magnetic resonance ventilation imaging of the lung in cystic fibrosis: comparison with high resolution CT and spirometry. Eur Radiol 2006; 16: 2483–2490. 97. van Beek EJ, Hill C, Woodhouse N, et al. Assessment of lung disease in children with cystic fibrosis using hyperpolarized 3-helium MRI: comparison with Shwachman score, Chrispin–Norman score and spirometry. Eur Radiol 2007; 17: 1018–1024. 98. Mentore K, Froh DK, de Lange EE, et al. Hyperpolarized HHe 3 MRI of the lung in cystic fibrosis: assessment at baseline and after bronchodilator and airway clearance treatment. Acad Radiol 2005; 12: 1423–1429. 99. Woodhouse N, Wild JM, van Beek EJR, et al. Assessment of hyperpolarized 3He lung MRI for regional evaluation of interventional therapy: a pilot study in pediatric cystic fibrosis. J Magn Reson Imag 2009; 30: 981–988. 100. Eberle B, Weiler N, Markstaller K, et al. Analysis of intrapulmonary O2 concentration by MR imaging of inhaled hyperpolarized helium-3. J Appl Physiol 1999; 87: 2043–2052. 101. Kauczor H-U. Hyperpolarized helium-3 gas magnetic resonance imaging of the lung. Top Magn Reson Imaging 2003; 14: 223–230. 102. Dollery CT, Hugh-Jones P. Distribution of gas and blood in the lungs in disease. Br Med Bull 1963; 19: 59–63. 103. Singh MM, Talwar D, Jena A, et al. Ventilation–perfusion studies in bronchiectasis. Ind J Tub 1987; 34: 182–186. 104. Pifferi M, Caramella D, Bulleri A, et al. Pediatric bronchiectasis: correlation of HRCT, ventilation and perfusion scintigraphy, and pulmonary function testing. Pediatr Pulmonol 2004; 38: 298–303. 105. Donaldson SH, Corcoran TC, Laube BL, et al. Mucociliary clearance as an outcome measure for cystic fibrosis clinical research. Proc Am Thorac Soc 2007; 4: 399–405. 106. Bennett WD, Olivier KN, Zeman KL, et al. Effect of uridine 5’-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med 1996; 153: 1796–1801. 107. Robinson M, Eberl S, Tomlinson C, et al. Regional mucociliary clearance in patients with cystic fibrosis. J Aerosol Med 2000; 13: 73–86. 108. Yeates DB, Gerrity TR, Garrard CS. Characteristics of tracheobronchial deposition and clearance in man. Ann Occup Hyg 1982; 26: 245–257. 109. Wilkey DD, Lee PS, Hass FJ, et al. Mucociliary clearance of deposited particles from the human lung: intra- and inter-subject reproducibility, total and regional lung clearance, and model comparisons. Arch Environ Health 1980; 35: 294–303. 110. Marthin JK, Mortensen J, Pressler T, et al. Pulmonary radioaerosol mucociliary clearance in diagnosis of primary ciliary dyskinesia. Chest 2007; 132: 966–976. 111. Pavia D, Sutton PP, Agnew JE, et al. Measurement of bronchial mucociliary clearance. Eur J Respir Dis 1983; 64: Suppl. 127, 41–56. 112. Mortensen J, Lange P, Nyboe J, et al. Lung mucociliary clearance. Eur J Nucl Med 1994; 21: 953–961. 113. Laube BL, Karmazyn YJ, Orens JB, et al. Albuterol improves impaired mucociliary clearance after lung transplantation. J Heart Lung Transplant 2007; 26: 138–144. 114. Isawa T, Teshima T, Hirano T, et al. Mucociliary clearance in pulmonary vascular disease. Ann Nucl Med 1988; 2: 41–47. 115. Rowe S, Accurso F, Clancy JP. Detection of CFTR activity in early phase clinical trials. Proc Am Thorac Soc 2007; 4: 387–398.
67
P.L. PERERA AND N.J. SCREATON
116. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241–250. 117. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678–685.
Chapter 6
Microbiology of nonCF bronchiectasis J.E. Foweraker* and D. Wat#
MICROBIOLOGY
Summary Non-cystic fibrosis (CF) bronchiectasis is a complex disorder characterised by recurrent chest infections and poorly regulated respiratory innate and adaptive immunity. These lead to a ‘‘vicious cycle’’ of impaired mucociliary clearance, chronic infection, bronchial inflammation and progressive lung injury. The most prevalent pathogenic bacteria are Haemophilus influenzae, Pseudomonas aeruginosa, Streptococcus pneumoniae, Staphylococcus aureus and Moraxella catarrhalis although variations in sampling techniques and detection methods have influenced their isolation rates. These organisms can inhibit mucociliary clearance, destroy respiratory epithelium and produce biofilms that promote persistent infection by blocking innate immune defences and increasing antibiotic resistance. While numerous studies have examined the role of different bacteria in CF and chronic obstructive pulmonary disease, little is known about how they contribute to the pathogenesis of nonCF bronchiectasis. There is also a paucity of data regarding the role of respiratory viruses in this condition. This chapter describes the microbiology of non-CF bronchiectasis, defines the bacterial mechanisms that may contribute to persistent infection and airway damage and discusses the potential role for respiratory viruses in this condition. Understanding the pathogenic properties of these microorganisms may allow the development of novel therapies for the management of respiratory exacerbations. Keywords: Anaerobes, Haemophilus, Moraxella, Pseudomonas, Streptococcus, viruses
P
*Dept of Microbiology, and # Lung Defence Unit, Papworth Hospital, Cambridge, UK. Correspondence: J.E. Foweraker, Dept of Microbiology, Papworth Hospital, Papworth Everard, Cambridge, CB23 3RE, UK, Email
[email protected]
Eur Respir Mon 2011. 52, 68–96. Printed in UK – all rights reserved. Copyright ERS 2011. European Respiratory Monograph; ISSN: 1025-448x. DOI: 10.1183/1025448x.10003610
68
atients with bronchiectasis are commonly colonised with potentially pathogenic microorganisms in the airways [1]. These microorganisms can cause lung infections and may produce a number of inflammatory mediators that can lead to progressive tissue damage and bronchial obstruction. The phenomenon of chronic infection, bronchial inflammation and progressive lung injury is a ‘‘vicious cycle’’ and is also the reason why prompt evaluation of infection is important [2].
Being able to identify the causative bacterium may allow appropriate antibiotic administration to break this vicious cycle. The most prevalent microorganisms found in non-cystic fibrosis (CF) bronchiectasis are discussed in this chapter and we have included the role of viruses, as well as some recent studies that have investigated microorganisms that are not usually considered to be pathogens in the respiratory tract. Surprisingly, there is little published data on the epidemiology and pathogenesis of infections in non-CF bronchiectasis. However, there are similarities with infections in CF bronchiectasis and chronic obstructive pulmonary disease (COPD). Where the literature for non-CF bronchiectasis is sparse, studies in CF and COPD have been drawn upon as these may aid the understanding of the microbiology; in particular the adaptations that take place to enable microorganisms to establish and maintain chronic infection and the role taken in the development of exacerbations. Fungal infections, including allergic bronchopulmonary aspergillosis (ABPA), are discussed further by HILVERLING et al. [3], while nontuberculous mycobacteria infections are discussed further by DALEY [4] in this Monograph.
Several studies have reviewed the bacteria found in patients with non-CF bronchiectasis (table 1). A similar range of organisms is found in most studies, but the prevalence of each varies. Age, ethnicity, the underlying causes of bronchiectasis and the proportion of patients that were stable or had cultures taken during an exacerbation varies between the different studies and would be expected to affect the microbial flora found. The pattern of antibiotic usage, including long-term prophylaxis, may vary between different centres and could also have an affect on the type of microorganisms cultured. The type of respiratory specimen tested may also determine the rate of positive cultures found. The use of a protected specimen brush to take samples at bronchoscopy yielded the highest positivity rate when compared with sputum specimens in one study [7]. Finally the methodology used for analysis (quantification, culture and identification techniques) will vary between centres and could also affect the result. Haemophilus influenzae and Pseudomonas aeruginosa were the most common bacteria found in the majority of the studies and the most likely to cause long-term colonisation [12]. No potentially pathogenic microorganisms were cultured from 18–24% of the patients investigated and an absence of a potentially pathogenic microorganism was associated with the milder disease [9, 13].
Haemophilus influenzae
J.E. FOWERAKER AND D. WAT
Range of bacteria in patients with non-CF bronchiectasis
H. influenzae has been reported in 14–52% of patients with non-CF bronchiectasis. It is a Gramnegative coccobacillus with specific growth requirements, which can be difficult to isolate in the laboratory if mixed with other flora. Some H. influenzae possess a polysaccharide capsule and can be typed using type-specific anticapsule antisera. Those with the type B capsule (Hib) can cause invasive infection with bacteraemia, and are most familiar as a cause of meningitis or epiglottitis. The use of Hib vaccine has greatly reduced the incidence of these life-threatening conditions. H. influenzae with capsule types other than type B are relatively rare and are far less pathogenic. The nonencapsulated strains, referred to as nontypeable H. influenzae (NTHi), are also less pathogenic than Hib and only rarely cause bacteraemia. They live as commensals in the human upper respiratory tract but can cause otitis media, sinusitis and conjunctivitis, often following a primary viral infection. NTHi are a common cause of lower respiratory infection in patients with underlying respiratory abnormalities including non-CF bronchiectasis [9]. The Hib vaccine does not prevent infection with NTHi as it only contains the H. influenzae type B capsule antigen.
69
NTHi could be an oral contaminant in expectorated sputum; however, studies using a protected specimen brush (PSB) at bronchoscopy found NTHi in significant numbers in non-CF bronchiectasis, confirming its presence in the lower respiratory tract [7]. In contrast
15 (10) 9 (6) 47 (33) 47 (33) Colonised subgroup"
13 (9)
21 (14) 39 (27) 30 (20) 39 (27) 20 (13) 42 (30) 46 (31) 62 (43) 52 (35) 75 (52) ND ND Sputum Sputum PASTEUR [10] MACFARLANE [11]
UK UK
150 143
60.6 (16–90)
3 (4) 7 (8) 6 (7) 11 (12) 42 (47) Stable Sputum 89 KING [9]
Australia
57¡14
9 (7) 3 (2) 13 (11) 38 (31) 37 (30) ND Sputum 123 USA NICOTRA [8]
57.2¡16.7
2 (3) 3 (4) 6 (8) 12 (16) 24 (32) Stable 58 (16–76) PSB 75 Spain ANGRILL [7]
Data are presented as mean (range), mean¡SD or n (%), unless otherwise stated. RTFlora: upper respiratory tract flora; PPM: potentially pathogenic microorganisms; ND: not described; K. pneumoniae: Klebsiella pneumoniae; GNB: Gram-negative bacilli; GPB: Gram-positive bacilli; PSB: protected specimen brush; A. xylosoxidans: Achromobacter xylosoxidans: E. coli: Escherichia coli; S. maltophilia: Stenotrophomonas maltophilia; #: some had more than one PPM cultured; ": bacteria were isolated on at least two occasions, 3 months apart, in 1 year.
7 (14) K. pneumonia 7 (14) GNB 2 (4) GPB 18 (24) RTFlora 1 (1) A. xylosoxidans 1 (1) E. coli ND 16 (13) GNB 2 (3) Anaerobes 19 (21) no PPM 2 (2) E. coli 1 (1) A. xylosoxidans ND 28 (20) 12 (8) S. maltophilia 4 (3) A. xylosoxidans 42 (30) Coliforms 2 (1) S. maltophilia 2 (1) A. xylosoxidans 13 (9) Coliforms
Sputum Sputum 92 50 Ireland Thailand ZAID [5] PALWATWICHAI [6]
,18 58 (30–85)
ND ND
50 (46) 7 (14)
8 (9) 10 (20)
34 (37) 3 (6)
9 (10) 2 (4)
14 (15)
ND 9 (18) RTFlora
Other RTFlora/ no PPM
Haemophilus Pseudomonas Streptococcus Moraxella Staphylococcus influenzae aeruginosa pneumoniae catarrhalis aureus
Patients with organisms cultured from respiratory tract# Stable or at exacerbation Age yrs Sample Subjects n Country First author [ref.]
Table 1. Range of microorganisms cultured from patients with non-cystic fibrosis bronchiectasis
MICROBIOLOGY
70
Haemophilus parainfluenzae, a common commensal organism found in the upper respiratory tract, may be cultured from sputum but was not found in PSB samples. In patients with COPD the presence of NTHi in sputum was associated with raised inflammatory cytokines, whereas patients with H. parainfluenzae in sputum had similar levels of cytokines to those who had no microorganisms cultured from their sputum, suggesting that even if present in the lower tract it does not have a direct pathogenic role [14, 15]. There is little published data on the epidemiology of H. influenzae in non-CF bronchiectasis. It may be cultured repeatedly from the same patient over several years, but without typing data it is not known if this is the persistence of a single strain or repeated episodes of infection [9]. In COPD patients, NTHi were found in higher numbers (.106 colony forming units (CFU)?mL-1) during exacerbation compared with when the patient was stable, and exacerbations in COPD may be associated with the appearance of a new strain [16, 17]. A prospective study in COPD using molecular typing of H. influenzae and direct analysis of amplified DNA from sputum showed persistence of the same strain over prolonged periods [18]. This suggests either long-term colonising infection in the lung or persistence in the upper respiratory tract with repeated deposition followed by clearance from the lung. In CF, sequential infection with different strains of H. influenzae was found in some patients and persistence of the same clone in other individuals [19]. NTHi have various properties that can help explain their pathogenicity and ability to persist in the lung. They can adhere to mucus and to various cell types in the human respiratory tract using pili and other adhesion molecules. Virulence factors include the endotoxin lipo-oligosaccharides
(LOS), and immunoglobulin (Ig)-A protease [20]. NTHi possess mechanisms to vary the structure and activity of LOS and these may explain variations in the pathogenicity of different isolates [21]. Studies comparing the proteome of H. influenzae grown in vitro, either in pooled sputum or chemically defined media, have shown that the organism is able to adapt to oxidative stress and limited nutrients [22]. This is thought to be because H. influenzae has the ability to generate a diverse population that allows rapid adaptation to changes in the environment by expansion of the clonal members that express the phenotypic characteristics needed to survive. Mechanisms used by H. influenzae to generate phenotypic diversity include altered gene expression, e.g. by phase variation, and altered gene content by mutation or by horizontal gene transfer, e.g. direct DNA uptaketransformation, or via bacteriophage [23].
H. influenzae (along with other bacteria infecting a bronchiectatic lung) may exist in biofilms in the respiratory tract. These are co-operative populations of bacteria surrounded by an amorphous matrix and could help the organism to survive in a hostile environment by resisting both host defences and antibiotics. The antibiotic resistance observed for bacteria growing in biofilms is in part attributable to its electrolyte content but also by reduced bacterial growth or even dormancy within the biofilm matrix. NTHi from patients with COPD can form biofilms in vitro, and NTHi biofilms were seen in the chinchilla model of otitis media [28, 29]. NTHi cultured from CF patients could form biofilms in vitro and on the surface of cultured airway epithelial cells. Structures consistent with biofilms containing H. influenzae were also found in bronchoalveolar lavage (BAL) samples from children with CF [30]. NTHi in biofilms were more resistant to antibiotics in vitro. Sub-inhibitory concentrations of azithromycin were found to reduce the size of both growing and established biofilms [31]. The prevalence of antibiotic resistant NTHi increases over time in patients with non-CF bronchiectasis [9]. Many are resistant to amidopenicillins (e.g. amoxicillin, ampicillin) either due to production of b-lactamase or alteration of penicillin binding proteins. Quinolone resistance is now recognised and resistance rates to trimethoprim and tetracycline are rising.
J.E. FOWERAKER AND D. WAT
NTHi may be able to evade the immune response by varying its surface antigens. Mechanisms include phase variation of LOS [24], and changes to outer membrane proteins (OMP) either by horizontal gene transfer or point mutations of the immuno-dominant OMP, i.e. P2. Antigenic drift, resulting from change in the P2 gene, has been observed in persistent infections in patients with COPD [25]. NTHi could be protected within host cells as they have been found inside macrophages in the chinchilla otitis media model and in macrophage-like cells in human adenoids. NTHi were able to enter cultured nonciliated respiratory epithelial cells and cross the respiratory epithelium [26]. Using in situ hybridisation, NTHi were identified inside cells in bronchial biopsies taken from patients with COPD [27].
Antibiotic resistance may occur by horizontal transfer of genetic material from other organisms in the complex polymicrobial environment of the mouth and upper respiratory tract. It may also take place in the lower respiratory tract, which may be polymicrobial in non-CF bronchiectasis. Alternatively, resistance may result from gene mutation. Some NTHi have a higher than usual mutation rate due to a mutation in mutS, which is one of the methyl-directed mismatch repair genes (MMR) that corrects errors in DNA. This hypermutability is not usually thought to be advantageous, as many random mutations can reduce bacterial fitness. However, if mutations lead to antibiotic resistance, the hypermutable state may become beneficial to the bacterial population. Hypermutators are generally rare in acute infection but hypermutable H. influenzae have been found in patients with CF and these strains have more resistance to antibiotics compared with normo-mutators [19, 32]. Hypermutability is seen in other species causing chronic infection (as is discussed later in this chapter) and may be a general adaptation to long-term survival in the lung. The prevalence and role of hypermutable H. influenzae in non-CF bronchiectasis has yet to be assessed.
Pseudomonas aeruginosa
71
P. aeruginosa is a versatile nonfermentative Gram-negative bacillus that is found in a range of environments. It is an opportunistic human pathogen that can cause severe, acute and invasive
infections, such as necrotising ventilator-associated pneumonia and infections in immunocompromised patients often with bacteraemia [33]. It is one of the most common causes of infection in non-CF bronchiectasis and other chronic lung diseases, most notably CF, but may also be important in severe COPD. The epidemiology of P. aeruginosa, the mechanisms of pathogenicity and the genotypic and phenotypic changes in chronic infection have been extensively studied in CF, with fewer publications in non-CF bronchiectasis and COPD. There are many similarities between the infections in these different conditions, suggesting a common route of adaptation to chronic infection in the lung.
MICROBIOLOGY
P. aeruginosa in CF Early infections in CF are caused by genotypically distinct isolates, suggesting repeated episodes of acquisition. These early P. aeruginosa have the typical phenotype of isolates causing acute infections and environmental strains [34]. As chronic infection with P. aeruginosa can lead to an accelerated deterioration in lung function, antibiotic treatment regimens were developed to clear early infection and delay the onset of chronic infection [35]. CF patients eventually developed a persistent infection that seldom cleared despite aggressive antibiotic therapy. While there are some mixed infections, most CF patients carry a single genotype of P. aeruginosa, often for many decades [36, 37], and exacerbations do not appear to be due to the acquisition of a new strain of P. aeruginosa [38]. Early studies in CF showed that individual patients were infected with distinct strains that were thought to have been acquired from the environment. Some siblings shared strains but it was not known whether this was cross-infection or exposure to a common environmental source. More recently there have been reports in several countries of crossinfection between CF patients with what are termed ‘‘epidemic’’ strains. Some, in particular the Liverpool epidemic strain (LES), have been associated with increased morbidity [39, 40]. LES is now the most common epidemic strain in the UK affecting as many as 11% of patients in England and Wales [41].
P. aeruginosa in COPD P. aeruginosa has been cultured from 4–15% of patients with COPD and was more prevalent in patients with advanced disease, particularly those requiring mechanical ventilation for severe exacerbations. P. aeruginosa infection was associated with steroid use, prior antibiotics and a low forced expiratory volume in 1 second (FEV1) [42]. In a study of 126 patients with moderate-tosevere COPD over an 11-year period, 39 patients grew P. aeruginosa from one or more sputum culture. There was a significant association with the culture of a new strain of P. aeruginosa and symptoms of an exacerbation. However, of interest, two-thirds of new infections that later cleared from the sputum, did so without the use of specific antibiotic treatment [43]. Only 13 patients had carriage of the same clone for more than 6 months with four patients infected with mucoid strains. Chronic infection is therefore rare in COPD, but when it does occur P. aeruginosa has a range of colony forms (morphotypes) and adaptations including increased mutability, reduced motility, reduced protease production and increased antibiotic resistance, similar to those seen in CF [44].
P. aeruginosa in non-CF bronchiectasis P. aeruginosa is one of the most common isolates found in 12–43% of non-CF bronchiectasis patients (table 1). Stable patients with P. aeruginosa have poorer lung function and more sputum production when compared with patients with other potentially pathogenic microorganisms (PPM) [45] and it has been associated with a poorer quality of life and more frequent hospital admissions [46]. There is debate over whether infection with P. aeruginosa leads to a faster decline in lung function as is seen in CF, or whether it is a marker of more damaged lungs [47, 48].
72
A recent study compared long-term colonisation with P. aeruginosa in 21 patients, of which six had CF, 10 had non-CF bronchiectasis and five had COPD. The authors typed 125 sequential
isolates from sputa taken at least 1 month apart. The authors found a similar pattern of colonisation in all three diseases, with a dominant persistent clone, showing that the pattern of infection found in CF could also be shown in other conditions [49]. There have been no studies using genomic typing methods to investigate whether patients with nonCF bronchiectasis share strains of P. aeruginosa, but there has been one report of a patient with nonCF bronchiectasis acquiring LES from a relative with CF [50]. Interestingly, early studies using pyocin typing and examining mucinophilic and chemotactic properties of P. aeruginosa suggest that specific subpopulations may have a predilection to infect bronchiectatic lungs [51, 52].
Pathogenicity of P. aeruginosa P. aeruginosa possesses a range of virulence factors, although their expression may differ between isolates that cause acute infection and those responsible for chronic infection. Flagella, type IV pili, lipopolysaccharide and exopolysaccharides contribute to the adherence to cells and surfaces. Type I and type II secretion systems export protein toxins, such as alkaline protease, elastase, exotoxin A and phospholipase C, while type III secretion systems inject exoenzymes directly into eukaryotic cells. Other extra-cellular virulence factors include rhamnolipids, pyocyanin and hydrogen cyanide [53, 54]. Another pathogenicity factor is the ability to form alginate-enhanced biofilms [55], which contributes to the persistence of the organism rather than acute tissue damage and, together with other adaptations, promotes chronic infection (refer to later section).
P. aeruginosa is intrinsically resistant to many commonly used antibiotics and easily acquires resistance by chromosomal mutation or the acquisition of new genes from other microorganisms by horizontal transfer [56]. In addition, the biofilm mode of growth also protects P. aeruginosa from antibiotics by a variety of mechanisms [57]. Little has been published specifically on antibiotic susceptibility of P. aeruginosa from patients with non-CF bronchiectasis. In CF the prevalence of resistant P. aeruginosa is increasing as a result of repeated antibiotic courses. Resistance rates are significantly higher than for strains originating from patients without CF [58] and pan-resistant bacteria that are resistant to all antibiotics other than the polymixins have been described. P. aeruginosa can develop resistance by either: 1) producing enzymes that destroy the antibiotic, such as AmpC b-lactamase, carbapenemases or aminoglycoside modifying enzymes; 2) modifying the antibiotic target, such as gyrA for quinolone resistance; or 3) reducing exposure either by a decrease in permeability or increased removal of the antibiotic from the bacterial cell (efflux). Efflux mechanisms often affect more that one class of antibiotics and therefore contribute to multi-drug resistance [56].
J.E. FOWERAKER AND D. WAT
Antibiotic resistance
Antibiotic resistance and its regulation can be complex in P. aeruginosa and various mechanisms that affect resistance to a single antibiotic may be present in the same organism. For example, low level resistance to meropenem may be due to reduced permeability following changes to the membrane porin OprD. More resistance can result from an increase in an efflux pump that can remove the meropenem from the cell. Both mechanisms may be present and additive, leading to high-level resistance. Enzymes that can destroy meropenem (penemases such as VIM) do occur but are currently rare [56].
73
AmpC codes for an inducible cephalosporinase which, when production is increased, can result in resistance to nearly all b-lactam antibiotics except the penems. Treatment with piperacillin or ceftazidime can lead to the selection of bacteria that produce the enzyme constitutively rather than just on induction. These are called derepressed mutants and offer a survival advantage. Imipenem induces the AmpC b-lactamase, even though it is not affected by the enzyme, and it also induces genes involved with alginate production [59]. The regulation of ampC is exceedingly complex and
is intimately linked to cell wall recycling [60–62]. Some mutations can reduce biological competitiveness and more work is needed to assess the link between antimicrobial resistance and fitness [61]. AmpR does not just regulate ampC but is a global transcriptional regulator that regulates another b-lactamase PoxB, as well as proteases, quorum sensing and other virulence factors [63]. Antibiotic resistance may therefore be associated with a change in virulence and/or fitness. This could explain why some CF patients respond to treatment for acute exacerbation, even though some of the P. aeruginosa are resistant to the antibiotic used [64]. P. aeruginosa possesses multi-drug efflux pumps that can expel a wide range of antibiotics and are responsible for much of the organism’s intrinsic resistance to antimicrobials. For example, substrates for efflux pump MexAB-OprM include ticarcillin, aztreonam, piperacillin, ceftazidime and tetracycline [65]. MexXY uses the same exit duct OprM and can export aminoglycosides, cefepime and ciprofloxacin. Antibiotic resistance may arise from an increase in the efflux pump activity, e.g. MexXY-OprM over-expression may be due to mutation in the regulatory gene mexZ and/or to mutations in the MexXY translocase genes [66].
MICROBIOLOGY
Conversely, P. aeruginosa may be hyper-susceptible in vitro to some anti-pseudomonal antibiotics and susceptible to agents such as tetracycline and chloramphenicol to which P. aeruginosa would normally be intrinsically resistant. This has been described in chronic infection in both CF and non-CF bronchiectasis [67, 68], but the clinical relevance of these findings has not been investigated. It was found that 25 out of 46 CF patients had strains hyper-susceptible to ticarcillin due to deficiencies in MexAB-OprM efflux activity, resulting from various gene defects including reduced or abnormal expression of MexB and OprM [66]. It is unclear why this phenomenon exists. Efflux pumps do not just expel antibiotics and therefore reduced efflux may give a selective advantage under certain physiological conditions in the chronically infected lung.
Adaptations to chronic infection One of the characteristics of chronic infection with P. aeruginosa is the appearance in vitro of a variety of colony forms (morphotypes) that differ from those seen in environmental strains or those causing acute infection (fig. 1). Several different morphotypes may be found in the same sputum, even though the isolates are clonally related. These can include colonies lacking the typical pigmentation, mucoid forms, some that look like coliforms, ‘‘dwarf’’ forms and very slow growing ‘‘small colony variants’’. One of the most easily recognised is the mucoid morphotype. This results from over-production of the polysaccharide alginate, due to mutation in the regulatory genes. Hyper-alginate producers were originally thought unique to CF but they are also found in non-CF bronchiectasis and COPD [45, 49, 69]. They are thought to be an adaptation to chronic infection irrespective of the underlying cause. Alginate may protect against phagocytosis [70] and contribute to the formation of biofilms [71, 72]. Small colony variants (SCVs) have enhanced ability to form biofilms and may also contribute to persistence [73]. SCVs have only been described so far in CF but are easily missed unless cultures are prolonged.
Figure 1. Different pseudomonal morpho-
74
logical types of Pseudomonas aeruginosa found in a single sputum sample taken from a chronically infected individual.
The phenotypic changes found in chronic infection have been studied extensively in CF but not in non-CF bronchiectasis. They include loss of acute virulence factors, such as toxin production (e.g. elastase, phospholipase C, pyoverdin, hydrogen cyanide) and type III secretion [74]. Many virulence factors are regulated by the quorum sensing (QS) system. These are signalling
molecules that act on the regulators of gene transcription. Some QS molecules depend on population density, and only have their effect when the number of organisms reaches a critical concentration (or quorum). P. aeruginosa QS molecules comprise acyl-homoserine lactones and molecules of the PQS system. They can affect a large number of functions including pathogenicity, metabolic adaptation and persistence [75]. P. aeruginosa with mutations in QS genes, most frequently las R, do not respond to QS molecules and are surprisingly common, they were found in 19 out of 30 CF patients in a study by SMITH et al. [76]. Las R mutants form characteristic iridescent colonies and have also been cultured from patients with non-CF bronchiectasis (J.E. Foweraker, Papworth Hospital, Cambridge, UK; personal communication). These mutants do not produce the toxins elastase, phenazines or hydrogen cyanide. Las R mutants can use a more diverse range of compounds as a source of carbon, nitrogen, phosphorus or sulphur and have a growth advantage over the wild type when grown with phenylalanine, isoleucine or tyrosine. They therefore appear to be less pathogenic but better able to adapt to the local environment. Again, different phenotypes can co-exist so sputum may contain Las R mutants and organisms without the mutation. Longitudinal studies in CF have analysed strains from patients over several years. It is thought that with time the bacteria adapt to a form that is less virulent but better able to persist in the damaged lung [76]. Multiple phenotypic variants of the underlying clonal population of P. aeruginosa coexist and form a complex population in the chronically infected lung. This is described as ‘‘adaptive radiation’’ and is thought to give the bacteria an advantage in that they can rapidly respond to changes in the environment, as individual organisms that have the necessary adaptation may already be present in the population.
P. aeruginosa is thought to grow in biofilms in chronic infections in both CF and non-CF bronchiectasis. Biofilm formation is thought to be a general adaptation to a hostile environment and may allow persistence of infection by protecting the bacteria from the host response and the effects of antibiotics. Biofilm fragments have been seen in CF sputum [77] and may contain a mixture of P. aeruginosa plus other bacteria and even fungi, such as Candida spp. The extracellular matrix comprises alginate produced by P. aeruginosa plus proteins and DNA from other microorganisms and host cells. The biofilm contains a steep oxygen gradient and is anaerobic just below the surface. Different concentrations of nutrients and waste products will also be found in different areas of the biofilm. Therefore, the biofilm contains a wide range of physiological conditions, by which the bacteria possess a variety of adaptations that enable them to survive within these microniches [78].
J.E. FOWERAKER AND D. WAT
Biofilms
Alginate protects P. aeruginosa in biofilms from interferon (IFN)-c activated macrophages [79]. Neutrophils have been observed immobilised in the extra-cellular matrix, unable to penetrate the biofilm [80]. It is thought that neutrophils may actually enhance early biofilm formation, as biofilms formed in vitro in the presence of neutrophils are thicker and contain more bacteria [81]. If P. aeruginosa and neutrophils are combined, the bacteria aggregate around necrotic dying neutrophils. If neutrophil apoptosis is induced before the bacteria are added, the neutrophils are intact and the P. aeruginosa remain dispersed. Neutrophils can release DNA and F-actin complexed with histones and other cations, and these may form the framework for the biofilm. The combination of DNAse and anionic polymers has a synergistic effect in clearing early neutrophil-associated biofilms in vitro and is being studied as a potential treatment to prevent or disrupt early biofilm formation [81]. Neutrophil lysis is thought to be caused by rhamnolipid, a toxin produced by P. aeruginosa under QS control. Rhamnolipid may therefore help to protect the biofilm from disruption by neutrophils, especially in the early stages of formation [82].
75
Azithromycin is a macrolide antibiotic that does not directly inhibit or kill P. aeruginosa, but it can block QS and alginate polymer formation in vitro [83]. It can disrupt early biofilms formed by nonmucoid strains but has less effect on early biofilms formed by hyper-alginate producers
MICROBIOLOGY
(mucoid strains) or on established biofilms [84]. Azithromycin also has an anti-inflammatory effect in chronic lung infection and the relative importance of its diverse actions is yet to be established. Other antibiotics may also influence bacterial virulence. For example ciprofloxacin can suppress alginate biosynthesis at concentration well below minimum inhibitory concentration (MIC) [85]. Bacteria cultured in biofilms in vitro are more resistant to most antibiotics than when they are dispersed (planktonic). Several mechanisms have been proposed to explain this resistance [86]. It was thought that the extra-cellular matrix formed a physical barrier but there are channels within the biofilm through which most antibiotics can permea